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This dissertation involves the design and synthesis of new synthetic receptors and their 
application in the molecular recognition of methylated lysine and their use as tools for chemical 
biology. The dissertation is divided into four parts. The first section focuses on the development 
of a novel labeling method that is based on ligand-directed affinity labeling principles. In this 
labeling method, a synthetic receptor that binds to trimethyl lysine (Kme3) is attached through a 
linker to an electrophilic tag group that can react with a nucleophilic amine in a histone peptide. 
This affinity labeling probe, which we called CX4-ONBD, is equipped with an electrophilic tag 
that allows for turn-on fluorescence labeling of Kme3 histone peitdes. We show that the probe 
gives a pronounced turn-on fluorescence response when it is incubated with a histone peptide 
that contains Kme3 and a nearby reactive lysine. This probe also displays >5-fold selectivity in 
covalent labeling over an unmethylated lysine peptide. This represents the first time a synthetic 
receptor has been used for affinity labeling purposes, and it also expands on the chemical toolkit 
that is available for sensing PTMs like lysine methylation. 
In the second section, the supramolecular affinity labeling method that was optimized 
using CX4-ONBD was applied to the development of a real-time assay for measuring enzymatic 
activity. More specifically, the probe was used to create a turn-on fluorescence assay for histone 
deacetylase (HDAC) activity and for inhibitor screening and IC50 determination. Most 
iv 
commercial kits for HDAC activity have limited substrate scope, and other common methods 
used for characterizing enzymatic activity often require chromatographic separation and are 
therefore not high-throughput. This small molecule receptor-mediated affinity labeling strategy 
allowed for facile readout of HDAC activity and inhibition. Overall, this application of 
supramolecular affinity labeling expands on the possible ways for detecting PTMs and may find 
use in the development of new assays for enzymes that lack robust methods for measuring their 
activity. 
The third section explores the development of new small molecule receptors capable of 
selectively binding hydrophilic guests in water, such as the lower methylation states of lysine. 
We identified a receptor, A2I, that has improved binding affinity and selectivity for 
dimethyllysine (Kme2). The receptor was discovered and synthesized by using dynamic 
combinatorial chemistry (DCC) to redesign a small molecule receptor (A2B) that preferentially 
binds trimethyllysine (Kme3). Incorporating a biphenyl monomer with ortho-di-substituted 
carboxylates into the receptor lead to the formation of a salt bridge interaction with Kme2. These 
favorable electrostatic and hydrogen bonding interactions produced a receptor with 32-fold 
tighter binding to Kme2, which is the highest affinity synthetic receptor for Kme2 in the context 
of a peptide that has been reported. This work provides insight into effective strategies for 
binding hydrophilic, cationic guests in water and is an encouraging result toward a synthetic 
receptor that selectively binds Kme2 over other methylation states of lysine. 
 In the final section, a small molecule receptor for Kme3 (A2B) was redesigned using 
DCC to incorporate either aromatic or acidic amino acids into the receptor. We proposed that the 
incorporation of amino acids could introduce additional non-covalent interactions (such as 
cation-π, electrostatic, and hydrogen bonding) with a guest bound inside the pocket of the 
v 
receptor. However, selective non-covalent interactions between the amino acid side chain on the 
modified receptor and the bound methylated lysine guest could not be achieved. This is most 
likely due to the conformational flexibility of the amino acid-functionalized receptors. 
Furthermore, attaching amino acids to the receptor seemed to increase non-specific electrostatic 
interactions, resulting in tighter binding to the unmethylated lysine peptide (compared to A2B). 
Ultimately, this highlights the importance of incorporating monomers with less conformational 
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CHAPTER 1. Approaches for Site-Selective Labeling of Endogenous Peptides and Proteins 
Introduction 
The selective modification of proteins is an important aspect of biology. It allows for 
extraordinary levels of chemical diversity to arise from a limited pool of proteinogenic amino 
acids. In nature, this diversity is achieved primarily through the use of post-translational 
modifications (PTMs): covalent chemical modifications made to residues in proteins after 
translation from the ribosome.1 Common modifications include methylation,2 acetylation,3 
phosphorylation,4 ubiquitination,5 and glycosylation.6 These PTMs often allow for precise 
control of the structure and function of proteins and are crucial to normal biological function. In 
the field of chemical biology, site-specific labeling of amino acid residues in proteins is of 
extreme interest as it allows for interrogation of protein interactions and function and for 
manipulation of a protein’s properties for novel and creative applications.  
Several approaches have been developed for artificial chemical protein modification. One 
common method involves genetic manipulation to incorporate unnatural amino acids into 
proteins, a process pioneered by the Schultz lab.7,8 This approach has been used to incorporate 
many unnatural and often biorthogonal functional groups into proteins including azides, alkynes, 
ketones, fluorophores, crosslinking groups, and many others. While unnatural amino acid 
mutagenesis is a powerful tool for site-selective modification, there are some downsides to this 
approach. It requires prior knowledge of the target for modification, which can be limiting 
depending on the desired application. It also does not allow for protein function to be studied 
 
2 
under natural protein expression levels and is often limited to model organisms. Native chemical 
ligation (NCL) is another approach that has been used for site-selective labeling of proteins, 
specifically at the N-terminus.9 NCL allows for the synthesis of proteins from unprotected 
polypeptide fragments. One fragment contains an N-terminal cysteine, and the other contains a 
C-terminal α-thioester. Ligation occurs through a chemoselective trans-thioesterification 
followed by an S-to-N acyl shift to generate a native peptide bond.10 A related approach, 
expressed chemical ligation, uses recombinant proteins containing α-thioesters to react with 
synthetic peptides containing an N-terminal Cys.11 These recombinant thioesters are generated 
from inteins (polypeptide segments that are self-excised by formation of a thioester intermediate) 
that are incorporated into the protein sequence.12 While NCL and expressed chemical ligation are 
powerful strategies for the synthesis of homogeneous, site-specifically modified proteins, they 
are not well suited for labeling endogenous proteins. The approaches that this chapter will focus 
on are those that involve chemical modifications of endogenous proteins containing natural 
amino acids. Predictably, artificial site-selective modification of endogenous amino acids is a 
challenging task. However, it is a worthwhile endeavor as it allows protein function to be 
interrogated under ideal, native conditions. 
Chemical Reactions for Modification of Endogenous Amino Acids 
The chemical reactions used for the artificial modification (or labeling) of endogenous 
proteins have several basic requirements, especially if the labeling is to occur in live cells.13 
First, reactions must occur in water or under predominantly aqueous conditions, as many organic 
solvents are toxic to cells. The reactions also should operate near physiological pH and under a 
physiological temperature range. The reaction must not use toxic reagents and should work at 
 
3 
low concentrations. The reaction kinetics should also be adapted to fit the desired application 
(many applications require rapid labeling rates). 
Two of the most commonly modified amino acids are lysine and cysteine. Lysines are 
popular targets for modification as they are fairly abundant and often solvent exposed.13,14 
Cysteine is often a preferred target due to its exceptional nucleophilicity under physiological 
conditions. Several classical reactions (Figure 1.1) have been used to modify lysine and cysteine 
residues in proteins. N-hydroxysuccinimidyl esters, isocyanates, and isothiocyanates have been 
used to directly modify lysines through nucleophilic addition and elimination to give amide, 
urea, and thiourea conjugated products respectively.13,15 Aldehydes have also been used to 
modify lysine residues though reductive amination to give amine linkages.16 While electrophilic 
modification of lysines still finds common use, most of these classical reactions involve reagents 
that are non-selective and too reactive for use in labeling of proteins in cells. Traditionally, 
cysteine residues have also been modified using electrophilic reagents like maleimides and 
alpha-halocarbonyls.17,18 Despite their widespread use, these chemical modifications of Cys are 
limited by formation of an unstable linkage and non-specific reactivity depending on the 
conditions.19 Disulfides have also been used to target cysteine residues,20 but the resulting mixed 





Figure 1.1. Classical reactions used in modifying lysine and cysteine residues. Reproduced with 
permission from the American Chemical Society: Chem. Rev. 2015, 115, 2175. 
DOI: 10.1021/cr500399p. This is an open access article published under a Creative Commons 
Attribution (CC-BY) License. 
 
Several more recent chemistries have been developed that have vastly improved 
selectivities compared to the previously mentioned traditional reactions, making them far more 
amenable for use in chemical modification of proteins in live cells. One effective strategy for 
highly selective modification of lysine residues involves the reaction of lysine with an α,β,γ,δ-
unsaturated aldehyde.21 Imine formation followed by rapid aza-electrocyclization produces a 
stable, aromatic pyridinium conjugate. The reaction has been used to modify proteins in vivo 
with fluorescent dyes and PET imaging agents and shows remarkable selectivity for targeting 
solvent exposed lysines rather than interior lysines or the N-termini. Another selective reaction 
that has been used to modify lysines is by reaction with 2-formylphenyl boronic acids or 2-
acetylphenyl boronic acids to form stable iminoboronate conjugates.22,23 This reaction occurs 
readily under physiological conditions and is reversible by the addition of dopamine, fructose, or 
glutathione. For selective chemical modification of the N-terminus of proteins and peptides, 
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ketenes have been utilized.24 At pH 6.3, this reaction allows for almost perfect selectivity in 
labeling the N-terminus versus lysine side chains. 
 Several selective cysteine modifications that produce relatively stable conjugates have 
been developed recently. One modification involves the use of 3-arylpropiolonitriles as Michael 
acceptors to rapidly produce conjugates with cysteine that exhibit remarkable stability to 
hydrolysis.25 Hydroxymethyl naphthols have also been used to generate sulfhydryl-reactive 
Michael acceptors in situ upon irradiation with UV light.26 The resulting 2-
methylenecyclohexanone type intermediate reacts rapidly with cysteine to form a stable thioether 
bond.  Radical initiated reactions such as the thiol-ene and thiol-yne have also bene used to 
modify cysteines.27–29 In the case of thiol-ene chemistry, a stable thioether product is formed. For 
thiol-yne modifications a vinyl sulfide is formed initially, which can be reacted during a 
subsequent labeling step to produce a stable 1,2-dithioether. 
Tyrosine and tryptophan residues, which are less abundant than lysine and are not 
involved in structure-stabilizing bonds like cysteine,13 have also been modified selectively using 
a variety of approaches. A bench-stable formylbenzene aryl diazonium hexafluorophosphate has 
been used to directly modify tyrosine,30 removing the need for in situ preparation from aniline 
under acidic conditions and allowing for a secondary functionalization step with the aldehyde to 
install a tag unit of interest. A transitional metal catalyzed approach has also been developed for 
site-selective modification of tyrosine: palladium catalyzed allylic O-alkylation using an allylic 
carbamate and the water-soluble phosphine TPPTS.31 This modification occurs under mild 
conditions and has been used to prepare synthetic lipoproteins. Another reaction that has been 
used to label both tyrosine and tryptophan in proteins is the 3-component Mannich reaction.32 
This reaction requires the addition of an aniline and formaldehyde to give a stable amino-
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alkylated product and has been used to prepare spin-labeled proteins for characterization of 
structural transitions. For targeting tryptophan residues, many of the existing strategies require 
toxic transition metal and harsh acidic conditions that limit their utility. However, an approach 
involving N-oxyl 9-azabicyclo[3.3.1]nonane organoradical reagents has been used to selectively 
modify tryptophan under mild aqueous conditions to produce a conjugates that are stable under 
acidic, basic, and reducing conditions.33 
Activity Based Protein Profiling  
While the previously mentioned chemical reactions can be applied broadly to any protein 
that contains a certain amino acid residue in sterically unhindered position, more sophisticated 
strategies have been developed for targeting and modifying specific proteins (generally enzymes) 
based on molecular recognition and catalytic activity. One approach that has seen frequent use 
for enzymes is activity-based protein profiling (ABPP).34 ABPP uses carefully designed 
chemical probes to bind and covalently label at or near the active site of an enzyme. These 
probes typically contain several common components: a suicide inhibitor (frequently a substrate 
analog with a reactive electrophile or coordinating group), a linker, and a tag unit (alkynes or 
azides for conjugation in a secondary step,35 fluorescent dye for visualization, biotin for 
pulldown, radiolabel, or NMR-active nuclei like fluorine).36 Many ABPP probes also contain 
photo-crosslinking groups like benzophenones, phenyl azides, and diazirines to covalently tether 
the protein of interest to the probe.37–40 Several classes of enzymes have been characterized using 
activity-based protein profiling. Metalloproteases have been targeted using ABPP probes41 
containing a hydroxamic acid inhibitor that coordinates to zinc in the active site, a photoaffinity 
group for covalent tethering, and an alkyne handle to click on a fluorophore. Several kinases 
have been profiled using chemical probes42 that utilize ATP or ADP analogs conjugated to a tag 
 
7 
units, while phosphatases have been labeled and characterized using probes43 with self-
immolative phospho-tyrosine substrates that form electrophilic quinone methide reactive groups 
upon enzymatic cleavage of the phosphate group. In general, proteases have been subjected to 
ABPP by using probes with a reactive group (such as an epoxide or a phosphonate 
electrophile)44,45 linked to a known peptide substrate, which is then linked to a tag unit. 
Ligand-Directed Affinity Labeling 
 Another promising strategy for the labeling and modification of endogenous proteins is 
ligand-directed affinity labeling.36,46 This strategy, pioneered by the Hamachi lab, involves the 
use of high affinity ligands to bring a connected reactive group in close proximity to a 
nucleophilic amino acid residue on the protein. Ligand directed affinity labeling typically 
employs two types of chemical probes and can covalently modify a protein through one of two 
types of labeling mechanisms. One type of probe has a high affinity ligand (typically for an 
enzyme) connected through a spacer to electrophilic reactive group which is connected to a tag 
unit (fluorophore, pulldown handle, etc.).15,36,46–49 The second type of probe has the high affinity 
ligand connected through a linker to a catalyst that activates a particular amino acid functional 
group on the protein and requires the use of a secondary probe to label the protein with a tag 
unit.50,51 In terms of labeling mechanisms, one possibility is to design probes where the entire 
probe remains tethered to the protein target after covalent reaction with the reactive group. 
However, this results in inhibition of the protein or enzyme. Another possibility is a traceless 
approach where reaction of a nucleophile on the protein with the probe installs the tag unit and 
displaces the high affinity ligand. The second labeling mechanism is often preferred as it allows 
an enzyme to be labeled with a unique tag unit without permanently inhibiting the activity of the 
enzyme. One of the most widely explored chemistries for ligand directed affinity labeling is 
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ligand-directed tosylate (LDT) chemistry where a ligand for the protein is linked to tag unit 
through a tosylate reactive group which reacts via an SN2 type mechanism.46,52 LDT probes have 
been used label endogenous proteins in live cells and have successful been used to re-engineer 
proteins to serve as reporters of protein-protein interactions.53–55 The Hamachi lab has also 
developed several other chemistries including ligand-directed acyl imidazole labeling,47 affinity 
guided DMAP (AGD) catalysis,50 and ligand-directed dibromophenyl benzoate (LDBB) 
labeling.48 LDAI has been applied to the labeling of both intracellular and cell surface protein 
targets and has been used to engineer light-activatable caged enzymes.56 AGD has been used to 
label cell surface protein receptors in a highly efficient manner, while LDBB has been applied to 
site-selective labeling of purified proteins and intracellular protein targets. 
 Others have also developed ligand-directed affinity labeling approaches that rely on an 
SN2 type mechanism. Fenical and co-workers developed ligand-directed acyl phenol probes in 
order to elucidate the intracellular target of a marine natural product.49 Following a similar goal 
of validating a drug target, the Kakeya group has also prepared 5-sulfonyl tetrazole probes of 
cyclosporine A to label cyclophilin A intracellularly.57 
 Ligand-directed affinity labeling chemistries based on other reaction mechanisms have 
also been developed. The Sodeoka group developed a SNAr approach using probes with high 
affinity ligands attached to a bifunctional O-aryl nitrobenzoxadiazole (ONBD).58 Since the 
ONBD probe is dark and the NHNBD probe is fluorescent, reaction of the probe with a 
nucleophilic lysine that is close proximity produces a turn-on fluorescence response (Figure 1.2). 
Another creative ligand-directed labeling approach was developed by the Nakamura lab where 
single electron transfer catalysts were used for chemical modification of proteins.51 Probes 
containing a high affinity ligand were linked to a ruthenium tris(bipyridine) catalyst were used to 
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react with tyrosine residues to form a reactive tyrosyl radical, which can be trapped with a 
phenylenediamine tag unit to produce a carbon-carbon bonded conjugate. 
 
 
Figure 1.2. Ligand-directed ONBD chemistry. Reproduced with permission from Elsevier: 
Tetrahedron Lett., 2015, 56, 2130. https://doi.org/10.1016/j.tetlet.2015.03.065. This article is 
published under the terms of the Creative Commons Attribution-NonCommercial-No 




CHAPTER 2. Approaches for Detection of Histone Post-Translational Modifications 
 
DNA Organization and Chromatin Structure 
 DNA, commonly referred to as the blueprint of life, provides the genetic information 
necessary to construct every component of the cell and to regulate all functions necessary for life 
including cell growth, differentiation, and homeostasis. Over 223 million base pairs of DNA are 
contained within the largest human chromosome (chromosome 1).59 If the DNA in chromosome 
1 were extended out linearly, it would be close to 80 millimeters long.60 In addition, each cell 
contains around 6 billion base pairs of DNA; if all the DNA in a single cell was measured from 
end to end, it would correspond to a length of 2 meters.61 Since the average eukaryotic nucleus is 
only 6 micrometers in diameter, there must exist some way to package the DNA into smaller, 
higher order units so that it will fit inside the nucleus of the cell. This packaging and organization 
is accomplished through the use of chromatin. Each chromosome is made up of chromatin, and 
each unit of chromatin is made up of fundamental repeating units called nucleosomes. A 
nucleosome consists of 146 base pairs of DNA wrapped around eight proteins called 
histones.62,63 Histones are a group of highly positively charged proteins that bind and coil 
negatively charged DNA around themselves. There are four core histone proteins: H2A, H2B, 
H3, and H4. Two units of each core histone protein dimerize to form an octamer around which 
146 base pairs of DNA wrap.64 Histone H1 serves as a linker between nucleosomes and stabilizes 
the higher order structure of chromatin.65 The structure of each nucleosome can be thought of as 
a thread and spool, where the DNA is the thread that is tightly wound around the histone spool. 
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The nucleosomes fold on top of one another in a tight coil to form a fiber of chromatin that is 30 
nm in diameter.65 These packed chromatin fibers then form 300-nm long loops, which are folded 
even further to form a fiber that is 250 nm in width.66 This 250-nm wide fiber is wound tightly to 
create a single chromatid of the chromosome. The chromosome itself is 1400 nm wide, which 
can be efficiently packaged within the eukaryotic nucleus.66 
 
 
Figure 2.1. Packaging of chromosomal DNA by winding around histone proteins. Reproduced 




Covalent Modification of Histone Proteins 
 The higher order folding of nucleosomes into tightly coiled fibers leads to a form of 
chromatin called heterochromatin.67 In this form of chromatin, there is tight association between 
DNA and the histone proteins which blocks enzymes and transcription factors from binding to 
the DNA and prevents transcription from taking place. One of the primary ways by which the 
DNA is made accessible for transcription is through covalent (most commonly enzymatic) 
modification of the histone proteins. These modifications, referred to as post-translational 
modifications or PTMs, occur after translation from the ribosome and provide a form of 
epigenetic control since it is independent of DNA sequence.67 Each of the four core histones also 
contain unstructured peptide tails that extend from their globular domain. These unstructured 
tails can be chemically modified in order to alter the structure of chromatin and the accessibility 
of DNA within the gene complex. Some PTMs can lead to a state of chromatin called 
euchromatin where the DNA is partially dissociated from the histone complex allowing 
transcription factors to bind and transcription to occur.67 
 A wide variety of covalent modifications are made to amino acids on the tails of histone 
proteins including methylation,2 acetylation,3 phosphorylation,4 ubiquitination,5 and 
glycosylation.6 The process of post-translational modification can be thought of in terms of 
writers, erasers, and readers. Writers are the enzymes (methyltransferases, acetyltransferases, 
kinases, ubiquitin ligases) responsible for installing the covalent mark, while erasers are the 
enzymes (demethylases, deacetylases, phosphatases, deubiquitinases) that remove the PTM. 
Readers refer to the proteins that contain a domain that allows the protein to bind to a PTM or a 
pattern of PTMs in order to manipulate the structure of chromatin and affect gene expression. 
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 Histone PTMs are often categorized are being either activating or deactivating (or 
silencing). Histone H3 is the most extensively modified, and many of the marks have been well 
characterized. Expectedly, the majority of lysine acetylations and arginine citrullinations are 
activating, as the positive charge on the histone is reduced; this reduces the electrostatic 
interaction with the negatively charged DNA leading to dissociation from the gene complex. In 
addition to neutralizing charge, acetylated Lys also plays an active role in controlling gene 
expression via recognition by bromodomain reader proteins, which are part of larger protein 
complexes involved in transcription.68 Methylation of lysine and arginine can be activating or 
repressive. Lysine has three methylation states: monomethyllysine (Kme), dimethyllysine 
(Kme2), and trimethyllysine (Kme3); arginine also has three methylation states: 
monomethylarginine, symmetric dimethylarginine (SDMA), and asymmetric dimethylarginine 
(ADMA). One of the hallmarks of active transcription is trimethylation of H3K4 (the lysine in 
the fourth position of histone H3), a mark that leads to the formation of euchromatin through the 
recruitment of chromosome remodeling proteins like CHD1 and BPTF.69,70 Conversely, 
H3K9me3 is the trademark of repressive histone PTMs. This mark binds to heterochromatin 
protein 1 (HP1) and stabilizes the heterochromatin structure, which silences gene transcription.71 
For methylated arginine, active marks include H3R17me2a, H3R26me2a, H4R3me2a, and 
H2AR3me2a, while inactivating marks include H3R2me2a, H3R8me2s, H4R3me2s, and 
H2AR3me2s.72,73 
 Histone phosphorylation and ubiquitination also play important roles in controlling 
chromatin structure and regulating important nuclear processes. Several phosphorylation marks 
on histone H3 (H3S10, H3T11, and H3S28) have been found to coincide with histone acetylation 
and are thereby associated with activation of gene transcription.4 Phosphorylation of H3S10, 
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H3S28, and H2AT120 are key PTMs for mitosis as they serve as the driving force for the 
compaction and condensation of chromatin during division of the nucleus.74 Histone 
phosphorylation also plays a role in DNA repair as the H2AXS139ph mark is involved in 
recruiting DNA damage repair proteins to repair double-strand DNA breaks.75 Similar to 
phosphorylation, histone ubiquitination (such as polyubiquitination of H2AK36) also plays a role 
in DNA damage repair.5 Ubiquitination is also a mechanism by which gene transcription can be 
regulated. Monoubiquitination of K119 on H2A is involved in repressing transcription while 
monoubiquitination of K123 on H2B is transcriptionally activating.5 
 
Aberrant PTMs and Disease 
 Histone post-translational modifications are crucial for the normal development and 
function of cells and tissues. When normal processes involving PTMs become dysregulated 
(such as overexpression or mutation of the enzymes involved in installing or removing a 
modification), the effects are often deleterious. Many cancers are characterized by the disruption 
of natural epigenetic regulatory mechanisms. For example, loss of acetylation at H4K16 and 
trimethylation at H4K20 and commonly observed across many cancer cell lines including colon, 
breast, and lung cancer cell lines.76 Additionally, aberrant methylation of arginine residues is 
involved in blood cancers. More specifically, increased asymmetric dimethylation of H4R3 by 
the enzyme PRMT1 leads to overexpression of various oncogenes that are implicated in acute 
myeloid leukemia.77 Several neurological disorders also arise from dysregulation of histone 
PTMs. Hypertrimethylation of H3K9 and histone hypoacetylation are observed in patients with 




Current Methods to Detect Histone PTMs 
 The importance of histone PTMs in regulating various biological functions (including 
gene transcription, modification of chromatin structure, and DNA repair) and their role in the 
progression of many diseases necessitates the development of robust and sensitive tools for their 
detection. Currently, antibodies are the workhorse for many of the techniques used in the 
detection of histone post-translational modifications, with over one thousand antibodies with 
specificity for histone PTMs available for commercial use.79 The most commonly used methods 
for detection of histone PTMs are western blotting and mass spectrometry-based (MS-based) 
proteomics. In the analysis of PTMs from cellular samples, both methods typically require an 
enrichment step prior to analysis since many post-translational modifications are present in very 
low natural abundance. This enrichment is accomplished using techniques such as 
immunoprecipitation (IP), ionic interaction, or chemical derivatization.80 For IP, antibodies that 
bind to a specific PTM are immobilized on a solid support such as agarose beads. The cell lysate 
is then incubated with the affinity beads. Any proteins that do not contain the PTM of interest are 
washed off, and afterwards the desired modified protein is isolated. An affinity enrichment 
strategy used specifically for phosphopeptides is immobilized metal affinity chromatography 
(IMAC), which is based on the ionic interaction of the phosphate group for iron ions.81 Resin 
with immobilized Fe(III) is used to pulldown phosphopeptide by ion exchange and coordination 
to the iron. Chemical derivatization-based enrichment has been used for analysis of glycosylated 
peptides. Oxidation of the carbohydrate residues using sodium periodate generates aldehydes and 
allows the peptide or protein to be immobilized using hydrazide functionalized beads.82 The 
glycopeptide or glycoprotein can finally be release from the resin via enzymatic reaction. After 
enrichment of the peptide or protein of interaction, analysis can be performed using Western 
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blotting or MS-based proteomics. For Western blotting, the sample is subsequently separated by 
SDS-PAGE and subjected to immunostaining to visualize proteins containing the PTM. For MS 
proteomics, a bottom-up workflow is generally used. After PTM-specific protein enrichment by 
IP, the protein is digested into smaller peptide fragments using enzymes that predictably cleave 
after certain residues. The peptide fragments are then separated using reversed-phase HPLC 
before analysis by MS/MS.  
Both Western blotting and MS-based proteomics have several advantages for use in 
detecting PTMs. Western blotting has the benefit of being a very commonplace technique in 
biology that does not require any special equipment or expertise; MS-proteomics is a powerful 
detection method that offers the potential for unbiased, site-specific identification of histone 
PTMs.83 In spite of these advantages, both methods have limitations. Some of these limitations 
are related to the use of antibodies in either the enrichment step (for proteomics) or in the final 
detection step (for Western blotting). Antibodies are often too sequence specific and may not 
recognize its target if there is a neighboring PTM which can lead to false negatives.84 Batch-to-
batch variability of antibody affinity and specificity is another common complication.85 
Additionally, the is no universally approved method for validating antibody, and an antibody that 
works well for one application may not work well in another application.86 Western blotting 
suffers from the fact that it does not allow for the site of modification to be determined when 
pan-specific antibodies are used. For MS-based proteomics, the requirement of a mass 
spectrometer and expertise in operation of the spectrometer can be limiting factors. Also, 
extensive sample purification, enrichment, and preparation are essential for detecting low-
abundant PTMs by MS.87 Use of antibodies for enrichment often results in contamination of the 
sample with antibody fragments due to the harsh conditions needed to release the bound 
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peptides.83 Furthermore, analytical challenges that arise from issues like poor ionization and 
solubility may hinder detection of a PTM by MS. Lastly, MS is low throughput. 
 As a complement to Western blotting and MS-based proteomics, several methods based 
on chemical labeling have been developed for detecting histone PTMs. Direct covalent 
modification of citrulline has been developed to characterize citrullination using a 
phenylglyoxal-based probe.88 Incubation of peptides or proteins containing citrulline with the 
Rhodamine-conjugated-phenylglyoxal probe results in a chemoselective cyclization to form an 
imadazol-2-one adduct. The labeled targets can be visualized by in-gel fluorescence SDS-PAGE. 
For detecting methylated lysine by chemical means, a popular approach has been to engineer 
methyltransferase enzymes to accept unnatural S-adenosylmethionine (SAM) analogues in order 
to transfer alkynes or azides instead of methyl groups. Bertozzi and Gozani developed an alkyne-
containing SAM cofactor capable of transferring an alkyne to substrates of a lysine 
methyltransferase.89 After completion of the enzymatic reaction, click chemistry was label the 
alkyne-tagged protein with a FLAG tag. The Luo group improved on this approach by preparing 
a Se-Adenosyl-L-selenomethionine cofactor that has greater stability under physiological 
conditions.90 Luo and colleagues also generated azide-containing SAM analogs for biorthogonal 
profiling of protein methylation.91 
The development of small molecule receptors for the recognition of PTMs presents several 
advantages that could augment strategies using antibodies and mass spectrometry-based 
proteomics. Small molecules have much lower cost of production when compared to antibodies 
and can be synthesized reliably and reproducibly. Receptors of this kind also have the potential to 
bind to a PTM of interest in a non-sequence-specific manner due to its small size.  
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Several small molecule receptors that bind methylated lysine and arginine have been prepared 
using traditional rational design. One of the first reports92 came from the Hof group who have 
developed several receptors based on a p-sulfonatocalix[4]arene receptor that bind Kme3 with 
low micromolar affinity.93 More recently, tetracyanoresorcin[4]arene cyclophanes have been 
synthesized by Hamilton and co-workers that also bind to Kme3 with similar affinities as the 
calixarene receptors.94 Cucurbiturils have also been shown to bind methylated lysine (CB-6) and 
methylated arginine (CB-7).95 
The Waters lab has also developed small molecule receptors for methylated lysine and 
arginine by using a selection approach called dynamic combinatorial chemistry (DCC).96–99 In 
developing small molecule receptors for molecular recognition of PTMs, a selection approach 
provides an advantage over traditional rational design as it allows evolution to determine the best 
receptor. DCC is an effective selection approach first reported by Otto and Sanders that can be 
used to select the best receptor for a guest from a library of receptors.100,101 This technique allows 
macrocyles to be created from reversible exchange reactions of monomers under equilibrium 
conditions. If a guest with a PTM of interest is introduced in a DCC library (DCL), a host that 
forms favorable binding interactions with guest may be amplified. Rigid monomers with 
aromatic groups for molecular recognition through cation-π interactions, carboxylates for water 
solubility, and thiols for reversible disulfide exchange were used to generate mercaptophanes 
capable of binding methylated lysine and arginine with high affinity and impressive selectivity 
over unmethylated lysine. 
Several of these receptors have been applied toward the development of new 
supramolecular methods for detecting PTMs.  Hof, Waters, and Hooley have used synthetic 
receptors to create sensor array platforms for pattern recognition of combinations of PTMs on 
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histone peptides (known as the histone code).102–104 The sensor array platforms are based on 
indicator displacement assays, where a small molecule receptor binds and quenches the 
fluorescence of a dye, and addition of a PTM-containing histone peptide displaces the dye which 
generates a turn-on fluorescence response. Small molecule receptors have also been used to 
create affinity reagents for enrichment applications. The Hof group has developed a 
supramolecular affinity chromatography approach where a calixarene receptor that binds 
methylated lysine is attached to a solid support. This approach generates “methyl affinity 
columns” that can enrich methylated peptides from a mixture of enzymatically digested 
proteins.105 The Kanai group has also utilized small molecule receptors for affinity enrichment 
by synthesizing a multivalent calixarene-based affinity reagent that contains a biotin handle. The 
affinity reagent was able to pull-down methylated histone peptides, which could be detected 
through Western blotting.106  
 
Significance of This Work 
Significant progress has been made over the past decade in the detection of post-
translational modifications as there has been substantial improvements in proteomic mass 
spectrometry and methods involving antibodies. However, the challenges and limitations that are 
still faced by antibodies and MS-based proteomics highlight the need for alternative approaches 
such as chemical derivatization and small molecule receptors. Chemical methods for selective 
detection of peptides and proteins containing PTMs are still lacking. The research detailed in this 
dissertation expands the toolkit available for detection of three important histone PTMs: 
trimethyllysine, acetylated lysine, and dimethyllysine. Chapter 3 describes the detection of 
trimethyllysine using an approach termed supramolecular affinity labeling that combines 
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molecular recognition by a small molecule receptor with chemical derivatization. Detection of 
acetylated lysine is presented in Chapter 4 with the detection of histone deacetylase (HDAC) 
activity using a supramolecular affinity labeling probe. Finally, the design and synthesis of new 
synthetic receptors for dimethyllysine and trimethyllysine using iterative redesign by dynamic 




CHAPTER 3. Supramolecular Affinity Labeling of Histone Peptides1 
Introduction and Significance 
Methylation of Lys and Arg in histone proteins is involved in many vital biological 
processes that regulate the dynamic structure of chromatin and alter the interactions of DNA with 
protein complexes. Accordingly, there is great interest in mapping out the epigenetic role of these 
post-translational modifications (PTMs) in development and disease.87,107,108 Two of the most 
established methods to detect post-translational modifications of proteins include antibodies and 
mass spectrometry-based proteomics. While these methods are staples of PTM research, both 
face challenges and limitations. Antibodies often exhibit high sequence specificity, which 
complicates the detection of unknown PTMs.86,109 Additionally, some antibodies suffer from 
irreproducibility from batch to batch and have been shown to have cross-reactivity with off-
target antigens.84 MS-based proteomics has been used to explore a number of PTMs including 
methylation of lysine and arginine110–113, acetylation of lysine114,115, and phosphorylation of 
serine and threonine116. However, MS analysis is expensive and time consuming and can be 
complicated by analytical challenges including low natural abundance of PTMs, the presence of 






1 Reprinted (adapted) with permission from Gober, I. N.; Waters, M. L. J. Am. Chem. Soc. 2016, 
138, 9452–9459. Copyright (2016) American Chemical Society. 
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Innovative tools for detecting PTMs would augment existing detection methods and 
expand the chemical tool kit available for epigenetics research. New chemical methods have the 
potential to further our understanding of how these modifications regulate gene expression and 
how the PTMs themselves are regulated. Several non-covalent, supramolecular approaches have 
been developed using small molecule receptors for recognition of PTMs. Calixarenes,102 
mercaptophans,103 and cavitands104 have been used to create sensor arrays that are based on an 
indicator displacement scheme. In this scheme, a small molecule receptor binds and quenches the 
fluorescence of a dye, and addition of a guest (i.e. PTM-containing analyte) displaces the dye 
which generates a turn-on fluorescence response. Others have developed chemical approaches 
based on site-selective covalent labeling of proteins or peptides containing PTMs88,90 For 
example, direct covalent modification of citrulline has been developed to characterize 
citrullination.88  For trimethyllysine, indirect labeling methods are needed since it cannot be 
directly covalently labeled.  A popular approach has been to engineer methyltransferase enzymes 
to accept unnatural SAM analogs in order to transfer alkynes89 or azides91 instead of methyl 
groups, but this approach introduces additional challenges, such as differences in enzyme 
activity, cross-reactivity with native SAM, and validation of native substrate scope.  
Taking inspiration from ligand-directed affinity labeling chemistries developed by 
Hamachi et al.52,50,47 that demonstrate that high-affinity ligands with cleavable linkers can be 
used to promote traceless labeling of their target proteins, we looked to reverse the paradigm and 
use synthetic receptors92,96,93,97 to direct affinity labeling of histone peptides containing the PTM 
trimethyl lysine (Kme3) (the ligand). Herein we transform a synthetic receptor for Kme3 into a 
chemical probe capable of selective turn-on fluorescence labeling of histone peptides containing 
Kme3, resulting in the first example, to our knowledge, of a synthetic receptor-mediated affinity 
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labeling reagent. In our labeling scheme, receptor binding to Kme3 places the electrophile in 
close proximity to a nucleophilic lysine on the target peptide, facilitating covalent labeling 
(Figure 1). We also demonstrate the utility of this labeling strategy in the development of a turn-
on fluorescence assay for screening inhibitors of histone deacetylase activity (Chapter 4). This 
work represents the first example of synthetic-receptor directed affinity labeling and provides 
impetus for the use of synthetic receptors as agents for site-selective chemical modification of 
proteins mediated by PTMs. 
 
 
Figure 3.1. Turn-on fluorescence affinity labeling of a histone Kme3 peptide using a CX4-
ONBD probe 
 
Design and Synthesis of a Probe for Labeling for Kme3 
Analysis of histone sequences reveals that most known sites of Lys trimethylation contain 
another Lys 4-5 residues away, with a small number consisting of larger spacing between Kme3 
and a neighboring Lys.118 This pattern suggests that binding of a synthetic receptor to Kme3 
brings it into close proximity of a nucleophilic residue, such that an affinity-labeling strategy is 
feasible. With the goal of preparing affinity probes capable of selective covalent labeling of 
histone peptides containing both Kme3 and a pendant unmethylated lysine, we designed a probe 
that features a synthetic receptor for Kme3 conjugated via a short flexible linker to a fluorogenic 
nitrobenzoxadiazole (NBD) group. For the synthetic receptor, we chose a tri-sulfonated calix-[4]-
 
24 
arene (CX4-Ar) receptor first reported by the Hof group93 that shows preferential binding to 
trimethyl lysine over lower methylation states of lysine. An O-aryl NBD group was incorporated 
as a tag unit to allow for turn-on fluorescence labeling.  In this labeling chemistry58 developed by 
the Sodeoka lab, the ONBD unit serves as both an electrophilic site and a tag unit that selectively 
reacts with amines (i.e. lysine) with release of the receptor, leading to traceless fluorescent 
labeling of the target protein or peptide. 
We prepared the CX4-ONBD probe 5 by assembling three separate components:  
propargyl ONBD compound 1, CX4-Ar receptor 2, and amino-azide linker 3 (Scheme 1). First, 
the alkyne functionalized NBD compound 1 was prepared by treating NBD chloride with 
propargyl alcohol in the presence of tertiary amine base. The synthetic receptor 2 was prepared 
with minor alterations to published procedure.93 Likewise, the flexible amino-azide linker 3 was 
prepared according to previously reported procedure119 starting from tetraethylene glycol. After 
preparing each of the three components, tri-sulfonated CX4-Ar receptor 2 was functionalized 
with linker 3 using carbodiimide coupling to produce azide-functionalized 4. Finally, copper 
catalyzed azide-alkyne cycloaddition (CuAAC)120 was used to conjugate alkyne 1 to azide 4, 




Scheme 3.1. Synthesis of CX4-ONBD Probe 
 
Characterization of Binding by Isothermal Titration Calorimetry  
Previously reported binding studies93 of 2 indicate that the receptor has favorable binding 
to Kme3 in the context of a histone peptide (H-ARTKQTARKme3STGY-NH2), with a Kd of 
0.19 µM in 10 mM phosphate buffer at pH 7.4 and 25 oC.121 To determine whether covalent 
modification of this receptor influences binding, we measured the binding affinity of the CX4-
ONBD probe 5 with a histone 3 (H3) peptide containing Kme3 (Table 1) using isothermal 
titration calorimetry (ITC). Peptides were synthesized with an N-terminal WGG unit to facilitate 
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calculation of peptide concentration by measuring absorbance at 280 nm.  K9me3R14 was used 
in ITC experiments with 5, where the lysine at position 14 was substituted for an arginine to 
prevent covalent labeling over the course of the ITC experiment without changing the overall 
charge of the peptide. Under phosphate buffer conditions at pH 7.4 with no added salt (Table 1 
and Table 2, Entry 1), the CX4-ONBD probe had a Kd of 4.8 µM for K9me3R14. While most 
examples of ligand-directed affinity labeling typically take advantage of ligands with 
submicromolar or nanomolar binding to their targets, it has been demonstrated that micromolar 
affinity interactions can provide an increase in effective molarity that is satisfactory for 
proximity-driven labeling.122 Thus, we proceeded with evaluation of probe 5 as an affinity 
labeling probe. 
Table 3.1. Peptides Used for ITC, Fluorescence Labeling, and Deacetylase Activity Screening 












Table 3.2. Binding and Thermodynamic Data from ITC Experiments of 5 and 4 with K9me3K14 
and K9K14 
 
Entry Host Peptide Charge Kd ΔG (kcal/mol) 
1a 5 K9me3R14 +3 4.8 ± 1.5 −7.3 ± 0.2 
2b 4 K9me3K14 +3 18.3 ± 7.7 −4.9 ± 0.6 
3b 4 K9K14 +3 >390  
 
a 10 mM potassium phosphate, pH 7.4. Two trials using 82 µM probe 5 and 1.22 mM 
K9me3R14; One trial using 81 µM probe 5 and 1.03 mM K9me3R14. b 10 mM sodium borate, 
100 mM NaCl, pH 8.6. Three trials using 85 µM probe 4 and 0.93 mM K9K14. Two trials using 
85 µM probe 4 and 1.11 mM K9me3K14; One trial using101 µM probe 4 and 1.43 mM 
K9me3K14. 
 
Optimization of Receptor-Mediated Labeling 
To evaluate the reactivity of 5 toward histone peptides, the probe was incubated with 
either K9me3K14 or K9K14 in 10 mM potassium phosphate buffer (pH 7.4) at room temperature 
for 24 h (Table 3). The labeling reactions were analyzed by HPLC (See Experimental). Initially, 
concentrations well above the Kd were chosen for both probe and peptide to ensure complete 
host-guest complexation. Reaction yields after 24 h revealed slow reactivity of the CX4-ONBD 
probe toward the representative histone peptides with modest 2:1 selective labeling for 
K9me3K14 over K9K14 (29% and 12% labeling yield, respectively). Since the O-aryl NBD 
group is known to be more reactive toward amine nucleophiles at higher pH,58 the slow reactivity 
for our system could be attributed in part to the extent of protonation at pH 7.4 of the -amino 
group of the lysine residues in the histone peptides. Expectedly, increasing the pH of the buffer 
used in the labeling reaction to 8.6 resulted in a marked rate acceleration. Unfortunately, this rate 
acceleration was accompanied by a complete loss in labeling selectivity for K9me3K14 over the 
K9K14 peptide (75% and 70% labeling yield, respectively).   
To circumvent the issue of unselective labeling, we screened conditions with different 
concentrations of NaCl, as the concentration of salt in aqueous solutions is known to influence 
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the strength of electrostatic interactions involved in host-guest complexation.123 Varying NaCl 
concentration from 50 mM to 150 mM revealed two general trends: the overall labeling yield 
decreases slightly at higher concentrations of salt, while selectivity for K9me3K14 over K9K14 
improves with increasing salt. Finally, we looked to improve selectivity further by lowering the 
concentration of both probe and peptide. Under conditions containing 40 µM probe and 20 µM 
peptide, the labeling selectivity improved to nearly 6-fold for K9me3K14 over K9K14. Also, 
despite micromolar binding and high salt concentration, the labeling rate for the reaction is 
appreciable even at lower concentrations of reagents, and the rate compares favorably to ligand-
directed affinity labeling approaches.52,47,48  
To determine the binding selectivity for Kme3 over unmethylated lysine under these 
optimized conditions, we used azide-functionalized receptor 4 as a surrogate for the CX4-ONBD 
probe as the azide is unreactive toward lysine-containing peptides during the ITC experiment. 
Additionally, 4 would not be expected to have binding interactions that are considerably different 
from 5 since the differences in functional groups between the two compounds are not close to the 
binding pocket. In 10 mM borate buffer with 100 mM NaCl (pH 8.6), receptor 4 exhibited about 
20-fold selectivity for K9me3K14 over K9K14 with dissociation constants of 18.3 µM and 390 
µM, respectively (Table 2, entries 2 and 3). This suggests that the affinity labeling is not 
achieving the maximum selectivity possible.  Several factors likely contribute to this, including 
the flexibility of the linker that reduces the degree of pre-organization as well as the fact that the 




Table 3.3. Optimization of Labeling Reaction Conditions of CX4-ONBD Probe 5 with H3 
Peptides 
 
Peptide Conditions a,b Probe:peptide (μM) Labeling yield (%)c 
K9K14 pH 7.4a 100:100 12 
K9me3K14 pH 7.4a 100:100 29 
K9K14 pH 8.6b 100:50 70 
K9me3K14 pH 8.6b 100:50 75 
K9K14 pH 8.6, 50 mM 
NaClb 
100:50 59 
K9me3K14 pH 8.6, 50 mM 
NaClb 
100:50 82 
K9K14 pH 8.6, 100 mM 
NaClb 
100:30 28 
K9me3K14 pH 8.6, 100 mM 
NaClb 
100:30 68 
K9K14 pH 8.6, 150 mM 
NaClb 
100:30 22 
K9me3K14 pH 8.6, 150 mM 
NaClb 
100:30 65 
K9K14 pH 8.6, 100 mM 
NaClb 
40:20 11 




a10 mM potassium phosphate, pH 7.4. b10 mM sodium borate, pH 8.6. cYield is based on 
integration of the peaks in the HPLC trace; error is estimated at ±10% of the listed value for each 
entry. 
 
Turn-On Fluorescence Labeling of Kme3 Peptides 
Next, we explored the turn-on fluorescent labeling of histone peptides by 5 by monitoring 
the fluorescence emission at 520 nm (excitation at 485 nm). Using optimized conditions of 40 
µM probe 5 and 20 µM peptide in 10 mM phosphate buffer (100 mM NaCl, pH 8.6), 
measurements were taken every hour, and reactions were allowed to proceed under ambient 
temperature for 24 h (Figure 2). A pronounced turn-on fluorescence response was observed for 
labeling of K9me3K14 with 5 (blue diamonds). On the other hand, the turn-on response for 
labeling with the K9K14 peptide (green triangles) was significantly lower, even though the 
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peptide contains two reactive lysine residues.  Trials with probe 5 alone appear to show only a 
slight increase in fluorescence signal over time, presumably due to slow hydrolysis of the O-
NBD group. 
 
Figure 3.2. Turn-on fluorescence labeling of K9me3K14 and K9K14 peptides with Probe 5. 
Conditions: 40 μM 5 and 20 μM peptide in 10 mM sodium borate buffer, pH 8.6, 100 mM NaCl. 
 
Fluorescence labeling experiments were also performed with Propargyl ONBD 1 as a 
negative control to examine the contribution of the synthetic receptor to probe design and 
function. Under the same optimized reaction conditions employed for labeling with 5, negative 
control 1 was allowed to react with K9K14 and with K9me3K14 for 24 h. Unlike probe 5, 
labeling with the negative control was slow and non-selective (see Experimental). Moreover, 
compound 1 reacted with K9K14 to a greater extent than with K9me3K14 as the former contains 
two reactive lysine residues rather than just one. These results are consistent with HPLC analysis 
of labeling and further confirm that preferential binding of the receptor to Kme3 over K directly 
translates into favored turn-on fluorescence labeling of Kme3 histone peptides. To further 
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confirm that the enhanced labeling rate of K9me3K14 by probe 5 is receptor mediated, a 
competition reaction was performed in which addition of K9me3R14, which can bind but not 
react with the probe, inhibited fluorescence labeling of K9me3K14 by probe 5 (see 
Experimental). 
To probe the distance-dependence of labeling, we also investigated the reaction of probe 
5 with biologically relevant histone peptides with varying numbers of amino acids separating the 
Kme3 binding site and the pendant reactive amine: K23K27me3 (three amino acids), 
K36me3K37 (zero amino acids), K4me3 N-terminus (two amino acids), K4me3K9 (four amino 
acids), and K27K36me3 (eight amino acids). Reactions were performed using 40 µM 5 and 20 
µM peptide in 25 mM bicine buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, pH 8.02). 
Fluorescence measurements were taken after 24 h. Probe 5 reacted with K4me3K9 to the greatest 
extent, suggesting a preference for a spacing of four amino acids between Kme3 and the reactive 
amine (Figure 3). In contrast, K36me3K37 and K27K36me3, the two peptides with the shortest 
and longest spacing, respectively, showed considerably slower labeling. Interestingly, the peptide 
containing K4me3 and a free N-terminal amine (with a spacing of 2 amino acids) was the second 
most reactive in the series of peptides that were screened. This may be explained in part by the 
increased acidity of the alpha amino group relative to the Ɛ amine of the lysine sidechain, making 
it a better nucleophile at pH 8. Unexpectedly, probe 5 reacted with K23K27me3 (three amino 
acid spacing) the slowest, indicating that there may be subtleties in sequence and binding 
conformation that affect labeling rate in addition to amino acid spacing. While these results show 
some dependence on distance, all sequences tested gave a turn-on fluorescence response which 




Figure 3.3. Analysis of distance dependence in the labeling of histone peptides by probe 5. 
Conditons: 40 µM 5 and 20 µM peptide in 25 mM bicine, 137 mM NaCl, 2.7 mM KCl, 1 mM 
MgCl2, pH 8.02, 24 h. 
 
Conclusions 
Herein we have described the development of a synthetic receptor probe for affinity 
labeling of Kme3-containing histone peptides, providing a turn-on fluorescence signal for the 
presence of Kme3. To our knowledge, this is the first example of a labeling method using a 
synthetic receptor as an affinity labeling probe. We found that the rate and selectivity of the 
labeling reaction was considerably dependent on buffer pH, salt concentration, and reagent 
concentration. Using reaction buffer with slightly alkaline pH accelerated the labeling rate, while 
utilizing high salt concentration improved selectivity by minimizing non-specific electrostatic 
interactions between the probe and peptide. Labeling was further improved by selecting 
concentrations that maintained appreciable host-guest complexation while exploiting the weaker 
binding of the unmethylated histone peptide at lower concentrations. In the end, optimizing 
labeling conditions lead to selective covalent modification and turn-on fluorescence in the 

































































Synthesis of 1. 4-chloro-nitrobenzo[c][1,2,5]oxadiazole (0.100 g, 0.50 mmol, 1 equiv.) was 
dissolved in 5 mL CH2Cl2 under a nitrogen atmosphere. To this solution was added a mixture of 
propargyl alcohol (0.029 mL, 0.50 mmol, 1 equiv.) and DIPEA (0.087 mL, 0.50 mmol, 1 equiv.) 
in 5 mL CH2Cl2, and stirring was continued for 72 h. The solvent was removed under reduced 
pressure, and the crude product was purified by column chromatography (EtOAc/Hexanes 1:1) 
to give the product as a yellow-brown solid (0.053 g, 48%). 1H NMR (CDCl3, 400 MHz): 8.558 
(d, 1H, CH), 6.880 (d, 1H, CH), 5.129 (d, 2H, CH2), 2.720 (t, 1H, CH). MS (calculated): 242.02 
[M+Na+]. HRMS (observed, ESI+): 242.01701 [M+Na+]. 
 
 







Figure 3.5. High resolution mass spectrum of Compound 1. MS (calculated): 242.02 [M+Na+]. 
HRMS (observed, ESI+): 242.01701 [M+Na+]. 
 
Synthesis of 2. Compound 2 was synthesized according to published procedure93 on a 0.5 g scale 
but with a modified purification procedure. 5-bromo-25,26,27,28-tetrahydroxy-11-17-23-
trisulfonatocalix[4]arene (0.50 g, 0.067 mmol), PdOAc2 (0.003 g, 0.013 mmol), 
tetrabutylammonium bromide (0.0108 g, 0.034 mmol), Na2CO3 (0.027 g, 0.25 mmol), and 4-
carboxyphenylboronic acid (0.0112 g, 0.067 mmol) were dissolved in degassed H2O under an 
atmosphere of nitrogen. The reaction mixture was heated to reflux using an oil bath for 1h. After 
completion of the reaction, the aqueous solution was washed with DCM (3 x 20 mL) and EtOAc 
(3 x 25 mL). The aqueous solvent was removed under reduced pressure. The residue was taken 
up in MeOH/H2O (1:1), and palladium was removed by QuadraPure® TU resin. The resin (0.5 
g) was added to the solution and heated to reflux under nitrogen for 24 h. The mixture was 
filtered, and the solvent was removed under reduced pressure. The crude product was used 
without further purification. 
Synthesis of 3.  Compound 3 was prepared according to published procedure119. 
Synthesis of 4. EDC-HCl (0.087 g, 0.45 mmol, 2 equiv.) and N-hydroxysuccinimide (0.050 g, 
0.43 mmol, 2 equiv.) were added to a solution of 2 (0.176 g, 0.22 mmol, 1 equiv.) in 5 mL 
DMF/H2O (1:1) under a nitrogen atmosphere, and the mixture was stirred for 1 h. 3 (0.100 g, 
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0.46 mmol, 2.1 equiv.) was added, and the solution was allowed to stir at room temperature 
overnight. The solvent was removed under reduced pressure, and the resulting residue was used 
in the next step without further purification. 1H NMR (D2O, 600 MHz): 7.718 (d, 2H), 7.660 (d, 
2H), 7.587 (d, 2H),7.498 (d, 2H), 7.478 (s, 2H), 7.464 (s, 2H), 4.280 (d, 2H), 3.509-3.633 (m, 
12H), 3.321 (s, 2H), 3.052 (s, 2H), 2.765 (s, 2H), 2.263 (s, 2H), 1.787 (t, 2H). MS (calculated): 
983.18 [M-H], 1005.16 [M-2H+Na+], 491.09 [M-2H], 502.58 [M-3H+Na+]. HRMS (observed, 
ESI-) 983.17713 [M-H], 1005.15929 [M-2H+Na+], 491.08576 [M-2H], 502.57840 [M-3H+Na+]. 
 
 





























Figure 3.8. High resolution mass spectrum of Compound 4. MS (calculated): 983.18 [M-H], 
1005.16 [M-2H+Na+], 491.09 [M-2H], 502.58 [M-3H+Na+]. HRMS (observed, ESI-) 983.17713 
[M-H], 1005.15929 [M-2H+Na+], 491.08576 [M-2H], 502.57840 [M-3H+Na+]. 
 
Synthesis of 5: The crude residue containing 4 (0.037 g, 0.038 mmol, 1 equiv.) and 1 (0.049 g, 
0.22 mmol, 5.8 equiv.) were dissolved in 5 mL DMF/100 mM sodium acetate, pH 5.5 (4:1). 
Copper iodide (0.001 g, 0.005 mmol, 0.13 equiv.) was added, and the solution was allowed to 
stir at room temperature for 48 h. The solvent was removed under reduced pressure, and the 
resulting residue was purified by semi-preparative reversed-phase HPLC (solvent A: 10 mM 
NH4OAc in 9:1 H2O:CH3CN; solvent B: 10 mM NH4OAc in 9:1 CH3CN:H2O) using the 
gradient: 0-100% B from 0-60 min with a flow rate of 4.0 mL/min to produce the desired 
compound in 14% yield. 1H NMR (D2O, 600 MHz): 7.996 (s, 1H), 7.662 (s, 2H), 7.639 (s, 2H), 
7.264-7.295 (m, 4H), 7.104-7.128 (m, 5H), 6.630 (d, 1H), 5.167 (s, 2H), 4.502 (t, 2H), 3.841 (t, 
2H), 3.506-3.657 (m, 12H). MS (calculated) 1202.21 [M-H], 1224.18 [M-2H+Na+], 600.60 [M-
2H], 611.59 [M-3H+Na+]. HRMS (observed, ESI-) 1202.20580 [M-H], 1224.18764 [M-





Figure 3.9. Crude semi-preparative HPLC trace of 5 at 280 nm. 
 
 





































Figure 3.12. High resolution mass spectrum of compound 5 (ESI-). MS (calculated) 1202.21 
[M-H], 1224.18 [M-2H+Na+], 600.60 [M-2H], 611.59 [M-3H+Na+]. HRMS (observed, ESI-) 





Peptide Synthesis  
Peptides were synthesized on a 0.6 mmol scale via solid-phase peptide synthesis in a 
peptide synthesis flask using Fmoc protected amino acids. Coupling reagents were HOBt/HBTU 
in DMF (4 equiv each), with coupling times of 60 min, followed by rinsing with DMF, MeOH, 
and CH2Cl2.  Deprotection was performed with 20% piperidine in DMF. All peptides were 
acylated at the N-terminus with a solution of 5% acetic anhydride and 6% 2,6-lutidine in DMF. 
Cleavage was performed using a cocktail of 95% TFA/2.5% triisopropylsilane/2.5% H2O for 3 h. 
Peptides were purified by semi-preparative reverse-phase HPLC on a C18 column at a flow rate 
of 4 mL/min. Peptides were purified with a linear gradient of A and B (A: 95% H2O/5% CH3CN 
with 0.1% TFA, B: 95% CH3CN/5% H2O with 0.1 % TFA). 
Methylated peptides were synthesized with 2 equivalents of Fmoc-Lys(Me)2-OH HCl 
purchased from EMP Millipore and coupled for 5 h. The trimethyllysine containing peptides 
were synthesized by reacting corresponding dimethylated peptides (0.6 mmol scale) prior to 
cleavage from the resin with MTBD (7-Methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene, 10 equiv.) 
and methyl iodide (10 equiv.) in DMF (5 mL) for 5 h with bubbling nitrogen in a peptide flask. 
After washing the resin with DMF and CH2Cl2 and drying, the peptide was cleaved as normal. 
Acetylated peptides were prepared from 4 equivalents of Fmoc-Lys(ivDde)-OH purchased from 
Chem Impex with 1 h couplings. The ivDde group was deprotected using 5% hydrazine hydrate 
in DMF (3 x 10 mL) for 5 minutes. After washing resin with DMF, MeOH, and CH2Cl2, peptides 
were acetylated using a solution of 5% acetic anhydride and 6% 2,6-lutidine in DMF. Peptides 
















Figure 3.13. High resolution mass spectrum of K9 K14 (ESI +). MS calculated: 1374.73 [M+H], 







Figure 3.14. High resolution mass spectrum of K9me3 K14 (ESI +). MS calculated: 1416.77 










Figure 3.15. High resolution mass spectrum of K9me3 R14 (ESI +). MS calculated: 751.40 






Figure 3.16. High resolution mass spectrum of K4me3 K9 (ESI +). MS calculated: 730.90 






Figure 3.17. High resolution mass spectrum of K4me3 K9ac (ESI +). MS calculated: 751.91 









Figure 3.18. High resolution mass spectrum of K27 K36me3 (ESI +). MS calculated: 727.91 






Figure 3.19. High resolution mass spectrum of K27ac K36me3 (ESI +). MS calculated: 748.92 






Figure 3.20. High resolution mass spectrum of K23K27me3 (ESI +). MS calculated: 956.58 
[M], 1070.57 [M+TFA+H], 478.79 [M+H], 319.53 [M+2H]. MS observed: 956.57940 [M], 









 Figure 3.21. High resolution mass spectrum of K36me3K37 (ESI +). MS calculated: 1162.61 
[M+TFA+H], 524.81 [M+H], 350.21 [M+2H]. MS observed: 1162.60585 [M+TFA+H], 
524.81116 [M+H], 350.20994 [M+2H]. 
 




Figure 3.22. High resolution mass spectrum of K4me3 N terminus (ESI +). MS calculated: 






Figure 3.23. High resolution mass spectrum of K4me3 N terminus (ESI +). MS calculated: 
960.64 [M], 1074.63 [M+TFA+H], 480.82 [M+H]. MS observed: 960.64112 [M], 1074.62987 
[M+TFA+H], 480.82036 [M+H].  
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Extinction Coefficient Determination for 4. 
Compound 4 was purified using reversed phase-HPLC with 10 mM NH4OAc as the 
mobile phase additive. After purification, 4 was lyophilized for five days to remove volatile 
NH4OAc salts. The dried compound was then dissolved in anhydrous methanol and filtered using 
a 0.33 μm filter to remove any remaining salts. Methanol was evaporated and 4 was further dried 
under vacuum. The mass was accurately determined, and a 1 mM stock solution of 4 in 10 mM 
sodium borate buffer, 100 mM NaCl, pH 8.6 was prepared. The stock solution was serially 
diluted (80:20, 4:buffer) to give 12 concentrations. The absorbance at 315 nm was measured for 
each concentration, which was then plotted against the concentration. The extinction coefficient 
of 4 was determined from the slope of the line of regression using Beer’s law and was found to 




Figure 3.24. Extinction coefficient determination of 4 from the slope of the line of regression. 
  































Isothermal Titration Calorimetry 
 
ITC binding experiments were conducted using a Microcal AutoITC200. Titrations were 
performed at 25 oC in 10 mM potassium phosphate, pH 7.4 or 10 mM sodium borate, 100 mM 
NaCl, pH 8.6. The concentration of 5 was determined by measuring the UV–vis absorbance at 
373 nm, using a NanoDrop2000 with a xenon flash lamp, 2048 element linear silicon CCD array 
detector, and 1 mm path length. The concentration of 4 was determined from UV-vis absorbance 
at 315 nm. A solution of 0.9 – 1.2 mM of peptide was titrated into a 81-85 μM solution of 4 or 5, 
using 2.0 μL increments every 3 min. Heats of dilution (determined from separate runs where the 
peptide was titrated into the ITC buffer) were subtracted prior to fitting. Binding curves were 
produced using the supplied Origin software and fit using one-site binding models. 
 
Table 3.4. Summary of ITC data from using a one-site binding model. Values represent an 
average of 3 measurements. Errors are from standard deviation from three separate runs. 
 










5a K9me3R14 +3 
4.8 ± 
1.5 
-6.6 ± 0.4 6.6±2.9 1.03± 0.04 -7.3 ± 0.2 
4b K9K14 +3 
390 
±440 
- - 0.05 ± 0.05 - 
4b K9me3K14 +3 
18.3 ± 
7.7 
-4.9 ± 0.7 1.62 ± 0.9 
0.53 ± 
0.006 
-6.5 ± 0.2 
 
(a) 10 mM potassium phosphate, pH 7.4; (b) 10 mM sodium borate, 100 mM NaCl, pH 8.6 
N values that deviate from 1 are likely due to the error in concentration determination for 4, but 






Figure 3.25. Heat of dilution for titrating K9me3 R14 (1.22 mM) into 10 mM potassium 





Figure 3.26. One trial of three of K9me3 R14 (Ac-WGGQTARKme3STGGR-NH2) (1.22 mM) 





Figure 3.27. One trial of three of K9me3 R14 (Ac-WGGQTARKme3STGGR-NH2) (1.22 mM) 






Figure 3.28. One trial of three of K9me3 R14 (Ac-WGGQTARKme3STGGR-NH2) (1.03 mM) 







Figure 3.29. Heat of dilution for titrating K9K14 (Ac-WGGQTARKSTGGK-NH2) (1.43 mM) 





Figure 3.30. One trial of three of K9 K14 (Ac-WGGQTARKSTGGK-NH2) (1.43 mM) titrated 






Figure 3.31. One trial of three of K9 K14 (Ac-WGGQTARKSTGGK-NH2) (0.93 mM) titrated 







Figure 3.32. One trial of three of K9 K14 (Ac-WGGQTARKSTGGK-NH2) (0.93 mM) titrated 







Figure 3.33. Heat of dilution for titrating K9me3K14 (Ac-WGGQTARKme3STGGK-NH2) 





Figure 3.34. One trial of three of K9me3K14 (Ac-WGGQTARKme3STGGK-NH2) (1.43 mM) 





Figure 3.35. One trial of three of K9me3 K14 (Ac-WGGQTARKme3STGGK-NH2) (1.11 mM) 






Figure 3.36. One trial of three of K9me3 K14 (Ac-WGGQTARKme3STGGK-NH2) (1.11 mM) 





LCMS characterization of CX4-ONBD labeling of K9K14 and K9me3K14 
Reactions were analyzed by LCMS using a C18 column at a flow rate of 0.2 mL/min. 
Chromatographic separation was carried out using a 25-min linear gradient of solvent A (95% 
H2O, 5% CH3CN, and 0.1% formic acid) and solvent B (95% CH3CN, 5% H2O, and 0.1% formic 
acid). 
 




Figure 3.37. LCMS characterization of CX4-ONBD labeling of K9K14 and K9me3K14 
 (a) LCMS absorbance trace of the reaction of 100 µM 5 with 100 µM K9me3 K14 in 10 mM 
sodium borate buffer, pH 8.6 after 48 h. (b) MS analysis of the peak at ~8.25 min (unlabeled 
peptide). MS (calculated): 708.89 (M+2) [Unlabeled+1H], 472.93 (M+3) [Unlabeled+2H]. MS 
(observed, ESI+): 708.8926 (M+2) [Unlabeled+1H], 472.9329 (M+3) [Unlabeled+2H]. (c) MS 
analysis of the peak at ~9.75 min (labeled peptide). MS (calculated): 1579.77 (M+1) [Labeled], 













Figure 3.38. MS spectra of the reaction of 100 µM 5 with 100 µM K9 K14 in 10 mM sodium 
borate buffer, pH 8.6 after 24 h. (a) MS analysis of the peak at ~12.09 min (unlabeled peptide). 
MS (calculated): 687.87 (M+2) [Unlabeled+1H], 458.91 (M+3) [Unlabeled+2H]. MS (observed, 
ESI+): 687.86233 (M+2) [Unlabeled+1H], 458.91069 (M+3) [Unlabeled+2H]. (b) MS analysis 
of the peak at ~13.37 min (singly labeled).  MS (calculated): 769.37 (M+2) [Mono-Labeled+2H]. 
MS (observed, ESI+):  769.36277 (M+2) [Mono-Labeled+2H]. (c) MS analysis of the peak at 
~14.79 min (doubly labeled). MS (calculated): 850.88 (M+2) [Di-Labeled+2H]. MS (observed, 





HPLC Analysis of Labeling  
Reactions were analyzed by analytical HPLC using a C18 column at a flow rate of 1 
mL/min. Chromatographic separation was carried out using a 45 min linear gradient of solvent A 
(95% H2O, 5% CH3CN, and 0.1% TFA) and solvent B (95% CH3CN, 5% H2O, and 0.1% TFA). 




Figure 3.39. HPLC trace of the reaction of 100 µM 5 with 100 µM K9 K14 (top) or 100 µM 
K9me3 K14 (bottom) in 10 mM potassium phosphate buffer, pH 7.4 after 24 h showing labeled 
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Figure 3.40. HPLC trace of the reaction of 100 µM 5 with 50 µM K9 K14 (top) or 50 µM 
























6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00 21.00 22.00 23.00 24.00 25.00
5 + K9 K14 









Figure 3.41. HPLC trace of the reaction of 100 µM 5 with 50 µM K9 K14 (top) or 50 µM 
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Figure 3.42. HPLC trace of the reaction of 100 µM 5 with 30 µM K9 K14 (top) or 30 µM 
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Figure 3.43. HPLC trace of the reaction of 100 µM 5 with 30 µM K9 K14 (top) or 30 µM 
K9me3 K14 (bottom) in 10 mM sodium borate buffer, pH 8.6, 150 mM NaCl after 24 h showing 
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Figure 3.44. HPLC trace of the reaction of 40 µM 5 with 20 µM K9 K14 (top) or 20 µM K9me3 
K14 (bottom) in 10 mM sodium borate buffer, pH 8.6, 100 mM NaCl after 24 h showing labeled 
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Figure 3.45. HPLC trace of the reaction of 40 µM 1 with 20 µM K9 K14 (blue) or 20 µM 
K9me3 K14 (black) in 10 mM sodium borate buffer, pH 8.6, 100 mM NaCl after 24 h 































Kme3/K Competition Labeling Experiment 
To assess the ability of probe 5 to selectively label trimethylated peptides in the presence 
of a lysine-containing peptide, competition labeling experiments were conducted. 
RKme3GLLYK was used for the trimethylated peptide, and K9K14 was used for the unmodified 
lysine peptide. Two conditions were tested: one reacting 40 µM of 5 with a mixture of 20 µM 
RKme3GLLYK and 40 µM K9K14 and another reacting 40 µM of 5 with 30 µM 
RKme3GLLYK and 30 µM K9K14. Reactions were analyzed by analytical HPLC using a C18 
column at a flow rate of 1 mL/min. Chromatographic separation was carried out using a 100 min 
linear gradient of solvent A (95% H2O, 5% CH3CN, and 0.1% TFA) and solvent B (95% 




Figure 3.46. HPLC trace of a mixture of 40 µM K9K14 and 20 µM RKme3GLLYK in 10 mM 
sodium borate buffer, pH 8.6, 100 mM NaCl to provide a concentration reference. 
 
Table 3.5. Summary of peak integration data from HPLC trace of a mixture of 40 µM K9K14 
and 20 µM RKme3GLLYK. Error is estimated to be near 10%. 
 
 Retention Time Area % Area Height 
1 18.134 2210624 87.60 97325 
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Figure 3.47. HPLC trace of the reaction of 40 µM probe 5 with a mixture of 40 µM K9K14 and 
20 µM RKme3GLLYK in 10 mM sodium borate buffer, pH 8.6, 100 mM NaCl. After 24 h, 22% 
of K9K14 reacted with the probe while 59% of RKme3GLLYK was labeled by the probe. 
 
Table 3.6. Summary of peak integration and labeling data from the HPLC trace of the reaction of 
40 µM probe 5 with a mixture of 40 µM K9K14 and 20 µM RKme3GLLYK. 
 
 Retention Time Area % Area Height Percent of Peptide Labeled 
1 18.202 1725267 77.34 76903 22% 
2 21.065 127580 5.72 6488 59% 
3 23.080 215293 9.65 6974 - 




































Figure 3.48. HPLC trace of a mixture of 30 µM K9K14 and 30 µM RKme3GLLYK in 10 mM 
sodium borate buffer, pH 8.6, 100 mM NaCl to provide a concentration reference. 
 
Table 3.7. Summary of peak integration data HPLC trace of a mixture of 30 µM K9K14 and 30 
µM RKme3GLLYK. Error is estimated to be near 10%. 
 
 Retention Time Area % Area Height 
1 18.183 1689794 77.88 77563 
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Figure 3.49. HPLC trace of the reaction of 40 µM probe 5 with a mixture of 30 µM K9K14 and 
30 µM RKme3GLLYK in 10 mM sodium borate buffer, pH 8.6, 100 mM NaCl. After 24 h, 22% 
of K9K14 reacted with the probe while 64% of RKme3GLLYK was labeled by the probe. 
 
Table 3.8. Summary of peak integration data from the HPLC trace of the reaction of 40 µM 
probe 5 with a mixture of 30 µM K9K14 and 30 µM RKme3GLLYK. Error is estimated to be 
near 10%. 
 
 Retention Time Area % Area Height Percent of Peptide Labeled 
1 18.191 1324422 70.17 55268 22% 
2 21.088 174149 9.23 10016 64% 
3 22.958 192180 10.18 6424 - 








































Turn-On Fluorescence Labeling Control Experiments 
Fluorescence labeling experiments were performed in black 96 well optical bottom plates 
(non-treated, non-sterile, polystyrene) using a POLARstar Omega (BMG Labtech, Inc.) plate 
reader. A fluorescence optic with a 485 nm excitation filter and a 520 nm emission filter was 
used. Labeling reactions were carried out at ambient temperature, and Titer Tops® sealing film 
was used to prevent evaporation. Fluorescence intensity was measured every hour for 24 h. 
 
 
Figure 3.50. Turn-on fluorescence labeling negative control experiment. Labeling of 40 µM of 1 
alone (blue) or in the presence of 100 µM K9 K14 (red) or 100 µM K9me3 K14 (green) in 10 
mM potassium phosphate buffer (pH 7.4). Each data point represents an average of three runs. 

























1 + K9 K14






Figure 3.51. Turn-on fluorescence labeling competition experiment. 40 µM of 5 was reacted 
with 20 µM K9me3 K14 in the presence (red) or absence of 120 µM K9me3 R14 (blue) in 10 
mM sodium borate buffer (pH 8.6), 100 mM NaCl. Each data point represents an average of 






























CHAPTER 4. A Supramolecular Affinity Labeling-Based Turn-On Fluorescence Assay for 
Histone Deacetylase Activity1 
Turn-On Fluorescence Assay for HDAC Activity 
After establishing selective turn-on fluorescence labeling of a Kme3 histone peptide, we 
applied this labeling methodology toward the development of a chemical assay for histone 
deacetylase (HDAC) activity. HDACs play a crucial role in regulating chromatin structure and 
ultimately gene expression via removal of acetyl groups from the sidechains of acetylated lysine 
residues on histone tails.124,125 Generally, deacetylation of histones is associated with a 
condensed chromatin state and repression of gene transcription. Many HDACs function as part 
of multi-unit protein complexes and are implicated in processes ranging from cell differentiation 
to cell development.126,127 Expectedly, dysregulation of HDACs often has detrimental biological 
effects, in some cases promoting oncogenesis or the development of inflammatory disease.128,129 
Existing commercial kits for measuring HDAC activity predominantly rely on the use of 
a peptide or amino acid substrate with a C-terminal fluorogenic 7-amino-4-methylcoumarin tag 
directly linked to an acetylated lysine residue.130 Removal of the acetyl group by an HDAC 
allows trypsin to be used in a subsequent development step to cleave the C-terminal amide, 
releasing a fluorophore. While this method is convenient and widely used and HDACs generally 
lack significant in vitro sequence selectivity, it is nonetheless severely limited in substrate scope 
 
________________________ 
1 Reprinted (adapted) with permission from Gober, I. N.; Waters, M. L. J. Am. Chem. Soc. 2016, 
138, 9452–9459. Copyright (2016) American Chemical Society.  
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since the coumarin tag must be immediately adjacent to the acetyl lysine. Furthermore, when 
screening for novel HDAC inhibitors, the required secondary trypsin reaction presents the 
possibility of false positives.131,132 We envisioned designing a HDAC inhibitor assay in which 
probe 5 could be used to determine the extent of deacetylation in the context of a peptide 
containing an acetylated lysine residue adjacent to trimethyl lysine. Trimethylation and 
acetylation of lysine are known to co-exist and act cooperatively to influence the function of 
chromatin-modifying proteins.133 
To demonstrate this assay concept, we selected histone deacetylase 1 (HDAC1) as a 
model histone deacetylase. HDAC1 is a class I HDAC with a zinc dependent active site whose 
function is disrupted by inhibitors containing hydroxamate functionality, including vorinostat 
(SAHA).134 For our assay, we prepared two H3 peptides representative of biologically relevant 
HDAC substrates (K4me3K9ac and K27acK36me3). Histone H3 acetylation at K9 and K27 as 
well as methylation at K4 are histone PTMs known to be associated with active gene 
transcription.135,136 Conversely, methylation at K36 has been linked to heterochromatin and may 
signal the recruitment of HDACs.137,138 Furthermore, it has been shown that all four PTMs 
(K4me3, K9ac, K27ac, and K36me3) co-occur on a single H3 histone in cells treated with the 
HDAC inhibitor sodium butyrate.139 K4me3K9ac has the same spacing between the two Lys 
residues as our initial model peptide (K9me3K14), whereas the spacing is larger for 
K27acK36me3.  Thus, comparison of these two peptides provides information about the 
distance-dependence of labeling. 
Reactions between acetylated Kme3 peptides (200 µM) and HDAC1 (0.1 µg/µL) were 
carried out in 25 mM bicine buffer, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2 at pH 8.02 and 
37 °C in the presence or absence of SAHA (5 µM). After 1 h, reactions were diluted with the 
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bicine reaction buffer to quench the reaction before addition to a 96-well plate containing 5. 
Fluorescence labeling was performed with a final concentration of 40 µM 5 and 20 µM peptide 
at ambient temperature for 24 h. Samples containing only 5 and HDAC1 were used as negative 
controls and showed a slow increase in fluorescence over time, likely due to the presence of the 
primary amine Tris in the stock buffer of the commercial enzyme. H3 peptides K4me3K9 and 
K27K36me3 were used as positive controls for determining the maximum extent of fluorescence 
labeling possible for peptides deacetylated by HDAC1. Additionally, the CX4-ONBD showed no 
reactivity toward the hydroxamate group of the SAHA inhibitor (see Experimental), which 
further displays the probe’s selectivity toward amine nucleophiles. 
 
Figure 4.1. Turn-on fluorescence HDAC1 activity assay. Fluorescence monitoring of the 
deacetylation of histone H3 peptides K4me3 K9ac and K27ac K36me3 with probe 5 after 
reaction with HDAC1 in the absence or presence of 5 µM SAHA for 1 h at 37 °C. Enzymatic 
conditions are described in the text.  Fluorescence response is shown after labeling for 24 h. The 
fold increase in fluorescence intensity for each reaction was normalized to the reaction 
containing HDAC1 and 5. Blue bars: unacetylated control peptides K4me3K9 and K27K36me3; 
Red bars: acetylated peptides K4me3K9ac or K27acK36me3 + HDAC1; Green bars: acetylated 
peptides K4me3K9ac or K27acK36me3 + HDAC1 + SAHA. 
 
As seen in Figure 4, this assay clearly distinguishes between active and inhibited enzyme 
in the case of K4me3K9ac.  The fluorescence signal for the sample containing HDAC1 does not 







































under these conditions, as analyzed by HPLC (see Experimental).  Likewise, SAHA did not 
completely inhibit the reaction because conditions were not optimized to maximize inhibition.  
The fact that differences in fluorescence are clearly distinguishable despite the unoptimized 
conditions bodes well for application to inhibitor screens.  Moreover, analysis of the fluorescence 
output after 6 h exhibits identical results as the data at 24 h, despite low conversion, indicating 
that shorter assay times are feasible (see Experimental). 
To illustrate the distance-dependence on labeling in the context of our HDAC assay, we 
also investigated K27acK36me3, which has eight amino acids separating Kme3 and K compared 
to only four amino acids for K4me3K9. Not surprisingly, labeling of K4me3K9 was faster than 
that of K27K36me3, as indicated by the difference in fluorescence intensity of the positive 
controls (Figure 4). This distance dependence has a negative impact on the ability of the probe to 
report on HDAC activity for the K27acK36me3 peptide, as there is little difference in the degree 
of labeling in the absence or presence of SAHA (Figure 4). This suggests that the labeling may 
not be significantly receptor-mediated in this case.  Importantly, in histone 3, all but two Lys 
residues have another Lys within 5 residues or less (K56 and K79 are the exceptions), meaning 
that this first-generation probe is quite general already.  
In order to further validate the utility of our turn-on fluorescence assay for HDAC 
inhibitor screening, we carried out a dose-response experiment for the inhibition of 
HDAC3/NCOR1 by SAHA. For these experiments, inhibitor was serially diluted into 50 mM 
bicine buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.5 mg/mL BSA, pH 8.0), and 11.2 
nM HDAC3/NCOR1 was allowed to react with 100 µM K4me3K9ac for 4 h. After quenching 
each reaction by the addition of 10 µM SAHA, samples were added to a 96 well plate containing 
probe 5, giving a final concentration of 40 µM 5, 75 µM peptide, and 8.4 nM HDAC3/NCOR1. 
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Fluorescence measurements were made after 24 h and were used to generate a dose-response 
curve. An IC50 value of 1.5 µM was determined for the inhibition of HDAC3/NCOR1 by SAHA 
(Figure 5), which is in close agreement with a previously reported measurement for inhibition of 
the decrotonylase activity of HDAC3/NCOR1 by SAHA using a 7-amino-4-methylcoumarin 
tagged substrate.140 Overall these results demonstrate that probe 5 is able to efficiently detect 
deacetylase activity via a sensitive fluorogenic response and allows for accurate determination of 
IC50 values, making it amenable to HDAC inhibitor screening. 
 
Figure 4.2. Dose-response curve of the inhibition of the HDAC3/NCOR1 catalyzed 
deacetylation of K4me3K9ac by SAHA. Data are an average of duplicate measurements. 
Conditons: 40 µM 5, 75 µM peptide, serial dilution of SAHA (starting from 92 µM) in 50 mM 
bicine, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, pH 8.02, 24 h. 
 
Conclusions 
We also illustrated the utility of our labeling concept in the development of a turn-on 
fluorescence HDAC assay. Inhibition of HDAC1 and HDAC3/NCOR1 activity by a known 
inhibitor, SAHA, could be monitored without the need for chromatographic separation of 
reaction components or a secondary trypsin development step. While the assay was demonstrated 
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for monitoring deacetylase activity, this probe could theoretically be applied to other histone 
modifying enzymes such as acetyltransferases, demethylases, or methyltransferases.  Moving 
forward with this labeling methodology, the largest challenge will be gaining the selectivity 
necessary for many of the possible applications. Ultimately, we believe that the design of 
synthetic receptors with improved binding properties and the incorporation of alternative reactive 
group chemistries will be great assets in helping synthetic receptor-directed approaches to realize 
these potential applications. 
 
Experimental 
In Vitro HDAC Assay 
For HDAC1, enzymatic reactions were performed in 25 mM Bicine buffer, 137 mM 
NaCl, 2.7 mM KCl, 1 mM MgCl2 (pH 8.02) with 0.1 µg/µL HDAC1 (purchased from Active 
Motif) and 200 µM acetylated peptide at 37 °C. After 1 h, the reactions were diluted with buffer 
before adding to a 96-well plate containing probe 5 to give final concentrations of 20 µM 
peptide, 40 µM probe 5, and 10 ng/µL HDAC1 (reactions containing SAHA were diluted to 
contain 5 µM SAHA). Fluorescence labeling was monitored every hour for 24 h. 
For in vitro inhibition experiments with HDAC3/NCOR1, a 5.5 dilution series (starting 
with 92 µM SAHA) was prepared in 50 mM Bicine buffer, 137 mM NaCl, 2.7 mM KCl, 1 mM 
MgCl2, 0.5 mg/mL BSA (pH 8.02). Enzymatic reactions were performed using 11.2 nM 
HDAC3/NCOR1 (purchased from Enzo Life Sciences) and 100 µM acetylated peptide at 37 oC. 
After 4 h, the reactions were quenched with 10 µM SAHA before adding to a 96-well plate 
containing probe 5 to give final concentrations of 77 µM peptide, 40 µM probe 5, and 8.6 nM 
HDAC3/NCOR1. Fluorescence labeling was monitored after 24 h. The data were analyzed using 
KaleidaGraph version 3.6 to generate and fit a dose-response curve and to calculate IC50 values.  
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HPLC Analysis of HDAC1 and HDAC3/NCOR1 Reactions 
Reactions were analyzed by analytical HPLC using a C18 column at a flow rate of 1 
mL/min. Chromatographic separation was carried out using a 100-min linear gradient of solvent 
A (95% H2O, 5% CH3CN, and 0.1% TFA) and solvent B (95% CH3CN, 5% H2O, and 0.1% 




Figure 4.3. HPLC trace at 280 nm of a mixture of 20 µM K4me3 K9ac and 20 µM K4me3 K9 
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Figure 4.4. HPLC trace at 280 nm of a mixture of 20 µM K4me3 K9ac and 20 µM K4me3 K9  




Figure 4.5. HPLC trace at 280 nm of a mixture of 20 µM K27ac K36me3 and 20 µM K27 

























































Figure 4.6. HPLC trace at 280 nm of the reaction of 0.1 µg/µL HDAC1 with 20 µM K4me3 




Figure 4.7. HPLC trace at 280 nm of the reaction of 0.1 µg/µL HDAC1 with 20 µM K27ac 




Figure 4.8. Top: HPLC trace of a 1:1 mixture of 100 µM K4me3K9ac and 100 µM K4me3K9. 
Bottom: HPLC trace at 214 of the reaction of 11.2 nM HDAC3/NCOR1 with 100 µM 



























































Figure 4.9. Turn-on fluorescence HDAC1 activity assay. Fluorescence monitoring of the 
deacetylation of histone H3 peptides K4me3 K9ac and K27ac K36me3 with probe 5 after 
reaction with HDAC1 in the absence or presence of 5 µM SAHA for 1 h at 37 oC. Enzymatic 
reactions were performed in 25 mM Bicine buffer, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2 
(pH 8.02) with 0.1 µg/µL HDAC1 and 200 µM acetylated peptide. After 1 h, the reactions were 
diluted with buffer before adding to a 96-well plate containing probe 5 to give final 
concentrations of 20 µM peptide, 40 µM probe 5, and 10 ng/µL HDAC1 (reactions containing 
SAHA were diluted to contain 5 µM SAHA). Fluorescence labeling was monitored every hour 







































Figure 4.10. Turn-on fluorescence labeling SAHA control experiment. Labeling of 40 µM 5 
alone (red) or in the presence of 5 µM SAHA (blue) in 25 mM Bicine buffer, 137 mM NaCl, 2.7 
mM KCl, 1 mM MgCl2 (pH 8.02). Each data point represents an average of three runs. Error bars 













































Figure 4.11. Turn-on fluorescence HDAC1 activity assay: fluorescence increase of deacetylated 
K4me3 K9ac after labeling for 6, 12, or 24 h. Fold increase in fluorescence intensity was 
normalized to the negative control containing HDAC1 and 5 alone after 6, 12, or 24 h. Each data 




Figure 4.12. Turn-on fluorescence HDAC1 activity assay: fluorescence increase of deacetylated 
K27ac K36me3 after labeling for 6 ,12, or 24 h. Fold increase in fluorescence intensity was 
normalized to the negative control containing HDAC1 and 5 alone after 6, 12, or 24 h. Each data 


















































































Figure 4.13. Turn-on fluorescence HDAC3/NCOR1 activity assay: fluorescence increase of 
deacetylated K4me3K9ac after labeling for 24 h. Enzymatic reactions were performed using 11.2 
nM HDAC3/NCOR1, 100 µM acetylated peptide, and with or without 17 µM SAHA at 37 oC. 
After 4 h, the reactions were quenched with 10 µM SAHA before adding to a 96-well plate 
containing probe 5 to give final concentrations of 77 µM peptide, 40 µM probe 5, and 8.6 nM 





































Figure 4.14. Plot of the dose response curve for the inhibition of HDAC3/NCOR1 activity by 
SAHA as monitored by the CX4-ONBD turn-on fluorescence HDAC assay.  SAHA. Data are an 
average of duplicate measurements. Conditions: 40 µM 5, 75 µM peptide, serial dilution of 
SAHA (starting from 92 µM) in 50 mM bicine, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, pH 
8.02, 24 h. Error bars represent the standard deviation of each data point. In the equation 
provided for the IC50 fit, m1 and m2 correspond to the minimum and maximum Y values, 
respectively. The value m3 is the IC50 value (the X value at a Y value of 50), and m4 is the slope 




Z Factor Determination 
For determining the suitability of the fluorogenic assay for HTS screening, the Z factor141 
was calculated. Eight wells of positive control reaction and eight wells of negative control 
reaction were used in 96-well plate format. K4me3K9ac was used as a negative control, and 
K4me3K9 was used as a positive control. Reactions were performed with 40 µM probe 5 and 20 
µM peptide in 10 mM sodium borate buffer, pH 8.6, 100 mM NaCl. After 24 h, the fluorescence 
intensity was measured. 
 
 
Figure 4.15. Equation for calculating Z’. The values σp and σn are the standard deviation of the 
positive control and negative control respectively. The values µp and µn refer to the mean of the 




Figure 4.16. Fluorescence intensities of positive control reaction and negative control reactions 
for eight wells for Z’ determination. 
 
Table 4.1. Summary of Fluorescence Intensities and Z Factor Calculation 
 




Control 16337 17561 17439 18120 18052 16282 16802 16319 17114 776.68 0.71 
Negative 























𝑍′ = 1 −  
3( 𝜎p + 𝜎n )





CHAPTER 5. Design and Synthesis of Synthetic Receptors for Lower Methylation States of 
Lysine 
Introduction and Significance 
Over the past decade, supramolecular approaches for the recognition of lysine 
methylation (Figure 1), a protein post-translational modification that regulates gene expression, 
have expanded greatly. To date, at least three different classes of molecular receptor have been 
reported to bind to trimethyllysine (Kme3): cyclophanes (Waters and Hamilton)96,98,99, 
calixarenes (Hof)142, and cucurbiturils(Macartney)95. Additionally, several of these receptors 
have been applied to the field of chemical biology to develop sensors (Hof ,Waters, Nau, 
Hooley, and Zhong)102–104,143–145 and affinity reagents (Hof and Kanai)105,106.  Nonetheless, little 
progress has been made in developing synthetic receptors for the lower methylation states of 
lysine.  This is likely due to the greater hydrophilic nature of mono- and dimethyl lysine, which 
are protonated at physiological pH and hydrogen bond with water, resulting in a much higher 
desolvation penalty than Kme3.  In general, binding hydrophilic guests in aqueous environments 
is a significant challenge in the field of molecular recognition due to the necessity of overcoming 
interactions between the guest and water molecules.146–151 In spite of this thermodynamic hurdle, 
proteins overcome this challenge by incorporating buried polar interactions to bind a variety of 
hydrophilic molecules including sugars152, DNA153,154, and polar amino acids.155 The 
methyllysine “reader” proteins are another such example that utilize this strategy.156,157 While the 
reader proteins for Kme3 contain an aromatic cage which contributes to binding via cation-π 
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interactions, binding to lower methylation states is accomplished by directing an additional polar 
functional group, typically a carboxylate from Asp or Glu, into the pocket, which forms a salt 




Figure 5.1.  Methylation states of lysine. 
Herein, we use dynamic combinatorial chemistry (DCC)100,158 to develop a new receptor, 
A2I, which directs a carboxylate into its binding pocket to form a salt bridge with bound Kme2, 
with the goal of mimicking reader proteins for Kme2 (Figure 2). This receptor displays a 0.2 µM 
affinity for Kme2 in the context of a histone peptide, which represents a 32-fold enhancement 
over A2B. This is the highest affinity receptor for Kme2 to date and is also the first to bind Kme2 
as well or better than Kme3. This work highlights the power of DCC for the discovery of 
receptors with new binding properties by simple redesign of monomers and represents a step 
forward in the development of synthetic receptors that preferentially bind lower methylation 
states of lysine. 
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(a) (b)  (c) 
 
 
Figure 5.2. (a) Redesign of A2B to A2I. (b) Monomer I. (c) Gas-phase molecular model of one 
isomer of A2I (blue) bound to butyldimethyl ammonium (cyan), a mimic of Kme2. 
 
System Design 
 We previously reported97–99 the development of several small molecule receptors for 
methylated lysine and arginine that mimic the binding motif of reader proteins. These receptors 
were prepared using iterative redesign by DCC.  DCC100 has proven to be a powerful tool for 
identifying small molecule receptors for methylated lysine, as it allows for both facile synthesis 
of macrocyclic receptors from monomer building blocks and for rapid analysis of potential 
binders. In the redesign process, an individual monomer from a known receptor is synthetically 
modified or varied to introduce new structural elements and functional groups that are expected 
to influence guest binding. DCC is then used to rapidly screen for receptors that incorporate the 
new monomer and bind tightly or selectively to a particular guest. To date, receptors for 
methylated lysine have consistently shown a stronger preference for binding Kme3 over lower 
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methylation states of lysine. This is consistent with the fact that the lower methylation states are 
less hydrophobic and can hydrogen bond with water, which generally makes binding inside a 
hydrophobic aromatic pocket less favorable compared to Kme3. 
In designing new receptors for lower methylation states of lysine that mimic nature’s 
reader proteins, we took clues from protein engineering work on methyl lysine reader proteins. 
Li et. al investigated lysine methylation state specificity by mutating the residues near the 
aromatic binding pocket of the BPTF PHD Finger, a binding motif which specifically binds 
H3K4me3 in the context of a histone peptide (Figure 3a).159 By mutating a tyrosine to a glutamic 
acid, the selectivity in binding was reversed to favor binding Kme2 over Kme3 by a factor of two 
(Figure 3b). This change in selectivity was attributed to a salt-bridge interaction between the 
glutamic acid carboxylate and the N-H group of Kme2. By following an analogous redesign 
strategy, we looked to alter the methylation state specificity of a known receptor for Kme3 by 
introducing a favorably positioned carboxylate within the cavity to form a receptor with greater 
selectivity for Kme2. 
 
 
(a) (b)  
 
Figure 5.3.  (a) BPTF PHD domain bound to Kme3. (b) BPTF PHD domain Y17E mutation 
bound to Kme2. 
 
The synthetic receptor A2B has been shown to selectively bind Kme3 by forming an 
aromatic cage that is able to engage the methyl groups of Kme3 in cation-π interactions.96 
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Additionally, A2B was shown to bind Kme3 with two-fold tighter affinity compared to Kme2, 
presumably due to Kme2 having fewer methyl groups to engage in cation- π interactions and 
having a higher energetic cost of desolvation. We reasoned that selectivity for lower methylation 
states of lysine like dimethyllysine could be achieved by redesigning monomer B into a biphenyl 
monomer, I, with ortho-disubstituted carboxylic acids. A biphenyl monomer with two ortho 
carboxylates would force one of the carboxylic acids to be inside the cavity of the receptor. 
Theoretically, this would allow for a favorable salt bridge with Kme2, which is the combination 
of both electrostatic and hydrogen bonding interactions. Since Kme3 is not able to engage in a 
salt bridge due to its lack of a hydrogen bond donor, we expected that incorporation of monomer 
I into the receptor would reduce the preference for binding Kme3 over Kme2.  
Synthesis of Monomers I and J 
The control monomer J was synthesized following a similar synthesis reported for 
preparing monomer B (Scheme 1).101 Compound 1 was prepared according to literature 
procedure.160 The O-thiocarbamate intermediate 2 is prepared by reacting the hydroxyl groups of 
1 with DMTC. A Newman-Kwart rearrangement provides the S-thiocarbamate 3, and subsequent 
base hydrolysis affords the monomer J.  
Initial attempts to prepare monomer I via an O-thiocarbamate intermediate were 
unsuccessful, possibly due to the steric hindrance of the ortho-disubstituted biphenyl. An 
alternative synthetic approach that proved to be effective involving the incorporation of tert-butyl 
protected thiols prior to cross coupling. First, the di-S-t-butyl aryl bromide 4 was prepared 
according to literature procedure via an SNAr reaction between 1-bromo-3,5-difluorobenzene and 
tert-butyl thiol.161 Compound 4 was then converted to a boronic acid (5) through lithiation 
followed by borylation with triisopropylborate. The boronic acid 5 was used in a Suzuki-Miyaura 
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reation with compound 6 (prepared according to previously reported procedure162) to yield 
biphenyl precursor 7. The S-di-tbutyl groups of 7 were converted to thioacetate groups using 
boron tribromide and acetyl chloride. Finally, base hydrolysis of the ester and thioacetate groups 
produced the monomer I in good yield. 







Dynamic Combinatorial Library Screening 
 Following similar conditions reported for the preparation of A2B, five unbiased dynamic 
combinatorial libraries (DCLs) were prepared using 1 mM A, 1 mM biphenyl monomer, and 2 
mM of guest (or no guest for the untemplated library) in 50 mM sodium borate buffer at pH 8.5. 
Methylated butylamine guests were used as convenient Kmex side chain mimics: n-butylamine 
for K, N-butylmethylamine for Kme, N,N-dimethylbutylamine for Kme2, or 
butyltrimethylammonium bromide for Kme3. These Kmex mimics were used as they are 
inexpensive and commercially available or easily prepared in the case of 
butyltrimethylammonium bromide.163  
The DCLs were allowed to undergo disulfide exchange and equilibration for five days at 
room temperature in air before analysis by LCMS. For the libraries containing monomers A and 
I, two major species were amplified (Figure 4a) both of which corresponded to the mass of A2I, 
corresponding to rac- and meso-stereoisomers, since monomer A was used as a racemic mixture. 
Significant amplification of the receptor is seen even in the presence of the K mimic (3 to 4 fold 
above the untemplated); however the higher methylation state guests still amplify the receptor to 
the greatest extent (nearly 7-fold greater than the untemplated library) (Figure 4b). Interestingly, 
the two stereoisomers are amplified to different degrees depending on the guest. In the presence 
of the Kme2 mimic, the peak that elutes second by HPLC is preferentially amplified, whereas the 
isomer that elutes first is amplified to a greater extent in the presence of the Kme3 mimic. 
 After characterizing amplification, receptors A2I and A2J were synthesized on a 
preparative scale using butyltrimethylammonium bromide as a guest. Each preparative library 
contained 2.5 mM monomer A, 2.5 mM of the respective biphenyl monomer, and 10 mM guest 
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dissolved in 10 mM sodium borate buffer at pH 8.5. Prep scale DCLs were allowed to equilibrate 






Figure 5.4. (a) DCLs of monomers A and I with different methylated butylamine guests (1 mM 
A, 1 mM I, 2 mM guest, 50 mM sodium borate buffer, pH 8.5). (b) Amplification of A2I -1 and 
A2I-2 in the presence of Kmex mimics. Fold amplification is defined as the peak area of the 
guest-templated library divided by the peak area of the untemplated library determined from the 

















































NMR Characterization of Binding to Kme2 and Kme3 
In order to investigate the mode of binding of A2I-2 to methylated lysine, we observed 
the 1H NMR spectrum of the receptor in the presence of Ac-Kme2GGY-NH2 or Ac-Kme3GGY-
NH2 under concentrations where all the peptide is bound. Protons on functional groups that are 
bound within the pocket of the receptor would be expected to experience shielding from being in 
close proximity to aromatic rings. At room temperature, the chemical shifts of several of the 
protons from the lysine side chain of the peptide are perturbed, and the NMe2 or NMe3 protons in 
particular experience significant broadening. When the 1H NMR spectrum is measured at 40 oC, 
the NMe2/NMe3 protons become sharper and are shifted upfield by over 1 ppm. This indicates 
that A2I-2 binds to Kme2 or Kme3 by making cation-π interactions with the quaternary 
ammonium group. 
Table 5.1. Change in chemical shift (Δδ) upon binding of Ac-Kme2-Gly-Gly-Tyr-NH2 or Ac-
Kme3-Gly-Gly-Tyr-NH2 to A2I-2 
 
Peptide protons A2I-2 Δδ (ppm)
a A2B
b,c 
NMe2 -1.15 - 
NMe3 -0.93 -1.59 
 
a Conditions: 50 mM sodium borate-d3 in D2O, pH 8.5, 0.05 mM DSS at 40 
oC. b 1H NMR 
carried out at room temperature. c Data reported by Pinkin and Waters. 
 
ITC Binding Studies 
Isothermal titration calorimetry (ITC) was used to characterize the binding of A2I and 
A2J to a short model peptide consisting of methylated Lys (Kmex) appended with a C-terminal 
GGY tag for measuring peptide concentration by UV-Vis and/or a representative histone H3 
peptide containing different methylation states of lysine with an N-terminal WGGG tag, for 
comparison to previous host-guest studies98,99 (see Table 1). ITC experiments were conducted at 
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25 °C in 10 mM borate buffer at pH 8.5. The thermodynamic binding data collected from ITC 
binding studies of A2I and A2J are summarized in Table 2. 
Table 5.2. Peptides used for ITC binding studies 
Peptide Sequence 
KmexGGY (x = 2,3) Ac-KmexGGY-NH2 
H3 K9mex (x = 0-3) Ac-WGGG-QTARKmexSTG-NH2 
 
Influence of the Internal Carboxylate on Selectivity 
 Preliminary binding studies were performed using short model peptide KmexGGY (x = 2 
or 3) to determine the influence of the internal carboxylate on selectivity.  The second isomer of 
A2I (A2I-2) was used as it exhibited slightly greater amplification in the presence of Kme2 than 
Kme3.  Both the Kme2 and Kme3 peptides exhibited low micromolar affinity with a 1.3:1 
preference for Kme2 vs Kme3, consistent with the amplification data.  Thus, incorporation of an 
internal carboxylate did indeed result in a small reversal of selectivity, presumably due to a 
favorable salt bridge with Kme2 that that compensates for the loss of one cation-π interaction 
relative to Kme3.  
Comparison of A2I to A2B with a biologically relevant peptide 
Next, we investigated binding of A2I-1 and A2I-2 to a more biologically relevant peptide: 
the histone 3 tail containing Kmex (x = 0, 1, 2, or 3) at position 9. We have used this same 
peptide to evaluate A2B, such that a direct comparison can be made.98  Incorporation of 
monomer I had a pronounced influence on binding affinity to methylated lysine relative to A2B. 
Overall when compared to A2B, both isomers of receptor A2I bind to Kme2 with 32-fold higher 
binding affinity and represents the highest affinity small molecule receptor for Kme2 to date. 
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Additionally, receptor stereochemistry affected the affinity and selectivity for the 
different methylation states. ITC revealed that A2I-1 had 20-fold higher affinity for Kme3 (0.13 
µM ± 0.005 µM) than the parent A2B (2.6 µM ± 0.1) receptor and is roughly 2-fold more 
selective for binding Kme3 over K relative to A2B (16-fold versus 8-fold respectively) (Table 2). 
A2I-1 maintains slight selectivity for Kme3 over Kme2 in the context of the H3 peptide, with a 
selectivity of 1.4 compared to 2.4 for A2B.  
Interestingly, receptor A2I-2 displays essentially identical binding to Kme2 and Kme3 in 
the context of the H3 peptide sequence while maintaining the same selectivity for binding 
Kme2/3 over Kme and K as A2B. The tighter overall binding and nearly equal binding to Kme3 
and Kme2 with this histone peptide relative to the KmexGGY peptide suggests that additional 
interactions are contributing to binding.  Earlier studies164 from the Waters lab have 
demonstrated that the Arg in position 8 that neighbors Lys 9 in the histone H3 peptide sequence 
influences the binding affinity and selectivity of A2B and similar synthetic receptors for the 
different methylation states of lysine.  While the presence of the Arg slightly diminishes the 
Kme2/Kme3 selectivity by about 0.2 kcal/mol, it has a much more substantial influence on 
overall binding affinity, amounting to about 1.6-1.8 kcal/mol, presumably due to additional 




Table 5.3. Thermodynamic binding data for the biding of A2I and A2J to peptides shown in 
Table 5.1 as measured by ITC. 
 
Entry Receptor Peptide Charge Kd b(µM) Selectivity 
Factord 
ΔGc 
1 A2B H3 K9me3 +2 2.6 ± 0.1 - -7.63 ± 0.03 
2 A2B H3 K9me2 +2 6.3 ± 0.3 2.4 -7.10 ± 0.07 
3 A2B H3 K9me +2 13.9 ± 0.1 5.4 -6.64 ± 0.01 
4 A2B H3 K9 +2 22 ± 1 8.3 -6.38 ± 0.02 
5 A2I-2 H3 K9me3 +2 0.22 ± 0.03 
c - -9.11 ± 0.09 
6 A2I-2 H3 K9me2 +2 0.20 ± 0.01 0.9 -9.11 ± 0.09 
7 A2I-2 H3 K9me +2 1.00 ± 0.04 4.5 -8.18 ± 0.04 
8 A2I-2 H3 K9 +2 1.79 ± 0.1 
c 8 -7.88 ± 0.1 
9 A2I-1 H3 K9me3 +2 0.13 ± 0.005 - -9.39 ± 0.04 
10 A2I-1 H3 K9me2 +2 0.18 ± 0.01 1.4 -9.19 ± 0.2 
11 A2I-1 H3 K9me +2 1.23 ± 0.04 
c 9.5 -8.03 ± 0.06 
12 A2I-1 H3 K9 +2 2.09 ± 0.15 
c 16 -7.78 ± 0.2 
13 A2I-2 Kme3GGY +1 4.30 ± 0.33 - -7.32 ± 0.02 
14 A2I-2 Kme2GGY +1 3.32 ± 0.20 0.77 -7.48 ± 0.01 
15 A2J-1 H3 K9me3 +2 2.61 ± 0.23 - -7.62 ± 0.10 
16 A2J-1 H3 K9me2 +2 5.21 ± 0.44 2.0 -7.21 ± 0.10 
17 A2J-1 H3 K9me +2 6.36 ± 0.64 2.4 -7.09 ± 0.12 
18 A2J-1 H3 K9 +2 7.02 ± 0.75 2.7 -7.03 ± 0.13 
19 A2J-2 H3 K9me3 +2 2.25 ± 0.18 - -7.70 ± 0.09 
20 A2J-2 H3 K9me2 +2 6.74 ± 0.62 3.0 -7.05 ± 0.11 
21 A2J-2 H3 K9me +2 8.37 ± 1.0 3.7 -6.93 ± 0.14 
22 A2J-2 H3 K9 +2 10.60 ± 1.1 4.7 -6.79 ± 0.12 
 
a Conditions: 25° C in 10 mM sodium borate buffer, pH 8.5. b Errors are averages of the error in 
the fit as determined by the Origin 7 software. c Errors are from averages of the runs. d The 




Influence of Biphenyl Functional Group 
 Monomer J was used to assess whether or not the differences in affinity and selectivity 
exhibited by A2I relative to A2B were the result of carboxylate position or the effect of 
incorporating a phenyl group into the structure of monomer B. Measurement of binding by ITC 
showed that either isomer of A2J shows about a 2-fold to 3-fold preferential binding to Kme3 
over Kme2. Furthermore, the binding affinity of the receptor for Kme3 and Kme2 is nearly 
identical to the parent A2B receptor, indicating that incorporation of the biphenyl scaffold alone 
does not contribute favorably to binding for the higher methylation states of lysine.  
Conclusions 
 In summary, we have successfully employed DCC to redesign the receptor A2B, which 
has a 2.4-fold preference for Kme3 over Kme2, into A2I, which places a carboxylate directed 
into the pocket and provides the first receptor with a preference for Kme2.  This work illustrates 
the value of rationally designing monomers for DCC with unique architectures (i.e. ortho-
disubstituted biphenyls) for controlling interactions within a binding pocket.  It also provides 
insight into effective strategies for the binding and selective molecular recognition of hydrophilic 
guests in water. Placing anionic functionality near or inside a hydrophobic aromatic binding 
pocket likely minimizes competing interactions with water, lending selectivity for guests capable 
of forming hydrogen bonding and cation-π interactions inside an aromatic cavity. The result of 
this work was a synthetic receptor, A2I, with 32-fold greater affinity than A2B for Kme2 in the 
context of a H3 peptide. When controlling for the influence of neighboring positive charge, A2I -
2 displays a marginal preference for binding Kme2 over Kme3. The high binding affinities and 
the changes in selectivities can be attributed to the formation of a salt-bridge interaction with 
Kme2 that arises from directing a carboxylic acid into the aromatic binding pocket. This 
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represents the highest affinity receptor for Kme2 in the context of a peptide that has been 
reported and is a promising step toward a small receptor with appreciable selectivity in binding 
Kme2 over other methylation states of lysine. Looking forward, strategies to more rigidly direct 
a carboxylate into the binding pocket should significantly improve biding to Kme2 over Kme3. 
Additionally, the use of receptors for methylated lysine with small binding pockets should 
sterically occlude Kme3 leading to greater selectivities for Kme2. 
Experimental 
Monomer A was prepared according to a previously reported procedure.101 
DCLs were made from stock solutions of the monomers dissolved in 50 mM sodium 
borate at pH 8.5. Components of the library were mixed to give final monomer concentrations of 
1 mM at a total volume of 500 µL. The concentration of methylated butylamine guest was 
equivalent to the total of concentration of monomer in the library. DCLs were allowed to 
undergo oxidation and disulfide exchange equilibration for a week. After equilibration, the 
library was filtered using a 0.22 µm PVDF syringe filter and was analyzed by analytical reversed 
phase HPCL (Atlantis T3 4.7 x 150 mm 5 µm C-18 column) using by monitoring UV absorbance 
at 280. An optimized gradient of A and B (A: 100% H2O, 10 mM NH4OAc; B: 90% CH3CN, 
10% H2O, 10 mM NH4OAc) was used for DCL analysis. 
Analysis of DCLs by analytical HPLC was carried out using an Agilent Rapid Resolution 
LC-MSD instrument situated with an online degasser, binary pump, autosampler, heated column 
compartment, and diode array detector. Separations were achieved using a mobile phase of H2O 
(5 mM NH4OAc) and CH3CN (95% CH3CN, 5% H2O, 5 mM NH4OAc) at pH 5.5 on a Zorbax 
Extend C18 column (4.6 Å 2.1 x 50 mm, 1.8 micron). Negative ion electrospray ionization MS 
 
104 
analysis was performed with a single quad mass spectrometer. Data were analyzed using the 
Agilent ChemStation software. 
ITC binding experiments were conducted using a Microcal AutoITC200. Titrations were 
performed at 25 °C in 10 mM sodium borate buffer at pH 8.5. The concentration of receptor was 
determined by measuring the UV–vis absorbance at 300 nm or 315 nm, using a NanoDrop2000 
with a xenon flash lamp, 2048 element linear silicon CCD array detector, and 1 mm path length. 
Solutions of 0.2–1.3 mM of peptide were titrated into a 20–91 μM solution of receptor, using 2.0 
μL increments every 3 min. Heats of dilution were taken as the last three or four points and 
subtracted prior to fitting. Binding curves were produced using the supplied Origin software and 
fit using one-site binding models. 




Synthesis of 1. Compound 1 was prepared according to published procedure.160  
 
Synthesis of 2. Compound 1 (0.23 g, 0.94 mmol, 1 equiv.) was dissolved in 2 mL of anhydrous 
DMF under a nitrogen atmosphere, and the solution was cooled to 0oC. To this solution was 
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added 1,4-diazabicyclo[2.2.2]octane (0.42 g, 3.7 mmol, 4 equiv.) in small portions. A solution of 
dimethylthiocarbamoyl chloride (0.47 g, 3.7 mmol, 4 equiv.) in 2 mL anhydrous DMF was 
added dropwise to the resulting suspension. The reaction mixture was allowed to warm to room 
temperature and stirred for 24 h. Afterward, 40 mL of water was added to the reaction mixture to 
precipitate out the crude solid, which was collected by filtration to yield a white solid (0.37 g, 
95%). 1H NMR (CDCl3, 600 MHz): 8.087,8.073 (d, 2H, CH), 7.664,7.650 (d, 2H, CH), 
7.249,7.245 (d, 2H, CH), 6.893 (t, 1H, CH), 3.935 (s, 3H, CH3), 3.466 (s, 6H, N-CH3), 3.361 (s, 
6H, N-CH3). 
13C NMR (CDCl3, 600 MHz): 187.336, 167.000, 154.586, 143.833, 141.448, 
130.241, 127.288, 119.516, 117.731, 52.324, 43.498, 39.025. MS (calculated): 419.11 [M+H], 
441.09 [M+Na+], 837.23 [2M+H], 859.21 [2M+Na+]. HRMS (observed, ESI+): 419.10986 
[M+H], 441.09189 [M+Na+], 837.21382 [2M+H], 859.19383 [2M+Na+]. 
 
 
















Synthesis of 3. Compound 2 (0.30 g, 0.72 mmol, 1 equiv.) was dissolved in 5 mL of warm 
diphenyl ether and heated to 230oC for 3 h. The reaction mixture was cooled to room 
temperature and diluted with 15 mL hexanes. The solution was purified by column 
chromatography (ethyl acetate/hexanes gradient from 0 to 50%) to obtain a white solid (0.25 g, 
83%). 1H NMR (CDCl3, 600 MHz): 8.084, 8.070 (d, 2H, CH), 7.768, 7.765 (d, 2H, CH), 7.663, 
7.660 (d, 2H, CH), 7.650 (s, 1H, CH), 3.934 (s, 3H, CH3), 3.013 (s, 6H, N-CH3), 3.035 (s, 6H, N-
CH3). 
13C NMR (CDCl3, 600 MHz): 167.056, 166.371, 144.104, 141.550, 141.390, 135.328, 
130.276, 130.210, 129.459, 127.460, 52.294, 37.113. MS (calculated): 419.11 [M+H], 441.09 
[M+Na+], 837.23 [2M+H], 859.21 [2M+Na+]. HRMS (observed, ESI+): 419.11038 [M+H], 



















Synthesis of J. Potassium hydroxide (0.80 g, 14 mmol, 33 equiv.) was dissolved in a solution of 
ethanol (2 mL) and water (4.5 mL), and the solution was degassed for 2 h. To this solution was 
added compound 3 (0.18 g, 0.43 mmol, 1 equiv.). The reaction was refluxed for 3 h and then 
cooled to room temperature. Ethanol was removed under reduced pressure, and 10% HCl (10 
mL) was added.  The precipitate was collected by vacuum filtration and dried under vacuum to 
give a white solid (0.102 g, 92%). 1H NMR (CD3OD 600 MHz): 8.093, 8.079 (d, 2H, CH), 
7.684, 7.670 (d, 2H, CH), 7.343, 7.340 (d, 2H, CH), 7.234 (s, 1H, CH). 13C NMR (CDCl3, 600 
MHz): 169.560, 145.557, 142.835, 135.383, 131.365, 128.616, 128.040, 125.076. MS 
(calculated): 261.00 [M-H], HRMS (observed, ESI-): 261.00495. 
 



















Synthesis of 4. Compound 4 was synthesized according to published procedure.161 
 
Synthesis of 5. Compound 4 (0.50 g, 1.51 mmol) was dissolved in anhydrous THF (6 mL) at -78 
oC, and n-butyl lithium (2.5 M in hexanes, 0.75 mL, 1.9 mmol) was added dropwise. The 
solution was stirred at -78 oC for 1 h, and then triisopropyl borate (1.2 mL, 6.4 mmol) was added 
dropwise. The reaction was stirred at -78 oC for 3 h and then allowed to warm to room 
temperature overnight. Water (1 mL) was added to the reaction, and the solvent was removed 
under reduced pressure. The crude product was dissolved in dichloromethane, and 1N HCl (3 
mL) was added. After stirring for 1 h, the organic fraction was separated, and the product was 
purified by column chromatography (ethyl acetate/hexanes gradient from 10% to 35%) to give a 
white solid (0.404 g, 90% yield). 1H NMR (CDCl3, 600 MHz): 7.857,7.854 (d, 1H, CH), 7.752-
7.857 (m, 2H, CH), 1.275 (s, 18H, CH3). 
13C NMR (CDCl3, 600 MHz): 148.130, 147.303, 
142.906, 142.777, 132.515, 46.284, 31.088. MS (calculated): 577.23 [cyclic boronic ester dimer 
+ OH], 875.35 [open boronic ester trimer + OH], 1137.45 [cyclic boronic ester + OH], 1417.57 
[cyclic boronic ester pentamer + OH]. HRMS (observed, ESI-): 577.23339 [cyclic boronic ester 
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dimer + OH], 875.35906 [open boronic ester trimer + OH], 1137.46613 [cyclic boronic ester + 
OH], 1417.58859 [cyclic boronic ester pentamer + OH]. 
 
 











Figure 5.16. High resolution mass spectrum of Compound 5. 
 
Synthesis of 6. Compound 6 was synthesized according to published procedure.162  
 
Synthesis of 7. A solution of CsCO3 (3.60 g, 11 mmol) in H2O (4.8 mL), toluene (21 mL), and 
EtOH (21 mL) was degassed by bubbling with argon for 2 h. To this flask under an atmosphere 
of argon were added 6 (0.69 g, 2.5 mmol), 5 (0.78 g, 2.6 mmol), and Pd(PPh3)4 (0.30 g, mmol). 
The solution was heated to reflux and vigorously stirred overnight. After cooling to room 




purified by column chromatography (ethyl acetate/hexanes gradient from 15% to 35%) to give a 
white solid (0.59 g, 56% yield). 1H NMR (CDCl3, 600 MHz): 7.935, 7.922 (d, 2H, CH), 7.722 (s, 
1H, CH), 7.506 (t, 1H, CH), 7.400, 7.398 (d, 2H), 4.024, 4.012 (q, 4H, CH2), 1.303 (s, 18H, 
CH3), 1.010 (t, 6H, CH3). 
13C NMR (CDCl3, 600 MHz): 167.580, 144.815, 139.949, 137.854, 
133.349, 132.343, 127.801, 61.324, 46.339 31.069, 14.004. MS (calculated): 475.20 [M+H], 
949.39 [2M+H], 971.37 [2M+Na+]. HRMS (observed, ESI+): 475.19894 [M+H], 949.39195 















Figure 5.19. High resolution mass spectrum of Compound 7. 
 
Synthesis of I. Compound 7 (0.50 g, 1.1 mmol) was dissolved in a solution of toluene (2.2 mL) 
and acetyl chloride (1.12 mL, 15.7 mmol) under an atmosphere of nitrogen. The solution was 
cooled on an ice bath, and a 1.0 M solution of BBr3 in dichloromethane (2.47 mL, 2.5 mmol) 
was added dropwise. Afterward, the ice bath was removed and the reaction was allowed to warm 




(10 mL). The organic phase was separated, washed with water (3 x 10 mL), and dried over 
magnesium sulfate. The solvent was removed under reduce pressure to provide a crude 
thioacetate intermediate. A solution of potassium hydroxide (0.80 g, 14.3 mmol) in water (4.5 
mL) and ethanol (2 mL) was degassed by bubbling with nitrogen for 2 h. To this solution was the 
thioacetate intermediate (0.38 g, 0.91 mmol) under an atmosphere of nitrogen. The reaction was 
heated at reflux for 3 h. After cooling to room temperature, the solution was concentrated under 
reduced pressure. The product was precipitated out by addition of 3N HCl. The precipitate was 
collected by vacuum filtration and dried under vacuum overnight to give a white solid (0.24 g, 
73% yield over 2 steps). 1H NMR (CD3OD 600 MHz): 7.892, 7.879 (d, 2H, CH), 7.537 (t, 1H, 
CH), 7.170 (s, 1H, CH), 6.905, 6.902 (s, 2H, CH). 13C NMR (CDCl3, 600 MHz): 171.071, 
142.068, 140.533, 135.252, 133.333, 132.375, 128.777, 128.331, 127.169. MS (calculated): 
















Figure 5.22. High resolution mass spectrum of Monomer I. 
 
Synthesis of A2I and A2J 
 DCLs were prepared on a preparative scale using butyltrimethylammonium bromide as a 
guest for templating the formation of the desired receptor. Libraries were prepared using 2.5 mM 
A, 2.5 mM biphenyl monomer (I or J), and 10 mM guest in 50 mM sodium borate buffer at pH 




purified by semi-preparative reversed-phase HPLC (solvent A: 10 mM NH4OAc in H2O; solvent 
B: 10 mM NH4OAc in 9:1 CH3CN:H2O). For A2I, a gradient from 10% B to 100% B in 1 h was 
used for purification. For A2J, the following gradient was used: 0% B to 35% B over 1 min, 35% 
B to 40% B over 5 min, 40% B to 55% B over 30 min, and 55% B to 100% B over 30 min. 




Figure 5.23. Semi-preparative reversed-phase HPLC traces of the purification of A2I from a 






Figure 5.24. High resolution mass spectrum of A2I-1 (ESI -). MS calculated: 1010.98 [M-H]. 
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A2B_26C1_05_31_17 #1-100 RT: 0.01-1.49 AV: 100 NL: 2.38E6
T: FTMS - p ESI Full ms [150.00-2000.00]













































































Figure 5.25. High resolution mass spectrum of A2I-2 (ESI -). MS calculated: 1010.98 [M-H], 
504.99 [M-2H]. MS observed: 1010.98169 [M-H], 504.98764 [M-2H]. 
  
A2B_2_6C 3_7_17 #1-100 RT: 0.01-1.47 AV: 100 NL: 1.51E7
T: FTMS - p ESI Full ms [150.00-2000.00]















































































Figure 5.26. (a) Low resolution mass spectrum of background (ESI -). (b) High resolution mass 
spectrum of background (ESI -). 
 
Background_05_31_17 #1-100 RT: 0.00-0.36 AV: 100 NL: 1.69E2
T: ITMS - p ESI Full ms [150.00-2000.00]








































Background_FT_05_31_17 #1-100 RT: 0.01-1.49 AV: 100 NL: 9.30E4
T: FTMS - p ESI Full ms [150.00-2000.00]






















































































Figure 5.27. Semi-preparative reversed-phase HPLC traces of the purification of A2J from a 




Figure 5.28. High resolution mass spectrum of A2J-1 (ESI -). MS calculated: 966.99 [M-H], 
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Figure 5.29. High resolution mass spectrum of A2J-1 (ESI -). MS calculated: 966.99 [M-H], 
482.99 [M-2H]. MS observed: 966.99258 [M-H], 482.99271 [M-2H]. 
  
A2B_4C2_06_05_17 #1-100 RT: 0.01-1.48 AV: 100 NL: 3.32E6
T: FTMS - p ESI Full ms [150.00-2000.00]












































































NMR Characterization of A2I and A2J 
Structural characterization of A2I-1, A2I-2, and A2J-2 was conducted in 50 mM sodium 
borate-d3 D2O, pH 8.5 with 0.05 mM DSS (as a NMR standard) at room temperature using a 
Bruker 500 MHz instrument (40 oC, 400 scans each, 3s pre-saturation and water suppression). 




Figure 5.30. 1H NMR spectrum of A2I-1 in 50 mM sodium borate-d3 D2O, pH 8.5 at room 
temperature. 7.588 (d, 4H, Ar-H), 7.524 (s, 1H, Ar-H), 7.487 (s, 2H, Ar-H), 7.428 (m, 3H, Ar-






Figure 5.31. 1H NMR spectrum of A2I-2 in 50 mM sodium borate-d3 D2O, pH 8.5, 0.05 mM 
DSS (standard) at room temperature. 7.877 (s, 2H, Ar-H), 7.772 (s, 2H, Ar-H), 7.585 (s, 2H, Ar-
H), 7.438 (m, 3H, Ar-H), 7.273-7.7.351 (m, 7H, Ar-H), 7.118-7.132 (d, 2H, Ar-H), 5.372 (s, 2H, 





Figure 5.32. 1H NMR spectrum of A2J-1 in MeOD at 40 oC. 8.069 (d, 2H, Ar-H), 7.975 (s, 1H, 
Ar-H), 7.823 (s, 2H, Ar-H), 7.548-7.577 (m, 3H, Ar-H), 7.473 (s, 1H, Ar-H), 7.433 (d, 2H, Ar-
H), 7.223 (d, 2H, Ar-H), 7.170 (d, 2H, Ar-H), 7.102 (d, 2H, Ar-H), 7.063 (d, 2H, Ar-H), 5.895 






Figure 5.33. 1H NMR spectrum of A2J-2 in 50 mM sodium borate-d3 D2O, pH 8.5, 0.05 mM 
DSS (standard) at 40 oC. Due to difficulty in purification, the second isomer could only be 
obtained in 83% purity, with the impurity presumably arising from HPLC peak overlap with the 
first isomer. 7.827-7.843 (d, 1H, Ar-H), 7.568-7.616 (m, 2H, Ar-H), 7.464-7.490 (m, 3H, Ar-H), 
7.292-7.335 (m, 4 H, Ar-H), 7.196 (d, 1H, Ar-H), 7.146 (d, 2H, Ar-H), 7.003 (d, 2H, Ar-H), 












Figure 5.34. Overlaid HPLC traces of DCLs after 7 days containing 1 mM A, 1 mM J, and 2 
mM guest (absorbance at 280 nm). A2J is amplified in the presence of Kme2 and Kme3. 
 
  











*D AD 1 A , S ig=254,4  R ef=360,100 (IG \IG _D C L_2_16_17 2017-02-16 09-46-45\A_B4C _N O _G U EST_2_16_17.D )
*D AD 1 A , S ig=254,4  R ef=360,100 (IG \IG _D C L_2_16_17 2017-02-16 09-46-45\A_B4C _KM E2_2_16_17.D )
















Peptides were synthesized on a 0.6 mmol scale via solid-phase peptide synthesis in a 
peptide synthesis flask using Fmoc protected amino acids. Coupling reagents were HOBt/HBTU 
in DMF (4 equiv each), with coupling times of 60 min, followed by rinsing with DMF, MeOH, 
and CH2Cl2.  Deprotection was performed with 20% piperidine in DMF. All peptides were 
acylated at the N-terminus with a solution of 5% acetic anhydride and 6% 2,6-lutidine in DMF. 
Cleavage was performed using a cocktail of 95% TFA/2.5% triisopropylsilane/2.5% H2O for 3 h. 
Peptides were purified by semi-preparative reverse-phase HPLC on a C18 column at a flow rate 
of 4 mL/min. Peptides were purified with a linear gradient of A and B (A: 95% H2O/5% CH3CN 
with 0.1% TFA, B: 95% CH3CN/5% H2O with 0.1 % TFA). 
Methylated peptides were synthesized with 2 equivalents of Fmoc-Lys(Me)2-OH HCl or 
Fmoc-Lys(Me,Boc)-OH purchased from EMP Millipore and coupled for 5 h. The trimethyllysine 
containing peptides were synthesized by reacting corresponding dimethylated peptides (0.06 
mmol scale) prior to cleavage from the resin with MTBD (7-Methyl-1,5,7-
triazabicyclo[4.4.0]dec-5-ene, 10 equiv.) and methyl iodide (10 equiv.) in DMF (5 mL) for 5 h 
with bubbling nitrogen in a peptide flask. After washing the resin with DMF and CH2Cl2 and 
drying, the peptide was cleaved as normal. 
H3K9: Ac-WGGGQTARKSTG-NH2 











Figure 5.35. High resolution mass spectrum of H3K9 (ESI +). MS calculated: 1246.63 [M+H], 






Figure 5.36. High resolution mass spectrum of H3K9me (ESI +). MS calculated: 1260.64 
[M+H], 630.83 [M+2H]. MS observed: 1260.64346 [M+H], 630.82479 [M+2H]. 
H3 K9 3_13_17 #1-100 RT: 0.00-1.46 AV: 100 NL: 9.61E7
T: FTMS + p ESI Full ms [150.00-2000.00]






































































H3 K9me 3_13_17 #1-100 RT: 0.01-1.47 AV: 100 NL: 7.34E7
T: FTMS + p ESI Full ms [150.00-2000.00]










































































Figure 5.37. High resolution mass spectrum of H3K9me2 (ESI +). MS calculated: 1274.66 






Figure 5.38. High resolution mass spectrum of H3K9me3 (ESI +). MS calculated: 1288.68 
[M+H], 644.84036 [M+2H]. MS observed: 1288.67493 [M+H], 644.84 [M+2H]. 
H3 K9me2 3_3_17 #1-100 RT: 0.01-1.47 AV: 100 NL: 1.06E8
T: FTMS + p ESI Full ms [150.00-2000.00]





































































H3 K9me3 3_3_17 #1-100 RT: 0.01-1.47 AV: 100 NL: 1.07E8
T: FTMS + p ESI Full ms [150.00-2000.00]












































































Figure 5.39. High resolution mass spectrum of Kme2GGY (ESI +). MS calculated: 492.28 






Figure 5.40. High resolution mass spectrum of Kme3GGY (ESI +). MS calculated: 507.29 
[M+H]. MS observed: 507.29078 [M+H]. 
Kme2GGY_05_31_17 #1-100 RT: 0.01-1.47 AV: 100 NL: 6.01E7
T: FTMS + p ESI Full ms [150.00-2000.00]






































































Kme3GGY_05_31_17 #1-100 RT: 0.00-1.46 AV: 100 NL: 6.10E7
T: FTMS + p ESI Full ms [150.00-2000.00]








































































Extinction Coefficient Determination for A2I and A2J. 
Receptors were purified using reversed phase-HPLC with 10 mM NH4OAc as the mobile 
phase additive. After purification, they were lyophilized for five days to remove volatile 
NH4OAc salts. The dried compound was then dissolved in anhydrous methanol and filtered using 
a 0.33 μm filter to remove any remaining salts. Methanol was evaporated and the receptors were 
further dried under vacuum. The mass was accurately determined, and a stock solution of 
receptor (1.07 mM for A2I and 0.607 mM for A2J) in 10 mM sodium borate buffer, pH 8.5 was 
prepared. The stock solution was serially diluted (80:20, receptor: buffer) to give 10 to 12 
concentrations. The absorbance at 315 nm or 300 nm was measured for each concentration, 
which was then plotted against the concentration. The extinction coefficient of the receptors was 
determined from the slope of the line of regression using Beer’s law and was found to be 401.5 




Figure 5.41. Extinction coefficient determination of A2I from the slope of the line of regression. 
 
 

































Figure 5.42. Extinction coefficient determination of A2J from the slope of the line of regression. 
  

























Extinction Coefficient for A2J
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NMR Analysis of Binding to Kme2 and Kme3 
NMR binding experiments were conducted to characterize the mode of binding of A2I-2 
to a Kme2GGY and Kme3GGY peptide. Experiments were carried out in 50 mM sodium borate-
d3 D2O, pH 8.5 with 0.05 mM DSS (as an internal standard) at room temperature and 40 
oC 
using a Bruker 500 MHz instrument (400 scans each, 3s pre-saturation and water suppression). 
suppression). Stock solutions of receptor and peptide were prepared in the NMR buffer (the 
concentrations of each were determined using a NanoDropTM). Samples were prepared by 




Figure 5.43. 1H NMR spectrum of Kme2GGY (5.6 mM) alone in 50 mM sodium borate-d3 





Figure 5.44. 1H NMR spectrum of A2I-2 (0.75 mM) with Kme2GGY (0.70 mM) in 50 mM 





Figure 5.45. 1H NMR spectrum of A2I-2 (0.75 mM) with Kme2GGY (0.70 mM) in 50 mM 






Figure 5.46. 1H NMR spectrum of Kme3GGY (7.6 mM) alone in 50 mM sodium borate-d3 





Figure 5.47. 1H NMR spectrum of A2I-2 (0.75 mM) with Kme3GGY (0.70 mM) in 50 mM 





Figure 5.48. 1H NMR spectrum of A2I-2 (0.75 mM) with Kme3GGY (0.70 mM) in 50 mM 






Isothermal Titration Calorimetry 
ITC binding experiments were conducted using a Microcal AutoITC200. Titrations were 
performed at 25 °C in 10 mM sodium borate buffer at pH 8.5. The concentration of receptor was 
determined by measuring the UV–vis absorbance at 300 nm or 315 nm, using a NanoDrop2000 
with a xenon flash lamp, 2048 element linear silicon CCD array detector, and 1 mm path length. 
Solutions of 0.2–1.3 mM of peptide were titrated into a 20–91 μM solution of receptor, using 2.0 
μL increments every 3 min. Heats of dilution were taken as the last three or four points and 
subtracted prior to fitting. Binding curves were produced using the supplied Origin software and 





Table 5.4. Summary of A2I and A2J ITC data from using a one-site binding model. Values 




 Receptor Peptide Charge Kdb SFd ΔGc ΔHc TΔSc 
1 A2B H3 K9me3 
+2 
2.6 ± 0.1 - -7.63 ± 0.03   
2 A2B H3 K9me2 
+2 
6.3 ± 0.3 2.4 -7.10 ± 0.07   
3 A2B H3 K9me 
+2 
13.9 ± 0.1 5.4 -6.64 ± 0.01   
4 A2B H3 K9 
+2 
22 ± 1 8.3 -6.38 ± 0.02   
5 A2I-2 H3 K9me3 
+2 0.22 ± 0.03 





6 A2I-2 H3 K9me2 
+2 





7 A2I-2 H3 K9me 
+2 





8 A2I-2 H3 K9 
+2 





9 A2I-1 H3 K9me3 
+2 0.13 ± 





10 A2I-1 H3 K9me2 
+2 





11 A2I-1 H3 K9me 
+2 1.23 ± 0.04 





12 A2I-1 H3 K9 
+2 2.09 ± 0.15 





13 A2I-2 Kme3GGY 
+1 





14 A2I-2 Kme2GGY 
+1 





15 A2J-1 H3 K9me3 +2 2.61 ± 0.23 - -7.62 ± 0.8 - - 
16 A2J-1 H3 K9me2 +2 5.21 ± 0.44 2.0 -7.21 ± 0.7 - - 
17 A2J-1 H3 K9me +2 6.36 ± 0.64 2.4 -7.09 ± 0.7 - - 
18 A2J-1 H3 K9 +2 7.02 ± 0.75 2.7 -7.03 ± 0.7 - - 
19 A2J-2 H3 K9me3 +2 2.25 ± 0.18 - -7.70 ± 0.7 - - 
20 A2J-2 H3 K9me2 +2 6.74 ± 0.62 3.0 -7.05 ± 0.7 - - 
21 A2J-2 H3 K9me +2 8.37 ± 1.0 3.7 -6.93 ± 0.7 - - 
22 A2J-2 H3 K9 +2 10.60 ± 1.1 4.7 -6.79 ± 0.7 - - 
 
a Conditions: 25 oC in 10 mM sodium borate buffer, pH 8.5. b Errors are averages of the error in 
the fit as determined by the Origin 7 software. c Errors are from averages of the runs. d The 





Figure 5.49. One trial of three of H3K9 (Ac-WGGGQTARKSTG-NH2) (1.33 mM) titrated into 






Figure 5.50. One trial of three of H3K9 (Ac-WGGGQTARKSTG-NH2) (1.33 mM) titrated into 






Figure 5.51. One trial of three of H3K9 (Ac-WGGGQTARKSTG-NH2) (1.33 mM) titrated into 






Figure 5.52. One trial of three of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (1.26 mM) 






Figure 5.53. One trial of three of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (1.26 mM) 






Figure 5.54. One trial of three of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (1.26 mM) 






Figure 5.55. One trial of three of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (197 µM) 






Figure 5.56. One trial of three of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (197 µM) 






Figure 5.57. One trial of three of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (197 µM) 






Figure 5.58. One trial of three of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (200 µM) 






Figure 5.59. One trial of four of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (200 µM) 






Figure 5.60. One trial of four of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (200 µM) 






Figure 5.61. One trial of four of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (225 µM) 






Figure 5.62. One trial of four of H3K9 (Ac-WGGGQTARKSTG-NH2) (900 µM) titrated into 






Figure 5.63. One trial of four of H3K9 (Ac-WGGGQTARKSTG-NH2) (900 µM) titrated into 






Figure 5.64. One trial of four of H3K9 (Ac-WGGGQTARKSTG-NH2) (900 µM) titrated into 






Figure 5.65. One trial of three of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (900 µM) titrated 






Figure 5.66. One trial of three of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (700 µM) titrated 





Figure 5.67. One trial of three of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (700 µM) titrated 






Figure 5.68. One trial of two of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (200 µM) 






Figure 5.69. One trial of two of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (200 µM) 






Figure 5.70. One trial of two of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (200 µM) 






Figure 5.71. One trial of two of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (200 µM) 







Figure 5.72. One trial of two of H3K9 (Ac-WGGGQTARKSTG-NH2) (817 µM) titrated into 





Figure 5.73. One trial of two of H3K9 (Ac-WGGGQTARKSTG-NH2) (817 µM) titrated into 






Figure 5.74. One trial of two of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (800 µM) titrated 






Figure 5.75. One trial of two of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (800 µM) titrated 






Figure 5.76. One trial of two of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (815 µM) 






Figure 5.77. One trial of two of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (815 µM) 






Figure 5.78. One trial of two of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (812 µM) 






Figure 5.79. One trial of two of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (812 µM) 






Figure 5.80. One trial of two of H3K9 (Ac-WGGGQTARKSTG-NH2) (849 µM) titrated into 






Figure 5.81. One trial of two of H3K9 (Ac-WGGGQTARKSTG-NH2) (849 µM) titrated into 






Figure 5.82. One trial of two of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (689 µM) titrated 






Figure 5.83. One trial of two of H3K9me (Ac-WGGGQTARKmeSTG-NH2) (689 µM) titrated 






Figure 5.84. One trial of two of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (807 µM) 






Figure 5.85. One trial of two of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (807 µM) 






Figure 5.86. One trial of two of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (808 µM) 






Figure 5.87. One trial of two of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (808 µM) 






Figure 5.88. One trial of two of Kme2GGY (Ac-Kme2GGY-NH2) (867 µM) titrated into A2I-2 






Figure 5.89. One trial of two of Kme2GGY (Ac-Kme2GGY-NH2) (867 µM) titrated into A2I-2 






Figure 5.90. One trial of two of Kme3GGY (Ac-Kme3GGY-NH2) (883 µM) titrated into A2I-2 






Figure 5.91. One trial of two of Kme3GGY (Ac-Kme3GGY-NH2) (883 µM) titrated into A2I-2 





CHAPTER 6. Redesign of a Small Molecule Receptor for Methylated Lysine via 
Incorporation of Aromatic and Acidic Amino Acids 
Introduction and Significance 
Current methods to detect post-translational modifications of proteins (such as lysine 
methylation) include the use of antibodies and mass spectrometry-based proteomics. Even 
though these methods have been used successfully to identify PTMs, they both face challenges 
and limitations. While antibodies have been widely used with Western blotting for the 
identification of PTMs, they are sequence specific and generally require the protein or peptide 
sequence of interest to be known.86,109 This makes the detection of unknown post-translational 
modifications difficult. Their sequence specificity also hinders the detection of the patterns of 
PTMs that make up the histone code. Additionally, antibodies suffer from high cost of 
production and irreproducibility of quality from batch to batch.85 One major challenge facing 
mass spectrometry-based proteomics is the low natural abundance of post-translational 
modifications.165 This significantly complicates detection of proteins with PTMs as the protein of 
interest is present only in small amounts in a complex mixture of other proteins. Analysis is 
further complicated by the fact that purification, enrichment, and sample preparation for proteins 
with a specific PTM are challenging and involve multiple steps.87,117 Complications with both 
antibodies and MS-proteomics highlight the need for new tools for detection of PTMs. 
The development of small molecule receptors for the recognition of PTMs presents 
several advantages that would augment strategies using antibodies and mass spectrometry-based 
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proteomics. Small molecules have much lower cost of production when compared to antibodies 
and can be synthesized reliably and reproducibly. Receptors of this kind also have the potential 
to bind to a PTM of interest in a non-sequence-specific manner due to their smaller size.  
The Waters lab has developed a small molecule receptor, A2B, that binds trimethyllysine 
(Kme3) using dynamic combinatorial chemistry.96 Rigid monomers with aromatic groups for 
molecular recognition through cation-π interactions, carboxylates for water solubility and 
electrostatic interactions, and thiols for reversible disulfide exchange were used in dynamic 
combinatorial libraries (DCLs) to rapidly screen for macrocycles that bind Kme3. The identified 
receptor bound to histone peptide Ac-WGGGQTARKme3STG-NH2 with a Kd of 2.6 µM for 
racemic A2B, which is comparable to the binding affinity of the native Kme3 reader 
chromodomain, Heterochromatin Protein 1 (HP1).98 Additionally, the receptor displayed a 
modest 2-fold selectivity over the Kme2 variant of the peptide.  
We sought to redesign receptor A2B with two goals in mind: to improve the affinity and 
selectivity of the receptor for Kme3 and to reverse the selectivity of the receptor to favor binding 
to dimethyllysine (Kme2). Here, we use dynamic combinatorial chemistry (DCC) to expolore the 
effect of covalently attaching amino acids with either aromatic or acidic functionality to a known 
small molecule receptor for Kme3, A2B.  
System Design 
A biomimetic approach derived from PTM-binding effector modules was used in an 
effort to identify synthetic receptors with improved selectivity for Kme3 and Kme2. These 
modules are known as reader proteins, and they achieve specific molecular recognition of histone 
PTMs through a balance of cation-π, electrostatic, and hydrogen bonding interactions in the 
protein’s binding pocket.156 Li et al. demonstrated that the selectivity of a nucleosome 
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remodeling protein BPTF can be switched from Kme3 to Kme2 by changing the balance of non-
covalent interactions in the binding pocket of the protein.159 The wild-type BPTF binds Kme3 
through an aromatic cage consisting of three tyrosines and a trytophan. By simply  mutating the 
tyrosine at position 17 to a glutamic acid, the BPTF protein was engineered to selectively 
recognize the lower methylation state Kme2 over Kme3. 
We looked to mimic this strategy by coupling amino acids to monomer B to introduce 
new functionality that can participate in non-covalent interactions with a guest bound to receptor 
A2B. We posited that the binding affinity of A2B for Kme3 could be improved by attaching 
aromatic amino acids like phenylalanine, tyrosine, and tryptophan to monomer B. Modeling 
suggests that this could position an aromatic group over the top of the receptor that should add 
more cation-π contact area and increase binding to Kme3 peptides (Figure 6.1). Previous studies 
have shown that the carboxylate of monomer B can be converted to an amide without disrupting 
the function of A2B, suggesting that the proposed modifications will not negatively affect 
binding.166 To re-design A2B to be selective for Kme2, we looked to functionalize monomer B 
with an amino acid like apartic acid that is capable of making hydrogen bonding and electrostatic 
interactions with bound Kme2. Modeling suggests that the side chains of the derivatized 





   
Figure 6.1. Gas phase molecular models of one isomer of A2B-Asp (left) and A2B-Trp (right) 
bound to butyldimethyl ammonium and butyltrimethyl ammonium respectively.  
 
Synthesis of Monomers 
 The amino acid-functionalized monomers were synthesized starting from monomer B. 
First, the thiol groups were protected with trityl groups by reacting the monomer with 
triphenylmethanol and boron trifluoride. The trityl protected monomer (Trt B) was then 
converted to the N-hydroxysuccinimidyl ester (Trt B Osu) using carbodiimide coupling 
chemistry. Trt B Osu was then used to prepare each of the amino acid-functionalized monomers 
by reacting with either phenylalanine tertbutyl ester, tyrosine methyl ester, tryptophan methyl 
ester, or aspartic acid dimethyl ester. Deprotection with TFA gives monomer B-Phe, while TFA 
deprotection and a subsequent lithium hydroxide (or potassium hydroxide for B-Asp) hydrolysis 
is required to obtain B-Try, B-Trp, and B-Asp.  











Dynamic Combinatorial Library Screening 
DCC was used for rapid screening of receptors that incorporate the new monomers and 
that bind to the desired guest. To evaluate the effect of incorporating aromatic amino acids, five 
unbiased dynamic combinatorial libraries (DCLs) were prepared containing 1 mM A, 1 mM B-
Phe, 1 mM B-Tyr, 1-mM B-Trp and 4 mM of guest (or no guest for the untemplated library) in 
50 mM sodium borate buffer at pH 8.5. Methylated butylamine guests were used as convenient 
Kmex side chain mimics: n-butylamine for K, N-butylmethylamine for Kme1, N,N-
dimethylbutylamine for Kme2, or butyltrimethylammonium bromide for Kme3. These Kmex 
mimics were used as they are inexpensive and commercially available or easily prepared in the 
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case of butyltrimethylammonium bromide.163 For monomer B-Asp, a discovery library was not 
prepared. A prep library (described below) was prepared to isolate receptor for characterization 
of binding by ITC. 
The DCLs were allowed to undergo disulfide exchange and equilibration for four days at 
room temperature in air before analysis by LCMS. For the library containing A and the 
monomers functionalized with aromatic amino acids, two sets of peaks were amplified according 
to the HPLC trace. One set of peaks highlighted in red in Figure 6.2 corresponded to the mass of 
A2B-Tyr. The other set of peaks highlighted in blue corresponding to both A2B-Phe and A2B-
Trp (which indicates that the two receptors have similar retention times). Due to peak overlap 
and the complexity of the DCL, values for the extent of amplification compared to the 
untemplated library could not be accurately determined. 
 Receptors A2B-Phe, A2B-Tyr, A2B-Trp, and A2B-Asp were synthesized individually on 
a preparative scale using butyltrimethylammonium bromide as a guest. For the aromatic amino 
monomers, each preparative library contained 2.5 mM monomer A, 2.5 mM of the amino acid-
functionalized monomer, and 10 mM guest dissolved in 50 mM sodium borate buffer at pH 8.5. 
For the preparation of A2B-Asp, the library contained 5 mM monomer A, 5 mM of the amino 
acid-functionalized monomer, and 10 mM guest dissolved in 50 mM sodium borate buffer at pH 
8.5. Prep scale DCLs were allowed to equilibrate for a week before purification by semi-
preparative reversed-phase HPLC. For A2B-Phe, A2B-Tyr, and A2B-Trp, each receptor was 
purified as a mixture of racemic and meso isomers due to peak overlap of the isomers. For A2B-






Figure 6.2. Overlaid DCLs of monomer A, B-Phe, B-Tyr, and B-Trp with different methylated 
butylamine guests (1 mM A, 1 mM amino acid-functionalized monomer, and 4 mM guest, 50 
mM sodium borate buffer, pH 8.5).  
 
Binding Studies 
Binding of the receptors to model H3 histone peptides was characterized using ITC. The 
H3 peptides (corresponding to the different methylation states of lysine) contained a N-terminal 
WGGG tag for measuring peptide concentration by UV-Vis. The same peptide sequence that was 
used for characterizing binding of A2B was used so that a direct comparison could be made98,99 
(see Table 6.1). ITC experiments were conducted at 25 °C in 10 mM borate buffer at pH 8.5. The 
thermodynamic binding data collected from ITC binding studies of A2Phe, A2B-Tyr, A2B-Trp, 

























Table 6.1. Peptides used for ITC. 
 
Peptide Sequence 
H3 K9mex (x = 0, 2, or 3) Ac-WGGG-QTARKmexSTG-NH2 
 
Influence of Attaching Aromatic Amino acids to Monomer B 
Measurement of binding by ITC revealed that A2B-Phe and A2B-Trp bind Kme3 to the 
same extent (4.4 µM and 4.9 µM respectively), while A2B-Tyr binds slightly tighter with a Kd of 
1.6 µM. None of the receptors show a significant improvement in affinity for Kme3 when 
compared to the parent A2B receptor. Additionally, selectivity for binding Kme3 over the lower 
methylation states of lysine is reduced relative to A2B. It is likely that the side chains of the 
attached aromatic amino acids have too much conformational flexibility such that the arene 
spends a significant amount of time in conformations that do not contribute favorably to binding. 
The loss in selectivity over the lower methylation states may be due to non-specific electrostatic 
interactions with the peptide. These interactions may arise from the change in position of 
carboxylic acid on the B monomer which may bring it closer proximity to the neighboring Arg. 
Influence of Attaching an Acidic Amino Acid to Monomer B 
Analysis of binding of A2B-Asp to the model histone peptides showed that either isomer 
binds to Kme3 with similar affinity to the parent receptor A2B, with A2B-Asp-1 (the isomer that 
eluted from the HPLC first) having a Kd of 2.1 µM and A2B-Asp-2 having a Kd of 3.7 µM. Both 
isomers bound Kme3 and Kme2 to the same extent, indicating an improvement in binding to 
Kme2. However, the selectivity over unmethylated lysine was significantly decreased. The 
increase in affinity for Kme2 and K is likely due to non-specific electrostatic interactions, which 
may arise from repositioning of the carboxylate on B to bring it in closer proximity to a 
neighboring Arg. A more specific salt bridge interaction with the bound Kme2 guest is not 
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observed presumably due to the considerable conformational flexibility around the amide bond 
connecting B to Asp in addition to rotation around the side chain of the amino acid. 
Table 6.2. Thermodynamic binding data for the biding of A2B-Phe, A2B-Trp, A2B-Tyr, A2B-
Asp-1, and A2B-Asp-2 to peptides shown in Table 6.1 as measured by ITC. 
 
Entry Receptor Peptide Charge Kd 
b(µM) SFd ΔGc 
(kcal/mol) 
1 A2Ba H3K9 +2 22 ± 1 8.3 -6.38 ± 0.02 
2 A2Ba H3 K9me2 +2 6.3 ± 0.3 2.4 -7.10 ± 0.07 
3 A2Ba H3 K9me3 +2 2.6 ± 0.1 - -7.63 ± 0.03 
4 A2B-Phe H3K9 +2 7.9 ± 1.1 1.8 -6.96 ± 0.97 
5 A2B-Phe H3K9me2 +2 6.5 ± 0.4 1.5 -7.07 ± 0.44 
6 A2B-Phe H3 K9me3 +2 4.4 ± 0.2 - -7.31 ± 0.33 
7 A2B-Trp H3K9 +2 >16 3.2 >-6.56 
8 A2B-Trp H3 K9me2 +2 7.2 ± 0.5 1.5 -7.02 ± 0.49 
9 A2B-Trp H3 K9me3 +2 4.9 ± 0.2 - -7.24 ± 0.30 
10 A2B-Tyr H3K9 +2 8.6 ± 0.7 5.3 -6.91 ± 0.56 
11 A2B-Tyr H3 K9me2 +2 3.0 ± 0.2 1.9 -7.53 ± 0.50 
12 A2B-Tyr H3K9me3 +2 1.6 ± 0.1 - -7.91 ± 0.49 
13 A2B-Asp-1 H3K9 +2 6.3 ± 0.5 3.0 -7.10 ± 0.56 
14 A2B-Asp-1 H3 K9me2 +2 2.3 ± 0.1 1.1 -7.69 ± 0.33 
15 A2B-Asp-1 H3 K9me3 +2 2.1 ± 0.1 - -7.76 ± 0.37 
16 A2B-Asp-2 H3K9 +2 8.5 ± 0.8 2.3 -6.91 ± 0.65 
17 A2B-Asp-2 H3K9me2 +2 3.5 ± 0.2 0.9 -7.44 ± 0.43 
18 A2B-Asp-2 H3K9me3 +2 3.7 ± 0.3 - -7.42 ± 0.60 
 
a Reported by Pinkin and Waters.98 b Errors are from the error in the fit as determined by the 
Origin 7 software. c ΔG was calculated from the Kd. Errors are from the error in the fit as 
determined by the Origin 7 software d The selectivity factor is calculated as the Kd of Kmex 




 In summary, we have utilized DCC to explore the effect of covalently attaching various 
aromatic and acidic amino acids to a previously reported small molecule receptor for Kme3 
(A2B). Attaching Phe, Tyr, or Trp did not lead to an improvement in binding to Kme3. 
Furthermore, selectivity over the lower methylation states was diminished. Attaching Asp to A2B 
lead to a receptor with equal affinity for Kme3 and Kme2 but with weakened selectivity over K. 
Overall, selective non-covalent interactions between the amino acid side chain and the bound 
methylated lysine guest could not be achieved, presumably due to the high conformational 
flexibility of the modified receptors. Additionally, we believe that non-specific electrostatic 
interactions are responsible for the tighter binding to the unmethylated lysine peptide (compared 
to A2B). Since attaching the aromatic amino acids produced receptors with the same overall 
charge as the parent A2B receptor, the non-specific electrostatic interactions cannot be due 
simply to an increase in overall charge. The non-specific interactions may be due to placing a 
carboxylate (on the amino acid) in closer proximity to the positively charge arginine on the 
peptide. Ultimately, monomers that more rigidly direct functional groups into the binding pocket 
of the receptor may hold more promise for either increasing cation-π interactions or introducing 





Monomer A was prepared according to a previously reported procedure.101 










Synthesis of Trt B 
Monomer B (1.0 g, 5.37 mmol) and triphenylmethanol (2.91 g, 11.18 mmol) were added 
to a round bottom flask and dissolved in 15 mL diethyl ether under an atmosphere of nitrogen to 
form an off-white slurry. Boron trifluoride diethyl etherate (48% in diethyl ether, 3.0 mL, 11.67 
mmol) was added dropwise to the flask (a yellow color develops upon addition). The slurry 
disappears as the reaction progresses, and a white precipitate precipitates out of solution. To 
create a homogenous solution, 10 mL of THF was added. After completion of the reaction 
(monitored by TLC, 100% CH2Cl2), the solvent was removed under vacuum. The crude solid 
was taken up in diethyl ether and washed with 1N NaOH (25 mL), H2O (25 mL), and brine (25 
mL). The organic fraction was dried over MgSO4, and the solvent was removed under reduced 






Figure 6.3. 1D 1H-NMR (400 MHz) of Trt B in CDCl3. 
 
Synthesis of Trt B Osu 
Trt B (1.5 g, 2.24 mmol), N-hydroxysuccinimide (0.27 g, 2.35 mmol), and N,N’-
dicyclohexylcarbodiimide (0.48 g, 2.32 mmol) were dissolved in 15 mL CH2Cl2 under an 
atmosphere of nitrogen. The reaction was allowed to stir overnight. After completion of the 
reaction (monitored by TLC, 100% CH2Cl2), the solvent was removed under reduced pressure. 
The crude was purified by silica column chromatography (100% CH2Cl2) to give a crystalline 






Figure 6.4. 1D 1H-NMR (400 MHz) of Trt B Osu in CDCl3. 
 
Synthesis of Trt B-Phe 
Trt B Osu (0.100 g, 0.13 mmol) and phenylalanine tert-butyl ester hydrochloride (0.134 
g, 0.52 mmol) were dissolved in 1.0 mL DMF in a flask under a nitrogen atmosphere. 
Triethylamine (0.15 mL, 1.08 mmol) was added, and the reaction progress was monitored by 
TLC (35% Ethyl acetate in hexanes). After the reaction was complete, it was diluted with toluene 
(20 mL). Solvent was removed under vacuum, and the crude was purified by flash column 
chromatography (1:2 EtOAc:hexanes) to give a whitish-gray solid (0.108 g, 95%). 1H NMR 
(CDCl3, 400 MHz): 7.056-7.310 (m, 36 H, CH); 6.840 (s, 2H, CH); 5.777, 5.758 (d, 1H, NH); 





Figure 6.5. 1D 1H-NMR (400 MHz) of Trt B-Phe in CDCl3. 
Synthesis of Trt B-Trp 
Trt B Osu (0.50 g, 0.65 mmol) and tryptophan methyl ester hydrochloride (0.66 g, 2.59 
mmol) were dissolved in DMF (5.0 mL) in a flask under a nitrogen atmosphere. DIPEA (0.91 
mL, 5.22 mmol) was added, and the reaction progress was monitored by TLC (35% Ethyl acetate 
in hexanes). After the reaction was complete, it was diluted with water (50 mL) to precipitate out 
a white solid, which was collected by vacuum filtration. The crude material was purified using 
silica column chromatography (0-1% MeOH in CH2Cl2) to give a yellow solid (0.53 g, 93%). 
1H 
NMR (CDCl3, 400 MHz): 7.107-7.772 (m, 34H, CH); 7.002 (s, 1H, CH); 6.777 (s, 2H, CH); 
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6.749 (s, 1H, CH); 5.686, 5.665 (d, 1H, NH); 4.930 (m, 1H, CH); 3.724 (s, 3H, CH); 3.297, 




Figure 6.6. 1D 1H-NMR (400 MHz) of Trt B-Trp in CDCl3. 
Synthesis of Trt B-Tyr 
Trt B Osu (0.50 g, 0.65 mmol) and tyrosine methyl ester hydrochloride (0.60 g, 2.59 
mmol) were dissolved in DMF (5.0 mL) in a flask under a nitrogen atmosphere. DIPEA (0.91 
mL, 5.22 mmol) was added, and the reaction progress was monitored by TLC (35% Ethyl acetate 
in hexanes). After the reaction was complete, it was diluted with water (50 mL) to precipitate out 
a white solid, which was collected by vacuum filtration. The crude material was purified using 




NMR (CDCl3, 400 MHz): 7.082-7.303 (m, 31H, CH), 6.808 (s, 2H, CH); 6.837, 6.858 (d, 2H, 
CH); 6.672, 6.693 (d, 2H, CH); 5.688, 5.668 (d, 1H, NH); 4.848, 4.828 (m, 1H, CH); 3.734 (s, 




Figure 6.7. 1D 1H-NMR (400 MHz) of Trt B-Tyr in CDCl3. 
 
Synthesis of Trt B-Asp 
Trt B Osu (0.50 g, 0.69 mmol) and aspartic acid dimethyl ester hydrochloride (0.206 g, 
1.04 mmol) were dissolved in DMF (4.0 mL) in a flask under a nitrogen atmosphere. DIPEA 
(0.36 mL, 2.09 mmol) was added, and the reaction progress was monitored by TLC (35% Ethyl 
acetate in hexanes). After the reaction was complete, it was diluted with water (50 mL) to 
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precipitate out a white solid, which was collected by vacuum filtration. The crude material was 
purified using silica column chromatography (1:2 EtOAc:hexanes) to give a white solid (0.49 g, 
92%). 1H NMR (CDCl3, 400 MHz): 7.177-7.325 (m, 30H, CH); 7.083 (s, 1H, CH); 6.862, 6.858 
(s, 2H, CH); 6.281, 6.261 (d, 1H, NH); 4.845 (m, 1H, CH); 3.763 (s, 3H, CH); 3.690 (s, 3H, 




Figure 6.8. 1D 1H-NMR (400 MHz) of Trt B-Asp in CDCl3. 
 
Synthesis of B-Phe 
A cocktail of TFA (10 mL), TIPS (0.5 mL), and CH2Cl2 (2 mL) was added to Trt B-Phe 
(0.50 g, 0.57 mmol) in a flask under a nitrogen atmosphere. The reaction progress was monitored 
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by TLC (35% Ethyl acetate in hexanes). After the reaction was complete, solvent was removed 
by bubbling with nitrogen. The crude was triturated in hexanes (3 X 5 mL) and dried under 
vacuum. The crude product was stored under nitrogen and was used without further purification 
(0.167 g, 87%). 1H NMR (MeOD, 400 MHz): 7.825 (s, 2H, CH); 7.683 (s, 1H, CH); 7.141-7.250 
(m, 5H, CH); 4.694 (m, 1H, CH); 3.099 (m, 2H, CH). MS (calculated): 332.04 [M-H], 665.09 









Figure 6.10. High resolution mass spectrum of B-Phe. MS (calculated): 332.04 [M-H], 665.09 
[2M-H]. MS (observed, ESI-): 332.12 [M-H], 665.12 [2M-H]. 
 
Synthesis of B-Tyr 
A cocktail of TFA (10 mL), TIPS (0.5 mL), and CH2Cl2 (2 mL) was added to Trt B-Tyr 
(0.40 g, 0.47 mmol) in a flask under a nitrogen atmosphere. The reaction progress was monitored 
by TLC (35% Ethyl acetate in hexanes). After the reaction was complete, solvent was removed 
by bubbling with nitrogen. The crude was triturated in hexanes (3 X 5 mL) and dried under 
vacuum. A solution of LiOH monohydrate (0.02 g, 4.7 mmol) in H2O was degassed by bubbling 
with nitrogen for 2 h. The crude solid was dissolved in 5 mL of the LiOH solution, and the 
reaction was allowed to stir overnight. The product was precipitated by addition of 5 mL of 1N 
HCl and collected by vacuum filtration. The crude product was used without further purification 
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(0.117 g, 71% over two steps). 1H NMR (MeOD, 400 MHz): 7.318 (s, 3H, CH); 7.057, 7.036 (d, 
2H, CH); 6.688, 6.667 (d, 2H, CH); 4.714 (m, 1H, CH); 2.926-3.214 (m, 2H, CH). MS 
(calculated): 349.04 [M-2H+D]. MS (observed, ESI-): 349.04 [M-2H+D]. Sample was run in 










Figure 6.12. High resolution mass spectrum of B-Tyr. MS (calculated): 349.04 [M-2H+D]. MS 
(observed, ESI-): 349.04 [M-2H+D]. Sample was run in MeOD, which lead to H/D exchange. 
 
Synthesis of B-Trp 
A cocktail of TFA (10 mL), TIPS (0.5 mL), and CH2Cl2 (2 mL) was added to Trt B-Phe 
(0.40 g, 0.46 mmol) in a flask under a nitrogen atmosphere. The reaction progress was monitored 
by TLC (35% Ethyl acetate in hexanes). After the reaction was complete, solvent was removed 
by bubbling with nitrogen. The crude was triturated in hexanes (3 X 5 mL) and dried under 
vacuum to give a crude solid. A solution of LiOH monohydrate (0.02 g, 4.7 mmol) in H2O was 
degassed by bubbling with nitrogen for 2 h. The crude solid was dissolved in 5 mL of the LiOH 
solution, and the reaction was allowed to stir overnight. The product was precipitated by addition 
of 5 mL of 1N HCl and collected by vacuum filtration. The crude product was used without 
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further purification (0.149 g, 87% over two steps). 1H NMR (MeOD, 400 MHz): 7.001-7.573 (m, 
6H, CH); 6.966, 6.983 (s, 2H, CH); 6.810, 6.806 (s, 1H, NH); 4.762 (m, 1H, CH); 3.452, 3.428 
(m, 2H, CH). MS (calculated): 373.06 [M-3H+2D]. MS (observed, ESI-): 373.07 [M-3H+2D]. 









Figure 6.14. High resolution mass spectrum of B-Trp. MS (calculated): 373.06 [M-3H+2D]. 
MS (observed, ESI-): 373.07 [M-3H+2D]. Sample was run in MeOD, which lead to H/D 
exchange. 
 
Synthesis of B-Asp 
A cocktail of TFA (9.65 mL), TIPS (0.25 mL), and CH2Cl2 (2.0 mL) was added to Trt B-
Asp (0.49 g, 0.61 mmol) in a flask under a nitrogen atmosphere. The reaction progress was 
monitored by TLC (35% Ethyl acetate in hexanes). After the reaction was complete, solvent was 
removed by bubbling with nitrogen. The crude was triturated in hexanes (3 X 5 mL) and dried 
under vacuum. The crude solid was dissolved in 10 mL of a solution of 10% KOH in 10:1 
H2O:MeOH (degassed by bubbling N2 for 2 h) and allowed to stir overnight for 24 h. The 
product was used without further purification (0.082 g, 45% over two steps). 1H NMR (MeOD, 
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400 MHz): 7.368 (s, 2H, CH); 7.272 (s, 1H, CH); 3.831 (m, 1H, CH), 2.830, 2.871 (m, 2H, CH). 








Figure 6.16. High resolution mass spectrum of B-Asp (ESI -). MS calculated: 300.00 [M-H]. 
MS observed: 300.00037 [M-H].  
B Asp 07_24_15 #1-99 RT: 0.00-1.46 AV: 99 NL: 6.02E6
T: FTMS - p ESI Full ms [150.00-2000.00]













































































Peptide Synthesis  
Peptides were synthesized on a 0.6 mmol scale via solid-phase peptide synthesis in a 
peptide synthesis flask using Fmoc protected amino acids. Coupling reagents were HOBt/HBTU 
in DMF (4 equiv each), with coupling times of 60 min, followed by rinsing with DMF, MeOH, 
and CH2Cl2.  Deprotection was performed with 20% piperidine in DMF. All peptides were 
acylated at the N-terminus with a solution of 5% acetic anhydride and 6% 2,6-lutidine in DMF. 
Cleavage was performed using a cocktail of 95% TFA/2.5% triisopropylsilane/2.5% H2O for 3 h. 
Peptides were purified by semi-preparative reverse-phase HPLC on a C18 column at a flow rate 
of 4 mL/min. Peptides were purified with a linear gradient of A and B (A: 95% H2O/5% CH3CN 
with 0.1% TFA, B: 95% CH3CN/5% H2O with 0.1 % TFA). 
Methylated peptides were synthesized with 2 equivalents of Fmoc-Lys(Me)2-OH HCl 
purchased from EMP Millipore and coupled for 5 h. The trimethyllysine containing peptides 
were synthesized by reacting corresponding dimethylated peptides (0.06 mmol scale) prior to 
cleavage from the resin with MTBD (7-Methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene, 10 equiv.) 
and methyl iodide (10 equiv.) in DMF (5 mL) for 5 h with bubbling nitrogen in a peptide flask. 








Synthesis of A2B-Phe, A2B-Tyr, A2B-Trp, and A2B-Asp 
 DCLs were prepared on a preparative scale using butyltrimethylammonium bromide as a 
guest for templating the formation of the desired receptor. For the aromatic amino monomers, 
each preparative library contained 2.5 mM monomer A, 2.5 mM of the amino acid-
functionalized monomer, and 10 mM guest dissolved in 50 mM sodium borate buffer at pH 8.5. 
For the preparation of A2B-Asp, the library contained 5 mM monomer A, 5 mM of the amino 
acid-functionalized monomer, and 50 mM guest dissolved in 50 mM sodium borate buffer at pH 
8.5. Prep scale DCLs were allowed to equilibrate for a week before purification by semi-
preparative reversed-phase HPLC (solvent A: 10 mM NH4OAc in H2O; solvent B: 10 mM 
NH4OAc in 9:1 CH3CN:H2O). For A2B-Phe, A2B-Tyr, and A2B-Trp, each receptor was purified 
as a mixture of racemic and meso isomers due to peak overlap of the isomers. For A2B-Asp, two 
isomers were purified and isolated. All receptors were purified using the following gradient: 0% 
B to 35% B over 1 min, 35% B to 40% B over 5 min, 40% B to 55% B over 30 min, and 55% B 




Figure 6.17. Semi-preparative reversed-phase HPLC traces of the purification of A2B-Phe from 























Figure 6.18. High resolution mass spectrum of A2B-Phe (ESI -). MS calculated: 518.51 [M-2H], 




Figure 6.19. Semi-preparative reversed-phase HPLC traces of the purification of A2B-Tyr from 
a preparative scale DCL. Absorbance measured at 214 nm.  
A2B Phe 06_22_15 #1-99 RT: 0.01-1.46 AV: 99 NL: 7.42E5
T: FTMS - p ESI Full ms [150.00-2000.00]

































































































Figure 6.20. High resolution mass spectrum of A2B-Tyr (ESI -). MS calculated: 526.51 [M-2H], 




Figure 6.21. Semi-preparative reversed-phase HPLC traces of the purification of A2B-Trp from 
a preparative scale DCL. Absorbance measured at 214 nm.  
 
A2B Tyr 06_22_15 #1-100 RT: 0.01-1.48 AV: 100 NL: 9.37E5
T: FTMS - p ESI Full ms [150.00-2000.00]




























































































Figure 6.22. High resolution mass spectrum of A2B-Trp (ESI -). MS calculated: 538.02 [M-2H], 




Figure 6.23. Semi-preparative reversed-phase HPLC traces of the purification of A2B-Asp from 
a preparative scale DCL. Absorbance measured at 214 nm.  
A2B Trp 06_22_15 #1-100 RT: 0.01-1.48 AV: 100 NL: 1.13E6
T: FTMS - p ESI Full ms [150.00-2000.00]




























































































Figure 6.24. High resolution mass spectrum of A2B-Asp-1 (ESI -). MS calculated: 1005.99 [M-




Figure 6.25. High resolution mass spectrum of A2B-Asp-2 (ESI -). MS calculated: 1005.99 [M-
H], 502.49206 [M-2H]. MS observed: 1005.98452 [M-H], 502.49063 [M-2H]. 
  
A2B_Asp Peak 1 08_24_15 #1-100 RT: 0.00-1.47 AV: 100 NL: 1.68E7
T: FTMS - p ESI Full ms [150.00-2000.00]




































































A2B_Asp Peak 2 08_24_15 #1-99 RT: 0.00-1.46 AV: 99 NL: 9.72E6
T: FTMS - p ESI Full ms [150.00-2000.00]






































































Extinction Coefficient Determination for A2B-Phe, A2B-Trp, and A2B-Tyr 
Receptors were purified using reversed phase-HPLC with 10 mM NH4OAc as the mobile 
phase additive. After purification, they were lyophilized for five days to remove volatile 
NH4OAc salts. The dried compound was then dissolved in anhydrous methanol and filtered using 
a 0.33 μm filter to remove any remaining salts. Methanol was evaporated and the receptors were 
further dried under vacuum. The mass was accurately determined, and a stock solution of 
receptor (1.0 mM) in 10 mM sodium borate buffer, pH 8.5 was prepared. The stock solution was 
serially diluted (80:20, receptor: buffer) to give 8 concentrations. The absorbance at 280 nm was 
measured for each concentration, which was then plotted against the concentration. The 
extinction coefficient of the receptors was determined from the slope of the line of regression 
using Beer’s law and was found to be 1300 M-1cm-1 for A2B-Phe, 1600 M-1cm-1 for A2B-Trp, 
and 800 M-1cm-1 for A2B-Tyr. For A2B-Asp-1 and A2B-Asp-2, the previously reported 




Figure 6.26. Extinction coefficient determination of A2B-Phe from the slope of the line of 
regression. 
 




































Figure 6.28. Extinction coefficient determination of A2B-Tyr from the slope of the line of 
regression. 
  


























































Isothermal Titration Calorimetry 
ITC binding experiments were conducted using a Microcal AutoITC200. Titrations were 
performed at 25 °C in 10 mM sodium borate buffer at pH 8.5. The concentration of receptor was 
determined by measuring the UV–vis absorbance at 300 nm or 315 nm, using a NanoDrop2000 
with a xenon flash lamp, 2048 element linear silicon CCD array detector, and 1 mm path length. 
Solutions of 0.94–1.14 mM of peptide were titrated into an 81–98 μM solution of receptor, using 
2.0 μL increments every 3 min. Heats of dilution were taken as an average of the last three points 
and subtracted prior to fitting. Binding curves were produced using the supplied Origin software 




Table 6.3. Thermodynamic binding data for the biding of A2B-Phe, A2B-Trp, A2B-Tyr, A2B-
Asp-1, and A2B-Asp-2 to peptides shown in Table 6.1 as measured by ITC. 
 







1 A2Ba H3K9 +2 22 ± 1 8.3 -6.38 ± 0.02 - - - 
2 A2Ba H3 K9me2 +2 6.3 ± 0.3 2.4 -7.10 ± 0.07 - - - 
3 A2Ba H3 K9me3 +2 2.6 ± 0.1 - -7.63 ± 0.03 - - - 
4 A2B-Phe H3K9 +2 




5 A2B-Phe H3K9me2 +2 




6 A2B-Phe H3 K9me3 +2 




7 A2B-Trp H3K9 +2 




8 A2B-Trp H3 K9me2 +2 




9 A2B-Trp H3 K9me3 +2 




10 A2B-Tyr H3K9 +2 




11 A2B-Tyr H3 K9me2 +2 




12 A2B-Tyr H3K9me3 +2 




13 A2B-Asp-1 H3K9 +2 6.3 ± 0.5 3.0 -7.10 ± 0.56 -8.23 ± 
0.17 
-3.80 0.516 
14 A2B-Asp-1 H3 K9me2 +2 2.3 ± 0.1 1.1 -7.69 ± 0.33 -11.88 ± 
0.11 
-14.1 0.413 
15 A2B-Asp-1 H3 K9me3 +2 2.1 ± 0.1 - -7.76 ± 0.37 -11.05 ± 
0.07 
-11.0 0.484 
16 A2B-Asp-2 H3K9 +2 8.5 ± 0.8 2.3 -6.91 ± 0.65 -8.56 ± 
0.31 
-5.51 0.453 
17 A2B-Asp-2 H3K9me2 +2 3.5 ± 0.2 0.9 -7.44 ± 0.43 -11.88 ± 
0.19 
-14.9 0.345 




a Reported by Pinkin and Waters.98 b Errors are from the error in the fit as determined by the 
Origin 7 software. c ΔG was calculated from the Kd. Errors are from the error in the fit as 
determined by the Origin 7 software d The selectivity factor is calculated as the Kd of Kmex 





Figure 6.29. One trial of H3K9 (Ac-WGGGQTARKSTG-NH2) (0.96 mM) titrated into A2B-Phe 






Figure 6.30. One trial of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (1.06 mM) titrated into 






Figure 6.31. One trial of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (1.14 mM) titrated into 






Figure 6.32. One trial of H3K9 (Ac-WGGGQTARKSTG-NH2) (0.96 mM) titrated into A2B-Tyr 






Figure 6.33. One trial of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (1.06 mM) titrated into 






Figure 6.34. One trial of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (1.14 mM) titrated into 






Figure 6.35. One trial of H3K9 (Ac-WGGGQTARKSTG-NH2) (0.96 mM) titrated into A2B-






Figure 6.36. One trial of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (1.06 mM) titrated into 






Figure 6.37. One trial of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (1.14 mM) titrated into 






Figure 6.38. One trial of H3K9 (Ac-WGGGQTARKSTG-NH2) (0.94 mM) titrated into A2B-





Figure 6.39. One trial of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (1.04 mM) titrated into 





Figure 6.40. One trial of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (1.13 mM) titrated into 





Figure 6.41. One trial of H3K9 (Ac-WGGGQTARKSTG-NH2) (0.94 mM) titrated into A2B-





Figure 6.42. One trial of H3K9me2 (Ac-WGGGQTARKme2STG-NH2) (1.04 mM) titrated into 





Figure 6.43. One trial of H3K9me3 (Ac-WGGGQTARKme3STG-NH2) (1.13 mM) titrated into 






(1)  Walsh, C. T.; Garneau-Tsodikova, S.; Gatto, G. J. Angew. Chemie Int. Ed. 2005, 44, 
7342–7372. 
(2)  Greer, E. L.; Shi, Y. Nat. Rev. Genet. 2012, 13, 343–357. 
(3)  Verdin, E.; Ott, M. Nat. Rev. Mol. Cell Biol. 2015, 16, 258–264. 
(4)  Rossetto, D.; Avvakumov, N.; Côté, J. Epigenetics 2012, 7, 1098–1108. 
(5)  Cao, J.; Yan, Q. Front. Oncol. 2012, 2, 26. 
(6)  Dehennaut, V.; Leprince, D.; Lefebvre, T. Front. Endocrinol. (Lausanne). 2014, 5, 155. 
(7)  Alexander Deiters; T. Ashton Cropp; Mridul Mukherji; Jason W. Chin; J. Christopher 
Anderson,  and; Schultz*, P. G. 2003. 
(8)  Wang, Q.; Parrish, A. R.; Wang, L. Chem. Biol. 2009, 16, 323–336. 
(9)  Dawson, P.; Muir, T.; Clark-Lewis, I.; Kent, S. Science (80-. ). 1994, 266. 
(10)  Malins, L. R.; Payne, R. J. Curr. Opin. Chem. Biol. 2014, 22, 70–78. 
(11)  Muir, T. W.; Sondhi, D.; Cole, P. A. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 6705–6710. 
(12)  Berrade, L.; Camarero, J. A. Cell. Mol. Life Sci. 2009, 66, 3909–3922. 
(13)  Boutureira, O.; Bernardes, G. J. L. Chem. Rev. 2015, 115, 150220140113005. 
(14)  Siemion, I. Z. Biosystems 1994, 32, 163–170. 
(15)  Gong, Y.; Pan, L. Tetrahedron Lett. 2015, 56, 2123–2132. 
(16)  Jentoft, N.; Dearborn, D. G. J. Biol. Chem. 1979, 254, 4359–4365. 
(17)  Massa, S.; Xavier, C.; De Vos, J.; Caveliers, V.; Lahoutte, T.; Muyldermans, S.; 
Devoogdt, N. Bioconjug. Chem. 2014, 25, 979–988. 
(18)  Hemantha, H. P.; Bavikar, S. N.; Herman-Bachinsky, Y.; Haj-Yahya, N.; Bondalapati, S.; 
Ciechanover, A.; Brik, A. J. Am. Chem. Soc. 2014, 136, 2665–2673. 
(19)  Cal, P. M. S. D.; Bernardes, G. J. L.; Gois, P. M. P. Angew. Chemie Int. Ed. 2014, 53, 
10585–10587. 
(20)  Rademann, J. Angew. Chemie Int. Ed. 2004, 43, 4554–4556. 
(21)  Tanaka, K.; Fukase, K.; Katsumura, S. Synlett 2011, 2011, 2115–2139. 
 
236 
(22)  Cal, P. M. S. D.; Vicente, J. B.; Pires, E.; Coelho, A. V; Veiros, L. F.; Cordeiro, C.; Gois, 
P. M. P. J. Am. Chem. Soc. 2012, 134, 10299–10305. 
(23)  Faustino, H.; Silva, M. J. S. A.; Veiros, L. F.; Bernardes, G. J. L.; Gois, P. M. P.; Huang, 
Y.; Liu, L.; Krall, N.; Cruz, F. P. da; Boutureira, O.; Bernardes, G. J. L.; Shannon, D. A.; 
Weerapana, E.; Boutureira, O.; Bernardes, G. J. L.; Koniev, O.; Wagner, A.; Takaoka, Y.; 
Ojida, A.; Hamachi, I.; Stephanopoulos, N.; Francis, M. B.; Chalker, J. M.; Bernardes, G. 
J. L.; Lin, Y. A.; Davis, B. G.; Chalker, J. M.; Gunnoo, S. B.; Boutureira, O.; Gerstberger, 
S. C.; González, M. F.; Bernardes, G. J. L.; Griffin, L.; Hailu, H.; Schofielda, C. J.; Davis, 
B. G.; Ratner, V.; Kahana, E.; Eichler, M.; Haas, E.; Moody, P.; Chudasama, V.; Nathani, 
R. I.; Maruani, A.; Martin, S.; Smith, M. E. B.; Caddick, S.; Cal, P. M. S. D.; Bernardes, 
G. J. L.; Gois, P. M. P.; Rashidian, M.; Kumarapperuma, S. C.; Gabrielse, K.; Fegan, A.; 
Wagner, C. R.; Distefano, M. D.; Maruani, A.; Smith, M. E. B.; Miranda, E.; Chester, K. 
A.; Chudasama, V.; Caddick, S.; Wang, T.; Riegger, A.; Lamla, M.; Wiese, S.; Oeckl, P.; 
Otto, M.; Wu, Y.; Fischer, S.; Barth, H.; Kuan, S. L.; Weil, T.; Hu, Q. Y.; Berti, F.; 
Adamo, R.; Patterson, D. M.; Nazarova, L. A.; Prescher, J. A.; Ngo, J. T.; Tirrel, D. A.; 
Xie, J.; Schultz, P. G.; Zhang, C.; Welborn, M.; Zhu, T.; Yang, N. J.; Santos, M. S.; 
Voorhis, T. V.; Pentelute, B. L.; Sachdeva, A.; Wang, K.; Elliott, T.; Chin, J. W.; Zhang, 
D.; Devarie-Baez, N. O.; Jack, Q. L.; Jr, R. L.; Xian, M.; Mühlberg, M.; Hoesl, M. G.; 
Kuehne, C.; Dernedde, J.; Budisa, N.; Hackenberger, C. P. R.; Kim, J.; Seo, M.-H.; Lee, 
S.; Cho, K.; Yang, A.; Woo, K.; Kim, H.-S.; Park, H.-S.; Grünewald, J.; Jones, D. H.; 
Brock, A.; Chiu, H.-P.; Bursulaya, B.; Ng, K.; Vo, T.; Patterson, P.; Uno, T.; Hunt, J.; 
Spraggon, G.; Geierstanger, B. H.; Nathani, R. I.; Moody, P.; Chudasama, V.; Smith, M. 
E. B.; Fitzmaurice, R. J.; Caddick, S.; Dawson, P.; Muir, T.; Clark-Lewis, I.; Kent, S.; 
Ren, H.; Xiao, F.; Zhan, K.; Kim, Y.-P.; Xie, H.; Xia, Z.; Rao, J.; Yuan, Y.; Liang, G.; 
Zhang, L.; Tam, J. P.; Casi, G.; Dezot, N. H.; Zuberbühler, K.; Scheuermann, J.; Neri, D.; 
Bernardes, G. J. L.; Steiner, M.; Hartmann, I.; Neri, D.; Casi, G.; Cal, P. M. S. D.; 
Vicente, J. B.; Pires, E.; Coelho, A. V.; Veiros, L. F.; Cordeiro, C.; Gois, P. M. P.; Cal, P. 
M. S. D.; Frade, R. F. M.; Chudasama, V.; Cordeiro, C.; Caddick, S.; Gois, P. M. P.; Cal, 
P. M. S. D.; Frade, R. F. M.; Cordeiro, C.; Gois, P. M. P.; Schmidt, P.; Stress, C.; 
Gillingham, D.; Bandyopadhyay, A.; Gao, J.; Dilek, O.; Lei, Z.; Mukherjee, K.; Bane, S.; 
Draganov, A. B.; Wang, K.; Holmes, J.; Damera, K.; Wang, D.; Dai, C.; Wang, B.; 
Bandyopadhyay, A.; Cambray, S.; Gao, J.; Koniev, O.; Leriche, G.; Nothisen, M.; Remy, 
J.-S.; Strub, J.-M.; Reiss, C. S.; Dorsselaer, A. V.; Baati, R.; Wagner, A. Chem. Sci. 2016, 
8, 101. 
(24)  Chan, A. O.-Y.; Ho, C.-M.; Chong, H.-C.; Leung, Y.-C.; Huang, J.-S.; Wong, M.-K.; Che, 
C.-M. J. Am. Chem. Soc. 2012, 134, 2589–2598. 
(25)  Koniev, O.; Leriche, G.; Nothisen, M.; Remy, J.-S.; Strub, J.-M.; Schaeffer-Reiss, C.; Van 
Dorsselaer, A.; Baati, R.; Wagner, A. Bioconjug. Chem. 2014, 25, 202–206. 
(26)  Arumugam, S.; Guo, J.; Mbua, N. E.; Friscourt, F.; Lin, N.; Nekongo, E.; Boons, G.-J.; 
Popik, V. V. Chem. Sci. 2014, 5, 1591–1598. 
(27)  Valkevich, E. M.; Guenette, R. G.; Sanchez, N. A.; Chen, Y.; Ge, Y.; Strieter, E. R. J. Am. 
Chem. Soc. 2012, 134, 6916–6919. 
 
237 
(28)  Li, F.; Allahverdi, A.; Yang, R.; Lua, G. B. J.; Zhang, X.; Cao, Y.; Korolev, N.; 
Nordenskiöld, L.; Liu, C.-F. Angew. Chemie Int. Ed. 2011, 50, 9611–9614. 
(29)  Conte, M. Lo; Staderini, S.; Marra, A.; Sanchez-Navarro, M.; Davis, B. G.; Dondoni, A.; 
Lo, A.; Bertozzi, C. R. Chem. Commun. 2011, 47, 11086. 
(30)  Gavrilyuk, J.; Ban, H.; Nagano, M.; Hakamata, W.; Barbas, C. F. Bioconjug. Chem. 2012, 
23, 2321–2328. 
(31)  Tilley, S. D.; Francis, M. B. J. Am. Chem. Soc. 2006, 128, 1080–1081. 
(32)  McFarland, J. M.; Joshi, N. S.; Francis, M. B. J. Am. Chem. Soc. 2008, 130, 7639–7644. 
(33)  Seki, Y.; Ishiyama, T.; Sasaki, D.; Abe, J.; Sohma, Y.; Oisaki, K.; Kanai, M. J. Am. Chem. 
Soc. 2016, 138, 10798–10801. 
(34)  Cravatt, B. F.; Wright, A. T.; Kozarich, J. W. Annu. Rev. Biochem. 2008, 77, 383–414. 
(35)  Kolb, H. C.; Sharpless, K. B. Drug Discov. Today 2003, 8, 1128–1137. 
(36)  Takaoka, Y.; Ojida, A.; Hamachi, I. Angew. Chem. Int. Ed. Engl. 2013, 52, 4088–4106. 
(37)  Brunner, J. Annu. Rev. Biochem. 1993, 62, 483–514. 
(38)  Knowles, J. R. Acc. Chem. Res. 1972, 5, 155–160. 
(39)  Singh, A.; Thornton, E. R.; Westheimer, F. H. J. Biol. Chem. 1962, 237, 3006–3008. 
(40)  Tanaka, Y.; Bond, M. R.; Kohler, J. J. Mol. Biosyst. 2008, 4, 473. 
(41)  Saghatelian, A.; Jessani, N.; Joseph, A.; Humphrey, M.; Cravatt, B. F. Proc. Natl. Acad. 
Sci. 2004, 101, 10000–10005. 
(42)  Patricelli, M. P.; Szardenings, A. K.; Liyanage, M.; Nomanbhoy, T. K.; Wu, M.; Weissig, 
H.; Aban, A.; Chun, D.; Tanner, S.; Kozarich, J. W. Biochemistry 2007, 46, 350–358. 
(43)  Lee-Chiang, L.; Te-Ling, P.; Chi-Hsien, K.; Ying-Ling, C.; Hsin-Yi, W.; Jing-Jer, L. J. 
Proteome Res. 2002, 1, 35–40. 
(44)  Liu, Y.; Patricelli, M. P.; Cravatt, B. F. Proc. Natl. Acad. Sci. 1999, 96, 14694–14699. 
(45)  Serim, S.; Haedke, U.; Verhelst, S. H. L. ChemMedChem 2012, 7, 1146–1159. 
(46)  Tsukiji, S.; Hamachi, I. Curr. Opin. Chem. Biol. 2014, 21, 136–143. 
(47)  Fujishima, S.; Yasui, R.; Miki, T.; Ojida, A.; Hamachi, I. J. Am. Chem. Soc. 2012, 134, 
3961–3964. 




(49)  Hughes, C. C.; Yang, Y.-L.; Liu, W.-T.; Dorrestein, P. C.; La Clair, J. J.; Fenical, W. J. 
Am. Chem. Soc. 2009, 131, 12094–12096. 
(50)  Koshi, Y.; Nakata, E.; Miyagawa, M.; Tsukiji, S.; Ogawa, T.; Hamachi, I. J. Am. Chem. 
Soc. 2008, 130, 245–251. 
(51)  Sato, S.; Nakamura, H. Angew. Chem. Int. Ed. Engl. 2013, 52, 8681–8684. 
(52)  Tsukiji, S.; Miyagawa, M.; Takaoka, Y.; Tamura, T.; Hamachi, I. Nat. Chem. Biol. 2009, 
5, 341–343. 
(53)  Tamura, T.; Kioi, Y.; Miki, T.; Tsukiji, S.; Hamachi, I. J. Am. Chem. Soc. 2013, 135, 
6782–6785. 
(54)  Tsukiji, S.; Wang, H.; Miyagawa, M.; Tamura, T.; Takaoka, Y.; Hamachi, I. J. Am. Chem. 
Soc. 2009, 131, 9046–9054. 
(55)  Tamura, T.; Tsukiji, S.; Hamachi, I. J. Am. Chem. Soc. 2012, 134, 2216–2226. 
(56)  Matsuo, K.; Kioi, Y.; Yasui, R.; Takaoka, Y.; Miki, T.; Fujishima, S.; Hamachi, I.; 
Tochio, H.; Shirakawa, M.; Hamachi, I.; Pingoud, A.; Tsien, R. Y. Chem. Sci. 2013, 4, 
2573. 
(57)  Otsuki, S.; Nishimura, S.; Takabatake, H.; Nakajima, K.; Takasu, Y.; Yagura, T.; Sakai, 
Y.; Hattori, A.; Kakeya, H. Bioorg. Med. Chem. Lett. 2013, 23, 1608–1611. 
(58)  Yamaguchi, T.; Asanuma, M.; Nakanishi, S.; Saito, Y.; Okazaki, M.; Dodo, K.; Sodeoka, 
M. Chem. Sci. 2014, 5, 1021. 
(59)  Gregory, S. G.; Barlow, K. F.; McLay, K. E.; Kaul, R.; Swarbreck, D.; Dunham, A.; Scott, 
C. E.; Howe, K. L.; Woodfine, K.; Spencer, C. C. A.; Jones, M. C.; Gillson, C.; Searle, S.; 
Zhou, Y.; Kokocinski, F.; McDonald, L.; Evans, R.; Phillips, K.; Atkinson, A.; Cooper, 
R.; Jones, C.; Hall, R. E.; Andrews, T. D.; Lloyd, C.; Ainscough, R.; Almeida, J. P.; 
Ambrose, K. D.; Anderson, F.; Andrew, R. W.; Ashwell, R. I. S.; Aubin, K.; Babbage, A. 
K.; Bagguley, C. L.; Bailey, J.; Beasley, H.; Bethel, G.; Bird, C. P.; Bray-Allen, S.; 
Brown, J. Y.; Brown, A. J.; Buckley, D.; Burton, J.; Bye, J.; Carder, C.; Chapman, J. C.; 
Clark, S. Y.; Clarke, G.; Clee, C.; Cobley, V.; Collier, R. E.; Corby, N.; Coville, G. J.; 
Davies, J.; Deadman, R.; Dunn, M.; Earthrowl, M.; Ellington, A. G.; Errington, H.; 
Frankish, A.; Frankland, J.; French, L.; Garner, P.; Garnett, J.; Gay, L.; Ghori, M. R. J.; 
Gibson, R.; Gilby, L. M.; Gillett, W.; Glithero, R. J.; Grafham, D. V.; Griffiths, C.; 
Griffiths-Jones, S.; Grocock, R.; Hammond, S.; Harrison, E. S. I.; Hart, E.; Haugen, E.; 
Heath, P. D.; Holmes, S.; Holt, K.; Howden, P. J.; Hunt, A. R.; Hunt, S. E.; Hunter, G.; 
Isherwood, J.; James, R.; Johnson, C.; Johnson, D.; Joy, A.; Kay, M.; Kershaw, J. K.; 
Kibukawa, M.; Kimberley, A. M.; King, A.; Knights, A. J.; Lad, H.; Laird, G.; Lawlor, S.; 
Leongamornlert, D. A.; Lloyd, D. M.; Loveland, J.; Lovell, J.; Lush, M. J.; Lyne, R.; 
Martin, S.; Mashreghi-Mohammadi, M.; Matthews, L.; Matthews, N. S. W.; McLaren, S.; 
 
239 
Milne, S.; Mistry, S.; M oore, M. J. F.; Nickerson, T.; O’Dell, C. N.; Oliver, K.; Palmeiri, 
A.; Palmer, S. A.; Parker, A.; Patel, D.; Pearce, A. V.; Peck, A. I.; Pelan, S.; Phelps, K.; 
Phillimore, B. J.; Plumb, R.; Rajan, J.; Raymond, C.; Rouse, G.; Saenphimmachak, C.; 
Sehra, H. K.; Sheridan, E.; Shownkeen, R.; Sims, S.; Skuce, C. D.; Smith, M.; Steward, 
C.; Subramanian, S.; Sycamore, N.; Tracey, A.; Tromans, A.; Van Helmond, Z.; Wall, M.; 
Wallis, J. M.; White, S.; Whitehead, S. L.; Wilkinson, J. E.; Willey, D. L.; Williams, H.; 
Wilming, L.; Wray, P. W.; Wu, Z.; Coulson, A.; Vaudin, M.; Sulston, J. E.; Durbin, R.; 
Hubbard, T.; Wooster, R.; Dunham, I.; Carter, N. P.; McVean, G.; Ross, M. T.; Harrow, 
J.; Olson, M. V.; Beck, S.; Rogers, J.; Bentley, D. R. Nature 2006, 441, 315–321. 
(60)  Mandelkern, M.; Elias, J. G.; Eden, D.; Crothers, D. M. J. Mol. Biol. 1981, 152, 153–161. 
(61)  Annunziato, A. T. Nat. Educ. 2008, 1, 26. 
(62)  Van Holde, K. E. Chromatin: Springer Series in Molecular Biology; Springer-Verlag: 
New York, 1988. 
(63)  Wolffe, A. P. Chromatin: Structure and Function; 3rd ed.; Academic: San Diego, 1999. 
(64)  Thomas, J. O.; Kornberg, R. D. Proc. Natl. Acad. Sci. U. S. A. 1975, 72, 2626–2630. 
(65)  Bednar, J.; Horowitz, R. A.; Grigoryev, S. A.; Carruthers, L. M.; Hansen, J. C.; Koster, A. 
J.; Woodcock, C. L. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 14173–14178. 
(66)  Pierce, B. Genetics: A Conceptual Approach; 2nd ed.; W H Freeman & Co: New York, 
2005. 
(67)  Kubicek, S. Epigenetics - A Primer http://www.the-
scientist.com/?articles.view/articleNo/30737/title/Epigenetics-A-Primer/ (accessed Jun 30, 
2017). 
(68)  Filippakopoulos, P.; Knapp, S. Nat. Rev. Drug Discov. 2014, 13, 337–356. 
(69)  Flanagan, J. F.; Mi, L.-Z.; Chruszcz, M.; Cymborowski, M.; Clines, K. L.; Kim, Y.; 
Minor, W.; Rastinejad, F.; Khorasanizadeh, S. Nature 2005, 438, 1181–1185. 
(70)  Li, H.; Ilin, S.; Wang, W.; Duncan, E. M.; Wysocka, J.; Allis, C. D.; Patel, D. J. Nature 
2006, 442, 91–95. 
(71)  Lehnertz, B.; Ueda, Y.; Derijck, A. A. H. A.; Braunschweig, U.; Perez-Burgos, L.; 
Kubicek, S.; Chen, T.; Li, E.; Jenuwein, T.; Peters, A. H. F. M. Curr. Biol. 2003, 13, 
1192–1200. 
(72)  Di Lorenzo, A.; Bedford, M. T. FEBS Lett. 2011, 585, 2024–2031. 
(73)  Gayatri, S.; Bedford, M. T. Biochim. Biophys. Acta 2014, 1839, 702–710. 
(74)  Kschonsak, M.; Haering, C. H. Bioessays 2015, 37, 755–766. 
 
240 
(75)  Pinto, D. M. S.; Flaus, A. In Sub-cellular biochemistry; 2010; Vol. 50, pp. 55–78. 
(76)  Fraga, M. F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; 
Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; Iyer, N. G.; P?rez-Rosado, A.; Calvo, E.; 
Lopez, J. A.; Cano, A.; Calasanz, M. J.; Colomer, D.; Piris, M. ?ngel; Ahn, N.; Imhof, A.; 
Caldas, C.; Jenuwein, T.; Esteller, M. Nat. Genet. 2005, 37, 391–400. 
(77)  Cheung, N.; Chan, L. C.; Thompson, A.; Cleary, M. L.; So, C. W. E. Nat. Cell Biol. 2007, 
9, 1208–1215. 
(78)  Urdinguio, R. G.; Sanchez-Mut, J. V; Esteller, M. Lancet Neurol. 2009, 8, 1056–1072. 
(79)  Perez-Burgos, L.; Peters, A. H. F. .; Opravil, S.; Kauer, M.; Mechtler, K.; Jenuwein, T. 
2003; pp. 234–254. 
(80)  Zhao, Y.; Jensen, O. N. Proteomics 2009, 9, 4632–4641. 
(81)  Kokubu, M.; Ishihama, Y.; Sato, T.; Nagasu, T.; Oda, Y. Anal. Chem. 2005, 77, 5144–
5154. 
(82)  Tian, Y.; Zhou, Y.; Elliott, S.; Aebersold, R.; Zhang, H. Nat. Protoc. 2007, 2, 334–339. 
(83)  Cytoskeleton. Post-translational Modification Detection Techniques. 
www.cytoskeleton.com/about-signal-seeker-ptm-detection (accessed Jun 30, 2017). 
(84)  Rothbart, S. B.; Dickson, B. M.; Raab, J. R.; Grzybowski, A. T.; Krajewski, K.; Guo, A. 
H.; Shanle, E. K.; Josefowicz, S. Z.; Fuchs, S. M.; Allis, C. D.; Magnuson, T. R.; 
Ruthenburg, A. J.; Strahl, B. D. Mol. Cell 2015, 59, 502–511. 
(85)  Nishikori, S.; Hattori, T.; Fuchs, S. M.; Yasui, N.; Wojcik, J.; Koide, A.; Strahl, B. D.; 
Koide, S. J. Mol. Biol. 2012, 424, 391–399. 
(86)  Blow, N. Nature 2007, 447, 741–744. 
(87)  Sidoli, S.; Cheng, L.; Jensen, O. N. J. Proteomics 2012, 75, 3419–3433. 
(88)  Bicker, K. L.; Subramanian, V.; Chumanevich, A. A.; Hofseth, L. J.; Thompson, P. R. J. 
Am. Chem. Soc. 2012, 134, 17015–17018. 
(89)  Binda, O.; Boyce, M.; Rush, J. S.; Palaniappan, K. K.; Bertozzi, C. R.; Gozani, O. 
Chembiochem 2011, 12, 330–334. 
(90)  Bothwell, I. R.; Islam, K.; Chen, Y.; Zheng, W.; Blum, G.; Deng, H.; Luo, M. J. Am. 
Chem. Soc. 2012, 134, 14905–14912. 
(91)  Islam, K.; Bothwell, I.; Chen, Y.; Sengelaub, C.; Wang, R.; Deng, H.; Luo, M. J. Am. 
Chem. Soc. 2012, 134, 5909–5915. 




(93)  Daze, K. D.; Ma, M. C. F.; Pineux, F.; Hof, F. Org. Lett. 2012, 14, 1512–1515. 
(94)  Peacock, H.; Thinnes, C. C.; Kawamura, A.; Hamilton, A. D. Supramol. Chem. 2016, 28, 
575–581. 
(95)  Gamal-Eldin, M. A.; Macartney, D. H.; Zhou, M.-M.; Kim, S.-Y.; Lee, J. W.; Hakamoto, 
S.; Yamaguchi, K.; Kim, K.; Kim, J.; Selvapalam, N.; Ryu, S. H.; Kim, K.; Gilson, M. K.; 
Kim, K.; Inoue, Y.; Mapelli, M.; Guccione, E. Org. Biomol. Chem. 2013, 11, 488–495. 
(96)  Ingerman, L.; Cuellar, M.; Waters, M. L. Chem. Commun. 2010, 46, 1839. 
(97)  James, L.; Beaver, J. E.; Rice, N.; Waters, M. L. J. Am. Chem. Soc. 2013, 135, 6450–
6455. 
(98)  Pinkin, N. K.; Waters, M. L. Org. Biomol. Chem. 2014. 
(99)  Beaver, J. E.; Peacor, B. C.; Bain, J. V.; James, L. I.; Waters, M. L. Org. Biomol. Chem. 
2015, 13, 3220–3226. 
(100)  Otto, S.; Furlan, R. L. E.; Sanders, J. K. M. Science 2002, 297, 590–593. 
(101)  Corbett, P. T.; Sanders, J. K. M.; Otto, S. Chemistry 2008, 14, 2153–2166. 
(102)  Minaker, S. A.; Daze, K. D.; Ma, M. C. F.; Hof, F. J. Am. Chem. Soc. 2012, 134, 11674–
11680. 
(103)  Peacor, B. C.; Ramsay, C. M.; Waters, M. L. Chem. Sci. 2017, 8, 1422–1428. 
(104)  Liu, Y.; Perez, L.; Mettry, M.; Gill, A. D.; Byers, S. R.; Easley, C. J.; Bardeen, C. J.; 
Zhong, W.; Hooley, R. J.; Cheng, Q.; Hooley, R. J.; Moghaddam, S.; Gilson, M. K.; Kim, 
K. M.; Inoue, Y. Chem. Sci. 2017, 8, 3960–3970. 
(105)  Garnett, G. A. E.; Starke, M. J.; Shaurya, A.; Li, J.; Hof, F. Anal. Chem. 2016, 88, 3697–
3703. 
(106)  Kimura, Y.; Saito, N.; Hanada, K.; Liu, J.; Okabe, T.; Kawashima, S. A.; Yamatsugu, K.; 
Kanai, M. ChemBioChem 2015, 16, 2599–2604. 
(107)  Carlson, S. M.; Gozani, O. J. Mol. Biol. 2014, 426, 3350–3362. 
(108)  Jones, P. A.; Baylin, S. B. Cell 2007, 128, 683–692. 
(109)  Kazanecki, C. C.; Kowalski, A. J.; Ding, T.; Rittling, S. R.; Denhardt, D. T. J. Cell. 
Biochem. 2007, 102, 925–935. 




(111)  Bremang, M.; Cuomo, A.; Agresta, A. M.; Stugiewicz, M.; Spadotto, V.; Bonaldi, T. Mol. 
Biosyst. 2013, 9, 2231–2247. 
(112)  Guo, A.; Gu, H.; Zhou, J.; Mulhern, D.; Wang, Y.; Lee, K. A.; Yang, V.; Aguiar, M.; 
Kornhauser, J.; Jia, X.; Ren, J.; Beausoleil, S. A.; Silva, J. C.; Vemulapalli, V.; Bedford, 
M. T.; Comb, M. J. Mol. Cell. Proteomics 2014, 13, 372–387. 
(113)  Geoghegan, V.; Guo, A.; Trudgian, D.; Thomas, B.; Acuto, O. Nat. Commun. 2015, 6, 
6758. 
(114)  Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, 
J. V; Mann, M. Science 2009, 325, 834–840. 
(115)  Choudhary, C.; Weinert, B. T.; Nishida, Y.; Verdin, E.; Mann, M. Nat. Rev. Mol. Cell 
Biol. 2014, 15, 536–550. 
(116)  Gronborg, M. Mol. Cell. Proteomics 2002, 1, 517–527. 
(117)  Witze, E. S.; Old, W. M.; Resing, K. A.; Ahn, N. G. Nat. Methods 2007, 4, 798–806. 
(118)  Ohe, Y.; Iwai, K. J. Biochem. 1981, 90, 1205–1211. 
(119)  Bonger, K. M.; van den Berg, R. J. B. H. N.; Heitman, L. H.; IJzerman, A. P.; Oosterom, 
J.; Timmers, C. M.; Overkleeft, H. S.; van der Marel, G. A. Bioorg. Med. Chem. 2007, 15, 
4841–4856. 
(120)  Rostovtsev, V. V; Green, L. G.; Fokin, V. V; Sharpless, K. B. Angew. Chem. Int. Ed. 
Engl. 2002, 41, 2596–2599. 
(121)  Florea, M.; Kudithipudi, S.; Rei, A.; González-Álvarez, M. J.; Jeltsch, A.; Nau, W. M. 
Chem. - A Eur. J. 2012, 18, 3521–3528. 
(122)  Huang, F.; Nie, Y.; Ye, F.; Zhang, M.; Xia, J. Bioconjug. Chem. 2015. 
(123)  Daze, K. D.; Jones, C. E.; Lilgert, B. J.; Beshara, C. S.; Hof, F. Can. J. Chem. 2013, 91, 
1072–1076. 
(124)  Cheung, W. L.; Briggs, S. D.; Allis, C. D. Curr. Opin. Cell Biol. 2000, 12, 326–333. 
(125)  Strahl, B. D.; Allis, C. D. Nature 2000, 403, 41–45. 
(126)  Lai, A. Y.; Wade, P. A. Nat. Rev. Cancer 2011, 11, 588–596. 
(127)  Denslow, S. A.; Wade, P. A. Oncogene 2007, 26, 5433–5438. 
(128)  Huang, L. J. Cell. Physiol. 2006, 209, 611–616. 




(130)  Hoffmann, K.; Jung, M.; Brosch, G.; Loidl, P. Nucleic Acids Res. 1999, 27, 2057–2058. 
(131)  Acker, M. G.; Auld, D. S. Perspect. Sci. 2014, 1, 56–73. 
(132)  Sodji, Q. H.; Kornacki, J. R.; Mrksich, M.; Oyelere, A. K. Epigenetic Technological 
Applications; Elsevier, 2015. 
(133)  Schwämmle, V.; Aspalter, C.-M.; Sidoli, S.; Jensen, O. N. Mol. Cell. Proteomics 2014, 
13, 1855–1865. 
(134)  Marks, P. A.; Breslow, R. Nat. Biotechnol. 2007, 25, 84–90. 
(135)  Martin, C.; Zhang, Y. Nat. Rev. Mol. Cell Biol. 2005, 6, 838–849. 
(136)  Eberharter, A.; Becker, P. B. EMBO Rep. 2002, 3, 224–229. 
(137)  Chantalat, S.; Depaux, A.; Héry, P.; Barral, S.; Thuret, J.-Y.; Dimitrov, S.; Gérard, M. 
Genome Res. 2011, 21, 1426–1437. 
(138)  Carrozza, M. J.; Li, B.; Florens, L.; Suganuma, T.; Swanson, S. K.; Lee, K. K.; Shia, W.-
J.; Anderson, S.; Yates, J.; Washburn, M. P.; Workman, J. L. Cell 2005, 123, 581–592. 
(139)  Young, N. L.; DiMaggio, P. A.; Plazas-Mayorca, M. D.; Baliban, R. C.; Floudas, C. A.; 
Garcia, B. A. Mol. Cell. Proteomics 2009, 8, 2266–2284. 
(140)  Madsen, A. S.; Olsen, C. A. Angew. Chemie Int. Ed. 2012, 51, 9083–9087. 
(141)  Zhang, J.; Chung, T.; Oldenburg, K. J. Biomol. Screen. 1999, 4, 67–73. 
(142)  Shaurya, A.; Dubicki, K. I.; Hof, F. Supramol. Chem. 2014, 26, 583–590. 
(143)  Gober, I. N.; Waters, M. L. J. Am. Chem. Soc. 2016, 138, 9452–9459. 
(144)  Norouzy, A.; Azizi, Z.; Nau, W. M. Angew. Chemie Int. Ed. 2015, 54, 792–795. 
(145)  Liu, Y.; Perez, L.; Mettry, M.; Easley, C. J.; Hooley, R. J.; Zhong, W. J. Am. Chem. Soc. 
2016, 138, 10746–10749. 
(146)  Kataev, E. A.; Müller, C. Tetrahedron 2014, 70, 137–167. 
(147)  Oshovsky, G. V.; Reinhoudt, D. N.; Verboom, W. Angew. Chemie Int. Ed. 2007, 46, 
2366–2393. 
(148)  Schneider, H.-J.; Yatsimirsky, A. K. Chem. Soc. Rev. 2008, 37, 263–277. 
(149)  Butterfield, S. M.; Julius Rebek, J. J. Am. Chem. Soc. 2006, 128, 15366–15367. 
(150)  Schrader, T.; Bitan, G.; Klärner, F.-G.; Mori, Y.; Sajiki, H.; Tremaine, L. M.; Gales, L.; 
Saraiva, M. J.; Almeida, M. R.; Gallo, G.; Buxbaum, J.; Shimada, K.; Takahashi, K.; 
 
244 
Yamamura, K.; Maeda, S.; Pham, E.; Masliah, E.; Gage, F. H.; Riek, R.; Wettig, B.; Heid, 
C.; Kirchhoff, F.; Weil, T.; Klärner, F. G.; Schrader, T.; Bitan, G.; Sanchez-Garcia, E.; 
Winter, R.; Shorter, J.; Münch, J. Chem. Commun. 2016, 52, 11318–11334. 
(151)  Huang, G.-B.; Wang, S.-H.; Ke, H.; Yang, L.-P.; Jiang, W. J. Am. Chem. Soc. 2016, 138, 
14550–14553. 
(152)  Berg, J. M.; Tymoczko, J. L.; Stryer, L. In Biochemistry. 5th edition; W H Freeman: New 
York, 2002. 
(153)  Pabo, C. O.; Sauer, R. T. Annu. Rev. Biochem. 1984, 53, 293–321. 
(154)  Tainer, J. A.; Cunningham, R. P. Curr. Opin. Biotechnol. 1993, 4, 474–483. 
(155)  Yun, M.; Wu, J.; Workman, J. L.; Li, B. Cell Res. 2011, 21, 564–578. 
(156)  Taverna, S. D.; Li, H.; Ruthenburg, A. J.; Allis, C. D.; Patel, D. J. Nat. Struct. Mol. Biol. 
2007, 14, 1025–1040. 
(157)  Adams-Cioaba, M. A.; Min, J. Biochem. Cell Biol. 2009, 87, 93–105. 
(158)  Corbett, P. T.; Leclaire, J.; Vial, L.; West, K. R.; Wietor, J.-L.; Sanders, J. K. M.; Otto, S. 
Chem. Rev. 2006, 106, 3652–3711. 
(159)  Li, H.; Fischle, W.; Wang, W.; Duncan, E. M.; Liang, L.; Murakami-Ishibe, S.; Allis, C. 
D.; Patel, D. J. Mol. Cell 2007, 28, 677–691. 
(160)  Percec, V.; Holerca, M. N.; Nummelin, S.; Morrison, J. J.; Glodde, M.; Smidrkal, J.; 
Peterca, M.; Rosen, B. M.; Uchida, S.; Balagurusamy, V. S. K.; Sienkowska, M. J.; 
Heiney, P. A. Chem. - A Eur. J. 2006, 12, 6216–6241. 
(161)  Umemoto, T.; Garrick, L. M.; Saito, N. Beilstein J. Org. Chem. 2012, 8, 461–471. 
(162)  Dahl, B. J.; Branchaud, B. P. Org. Lett. 2006, 8, 5841–5844. 
(163)  Meng, L.-B.; Zhang, W.; Li, D.; Li, Y.; Hu, X.-Y.; Wang, L.; Li, G.; Zhang, D.; Wang, L. 
Chem. Commun. 2015, 51, 14381–14384. 
(164)  Pinkin, N. K.; Liu, I.; Abron, J. D.; Waters, M. L. Chem. - A Eur. J. 2015, 21, 17981–
17986. 
(165)  Parker, C. E.; Mocanu, V.; Mocanu, M.; Dicheva, N.; Warren, M. R. Mass Spectrometry 
for Post-Translational Modifications; CRC Press/Taylor & Francis, 2010. 
(166)  Pinkin, N. K.; N. Power, A.; Waters, M. L. Org. Biomol. Chem. 2015, 13, 10939–10945. 
 
